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Abstract
Recombinant guinea-pig TNFa (gpTNFa) has been cloned, expressed and 
purified, and its in vivo biological activity in the guinea-pig lung examined. cDNA 
corresponding to the secreted form of gpTNFa was amplified by the polymerase chain 
reaction, cloned into the pMAL-p2 vector and expressed in E. coli. This system results 
in the expression of a maltose binding protein-gpTNFa fusion protein incorporating a 
factor Xa cleavage site. The fusion protein was extracted from the E. coli lysate by 
affinity chromatography. Factor Xa cleavage releases gpTNFa from the fusion protein, 
resulting in a 17kDa protein detectable with anti murine TNFa antibodies in western 
blotting. Hydroxyapatite, amylose and polymyxin B-bound agarose columns were used 
for further purification. gpTNFa exhibited a cytotolytic activity 4 fold greater than 
recombinant human TNFa standards in a murine TNFa bioassay.
The in vivo bioactivity of gpTNFa in the lung was characterised in guinea- 
pigs. gpTNFa induced a pronounced and protracted airway eosinophilia which was 
both time-related (peaking at 24 hours) and dose dependent. Pre-incubating gpTNFa 
with anti TNFa antibody or heat inactivating the protein, prior to tracheal instillation 
inhibited gpTNFa induced leukocyte accumulation. The instillation of human TNFa 
elicited a weaker inflammatory cell recruitment with different cellular characteristics 
than that induced by gpTNFa indicating species selectivity.
The role of TNFa in a guinea-pig model of allergic airway inflammation was 
also examined. Following antigen challenge temporal changes in lung leukocyte 
infiltration and chemokine-like activity in the airways were observed. The 
administration of anti TNFa antibody partially inhibited antigen-induced eosinophil 
accumulation. In addition, treatment with human IL-13, a cytokine which exhibits 
anti-inflammatory activities, inhibited both gpTNFa- and antigen-induced airway 
eosinophilia, and inhibited the generation of chemokine-like bioactivity in the airways 
in response to antigen.




1.1 Tumour necrosis factor a  (TNFa)
Cell to cell communication is a complex set of events involving receptor- 
ligand interactions, intracellular signaling pathways, gene expression and protein 
synthesis. In order to exert an effect on a biological system these events must occur in 
a coordinated manner. One system which is highly regulated by cell to cell 
communication is the immune/inflammatory system. The controlled modulation of 
immune-cell derived protein mediators is essential since these mediators not only 
orchestrate the inflammatory response, but are also involved in normal cellular growth 
and differentiation. One such mediator is tumour necrosis factor (TNF).
1.1.1 History, isolation, characterisation and cloning
The phenomenon of bacterial induced tumour necrosis was reported at the turn 
of the century by William Coley (Coley, 1893; Coley, 1906) and later further 
investigated by Shear and colleagues (Shear et al. 1943). This was probably the first 
report of the concept of TNF. Shear isolated a gram-negative bacterial factor 
responsible for the induced necrosis, now known as lipopolysaccharide (LPS), and 
then showed that LPS did not directly cause tumour necrosis (O'Malley et al. 1962). A 
decade later, 1975, Carswell et al. 1975 reported similar and more extensive findings 
that the serum derived from mice, rats and rabbits treated with Bacillus Calmette- 
Guerin (BCG) prior to injection of endotoxin contained a necrotising factor capable of 
acting upon tumours implanted in the skin of recipient mice with no apparent effect on 
the recipient. This activity of the serum was named TNF. Initial in vitro studies in 
1975, using the supernatant from endotoxin stimulated rat peritoneal macrophages 
provided evidence that TNF was cytotoxic to benzpyrene-induced sarcoma cells but 
not normal rat kidney or diaphragm cells (Currie & Basham, 1975). This cytotoxic 
selectivity was also observed by Helson (Helson, 1975) who induced lysis of human 
melanoma cells with partially purified murine TNF.
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The nature and sequence of the protein TNF was not identified until the mid- 
80’s when two forms were isolated from human sources and subsequently their cDNA 
was cloned (Aggarwal et al. 1985b; Pennica et al. 1984; Gray et al. 1984; Wang et al. 
1985; Shirai et al. 1985). The 2 forms of TNF defined as TNFa and lymphotoxin 
(TNFp) exhibited 34% amino acid sequence homology, with TNFa believed to be 
produced by monocytes/ macrophages and TNFp by lymphocytes. Originally it was 
generally perceived that these 2 proteins which exhibited structural homology and 
bound common receptors functioned similarly, but it is now becoming clear that TNFP 
is not a redundant aspect of TNFa biology. Indications that TNFp could induce 
separate biological functions from TNFa were implicated by the identification of a 
TNFP-specific receptor (Crowe et al. 1994) named TNF receptor related protein 
(TNFRrp). TNFP (TNFpa) binds to TNFR-rp as a heterotrimer produced by binding 
with a third member of the TNF ligand family TNFpp, forming a TNFPa2 :TNFPpi 
complex (Browning etal. 1993).
At a similar time a report described a factor, in a murine system, which was 
involved in the suppression of lipoprotein lipase and the induction of cachexia 
(Kawakami et al. 1982). Cachexia is a state of malnutrition which often complicates 
illness as the host continues to catabolise vital lipid and protein stores despite reducing 
food intake. This factor termed cachectin possessed similar biological activity and 
NH2 -terminal sequence homology to TNFa. Following the purification of cachectin it 
was found to be identical to TNFa (Beutler et al. 1985a). By the end of the eighties 
the sequencing and cloning of rabbit (Ito et al. 1986), murine (Pennica et al. 1985) and 
rat (Shirai et al. 1989) TNFa confirmed TNFa to be a 17kDa protein under denaturing 
conditions and 45-5 lkDa under native conditions, suggesting activity as a trimer. 
TNFa was subsequently classified as a cytokine, a large family of host-derived 
proteins which are involved in cell to cell communication.
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1.1.2 Regulation of TNF a  biosynthesis
TNFa is produced primarily by activated macrophages, but also by a wide 
variety of inflammatory and tissue cell types of which an abridged list is shown in 
table 1.1. The protein is also produced by a range of tumour cells (Cordingley et al. 
1988), and it is currently speculated that under the appropriate conditions all nucleated 
cell types are capable of producing TNFa. Although it was first thought that TNFa 
was solely synthesised de novo following cell activation it has been shown that in mast 
cells TNFa can exist in a stored form (Gordon & Galli, 1990). The biosynthesis of 
TNFa is highly regulated at the transcriptional, translational, and post-translational 
levels. The involvement of transcriptional regulation was noted in peritoneal murine 
macrophages by Beutler et al (Beutler et al. 1986a). In resting cells the TNFa gene 
was transcriptionally active and TNFa mRNA detected but TNFa protein was not 
measurable, indicating that the mRNA was not being translated. Cellular activation by 
LPS was postulated to mobilise the sequestered mRNA for translation and to stimulate 
the biosynthesis of additional message. Following stimulation the rate of transcription 
was increased approximately threefold whilst TNFa mRNA levels increased 50-100 
times and protein secretion 10,000 times (Beutler et al. 1986a; Chung et al. 1992), 
suggesting the involvement of transcriptional and translational regulation. 
Dexamethasone inhibits both gene transcription and mRNA translation, but 
dexamethasone will only suppress the latter if added prior to LPS stimulation (Beutler 
et al. 1986a). Once induction of the translation phase had occurred dexamethasone 
was incapable of regulating TNFa production, hence dexamethasone may only be an 
effective suppresser of TNFa biosynthesis in a prophylactic manner.
The use of protein synthesis inhibitors has demonstrated that post-translational 
mechanisms also regulate TNFa biosynthesis. The addition of cycloheximide 
increased mRNA levels and the gene transcription rate in phorbol ester stimulated
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Table 1.1: An abridged list of different cell types which produce TNFa.
Cell type Reference
monocytes (Beutler et al. 1985a)
neutrophils (Dubravec et al. 1990)
eosinophils (Costa ef al. 1993)
lymphocytes (Cuturi etal. 1987)
mast cells (Gordon & Galli, 1990)
smooth muscle cells (Warner & Libby, 1989)
endothelial cells (Shanahan et al. 1989)
epithelial cells (Spriggs al. 1988)
fibroblasts (Havell & Rogerson, 1993)
Kupffer cells (Karck etal. 1988)
mesangial cells (Baud etal. 1989)
cardiac myocytes (Kapadia et al. 1995)
astrocytes (Robbins et al. 1987)
monocytes. As mRNA levels were also increased in the presence of a combination of 
actinomycin D (an inhibitor of transcription) and cycloheximide this suggests that 
labile proteins may reduce the stability of TNFa mRNA and that gene activation can 
occur in the absence of protein synthesis presumably via modification of pre-existing 
cellular factors and the inhibition of repressor protein synthesis (Sariban et al. 1988; 
Chung et al. 1992; Collart et al. 1986). Such factors may include NF-kB which is 
activated by the phosphorylation and subsequent cleavage of an inhibitory factor I-kB. 
The TNFa gene promoter region contains NF-kB binding motifs which on activation 
by active NF-kB induces gene transcription (Collart et al. 1990). Another factor 
controlling gene expression is the regulation of mRNA stability. A region of 
3’-untranslated TNFa mRNA contains a long U + A exclusive region bearing 
overlapping and repeating octameric elements (UUAUUUAU) which is similar to 
3’-untranslated sequences in other cytokine mRNAs. Using gene constructs it has been 
shown that the A U region is involved in mRNA destabilisation and enhanced
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translation efficiency (Shaw & Kamen, 1986; Caput et a l 1986; Han et al. 1990). Due 
to TNFa biosynthesis being regulated at several levels it is perhaps not surprising that 
the agents capable of altering TNFa production are highly diverse, an abridged list is 
shown in table 1.2.
Table 1.2: An abridged list of agents capable of modulating TNFa production.
Induction of TN Fa production
Agent type example reference
Cytokines TNFa (Philip & Epstein, 1986)
interferon-y (IFNy) (Philip & Epstein, 1986)
IL-1 (Philip & Epstein, 1986)
IL-2 (Nedwin et al. 1985)
Drugs and inducers of PKC (phorbol esters) (Sariban et a l  1988)
biologically leukotrienes (Dubois etal. 1989)
active lipids platelet activating factor (PAF) (Dubois e ta l  1989)
Parasite products malaria exoantigens (Bate e ta l  1988)
Viruses influenza virus (Beutler et a l  1986b)
Bacterial LPS (Beutler et a l  1986a)
products Borrelia burgdorferi (Radolf e ta l  1991)
Suppression of TN Fa production
Agent type example reference
Cytokines IL-4 (Hart e ta l  1991)
IL-6 (AderkaetaZ. 1989)
TGF-p (Chantry et a l  1989)
Drugs and lipooxygenase inhibitors (Dubois e ta l  1989)
biologically dexamethasone (Beutler et a l  1986a)
active lipids phosphodiesterase inhibitors e.g. pentoxifylline (Doherty et a l  1991)
inhibitors of NF-kB (Takasuka et a l  1995)
cyclosporin A (Espevik e ta l  1987)
Viruses Epstein-Barr (Gosselin et a l  1991)
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1.1.3 Biosynthesis and processing of TNFa
TNFa is synthesised as a 26kDa, type II cell-surface associated, propeptide 
anchored to the cell membrane by an NH2 -terminal hydrophobic domain (Kriegler et 
al. 1988). In human cells mature TNFa is produced following the proteolytic cleavage 
of the membrane bound 233 amino acid protein resulting in the secretion of a 157 
amino acid 17kDa peptide (Jue et a l 1990). The enzyme or enzymes responsible for 
this process, termed TNFa converting enzyne (TACE) have yet to be fully 
characterised but have recently been cloned (Black et al. 1997; Moss et al. 1997). 
Both the transmembrane and mature protein are biologically active. Elegant studies by 
Perez et al (Perez et al. 1990) using transmembrane TNFa mutants which were 
resistant to proteolytic processing showed that the membrane form mediated tumour 
and virus-infected cell cytotoxicity by cell to cell contact. Further studies have 
implicated the membrane bound form of TNFa as a mediator of cell-cell interaction in 
co-stimulatory signalling for B lymphocyte activation by T lymphocytes (Aversa et al. 
1993). Secreted mature TNFa is active as a noncovalently associated homotrimer, the 
lack of biological activity induced by the monomeric form has been ascribed to the 
decreased affinity of a monomer for the receptor (Smith & Baglioni, 1987). Crystal 
structure resolution suggests that each monomer contains an elongated, antiparallel 
p-pleated sheet which displays the topology of the classical viral “jelly-roll” (Jones et 
a l 1989). A diagrammatic sketch of the homotrimer is shown in figure 1.1.
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Figure 1.1: Ribbon representation of the trimeric form of human TNFa. 
Individual subunits are coloured green, red and blue. The NH2-termini are 
marked by blue spheres and the COOH-termini by red spheres. The yellow 
spheres (near the top of the molecule) represent disulphide bridges. (From Jones 
etal. 1989).
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1.1.4 TNF a  receptors
TNFa binds to at least two types of receptor, the p55 receptor (also referred to 
as the p60 receptor, TNF receptor I, high affinity receptor and the TNF receptor type 
B) and to the p75 receptor (also referred to as the p80 receptor, TNF receptor II low 
affinity receptor and the TNF receptor type A) these having molecular weights of 
approximately 55kDa and 75kDa respectively (Loetscher et al. 1990; Lewis et al. 
1991; Gray et al. 1990). The two types of receptor mediate both overlapping and 
nonoverlapping functions (Tartaglia et al. 1991; Tartaglia & Goeddel, 1992b). The 
distribution of TNFa receptors is believed to be wide spread, being present to varying 
extents on virtually all cells except red blood cells. These receptors are members of 
large family of receptors which are all characterised by common cysteine-rich domains 
(3-6 domains/molecule) in the extracellular portion of the receptor and include; Fas, 
CD27, nerve growth factor receptor and TNFR-rp (Smith et al. 1990). Typical of all 
the members of this family p55 and p75 have distinct cytoplasmic domains. One 
exception is a short section of the p55 cytoplasmic domain which has homology with 
the Fas receptor (28% homology over 65 amino acids) (Tartaglia et al. 1993). 
Mutations of both the Fas and p55 receptor have indicated that this region is involved 
in the signal mediation of target cell apoptosis and cytotoxicity, respectively, and is 
referred to as the death domain (Tartaglia & Goeddel, 1992a; Tartaglia et al. 1993).
Results from crystal structure resolution of homotrimeric TNFP binding to the 
p55 receptor (Banner et al. 1993) and multi valent anti-TNF receptor antibodies 
mediating TNFa cytotoxicity (Engelmann et al. 1990) support a putative mechanism 
that on the binding of secreted TNFa homotrimer to the receptor, receptor clustering 
occurs with the trimer binding to 3 receptors and stabilising the complex (Banner et al. 
1993). If receptor clustering is required for optimum receptor signalling it can be 
postulated that this would render the monomeric form, which is unable to induce 
receptor clustering, less active than the oligomeric forms of TNFa. This would be in 
accordance with the findings of Smith & Baglioni, 1987 that monomeric TNFa lacks
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biological activity. The signalling events which occur following receptor activation are 
complex and not at present fully understood. Unravelling this complex signalling 
pathway to establish how the stimulation of a TNFa receptor can induce such diverse 
cellular responses is an expanding area of TNFa biology. TNFa receptor stimulation 
has been shown to recruit TNF receptor associated factors (e.g. TRAF-1, -2) to the 
receptor complex and subsequently induce the activation of various signalling 
pathways including serine/threonine kinases (e.g. protein kinase C (PKC) and 
extracellular signal-regulated kinases (ERK)), protein tyrosine kinases (e.g. mitogen- 
activated protein kinase (MAP)), acidic and neutral sphingomyelinase, phospholipase 
A2, transcription factors (e.g. NF-kB, AP-1). Although signalling will not be described 
in detail in this report a possible signalling pathway is shown in figure 1.2 and 
reference should be made to reviews and references in Beutler & Van Huffel, 1994; 
Warzocha et al. 1994 and Aggarwal & Natarajan, 1996.
Like TNFa, receptor expression has been shown to be regulated by a wide 
variety of agents with the modulation being cell type dependent. For example LFNy is 
capable of either upregulating and downmodulating receptor expression in different 
cell types (Aggarwal et al. 1985a; Drapier & Wietzerbin, 1991). The mechanisms for 
inducing up- and down-regulation are unclear, although both appear to involve protein 
phosphorylation. Receptor shedding is a major pathway for the downregulation of 
receptor expression and although the proteases responsible have not yet been 
identified metalloproteases have recently been implicated (Crowe et al. 1995; 
Mullberg et al. 1995). Interestingly, TNFa can regulate expression of its own receptor. 
(Higuchi & Aggarwal, 1994) showed that in histiocytic lymphoma U-937 cells TNFa 
induced the internalisation of the p55 receptor whereas the p75 form was secreted into 
the external environment. Conversely, in a human epithelial cell line it was 
demonstrated that TNFa could upregulate the expression of the p75 but not the p55 

















Figure 1.2: A schematic diagram to represent potential signalling pathways activated 
following activation of the p55 and p75 TNFa receptors. Both receptors are linked to 
PLA2, PC-PLC and SMase ultimately resulting in gene induction by the pathways 
shown. The transcription factor NF-kB heterodimer is bound to an inhibitor protein, 
I-kB, which blocks the dimer’s translocation to the nucleus. Phosphorylation and 
proteolysis of I-kB resulting in the activation of N F-kB involves multiple 
intermediates including ceramide, serine kinase, protein phosphatase and protein 
kinase. The transcription factor AP-1, which consists of homodimers (jun proteins) or 
heterodimers (jun and fos  proteins) is also activated by TNFa.
AA, arachidonic acid; AP-1 and NF-kB are both transcription factor complexes, A-SMase, acidic 
sphingomyelinase; CAPK, ceramide activated protein kinase, DAG, diacylglycerol; I-kB, inhibitor of 
N F-kB; LT, leukotrienes; PC, phosphatidylcholine; PC-PLC phosphatidylcholine-specific 
phospholipase C; PG, prostaglandins; PL, phospholipid; PLA2, phospholipase A2; PKC, protein kinase 
C, p50+p65; proteins o f NF-kB complex; N-SMase, neutral sphingomyelinase; SM, sphingomyelin; 
TRAF-1, -2, TNF receptor associated factor-1, -2; TRADD, TNF receptor associated death domain; 
5-HPETE, 5-hydroperoxyeicosatetraenoic acid; black area of p75 receptor, death domain.
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Soluble fragments of the TNFa receptors were initially isolated and purified as 
TNFa binding proteins (TNFa-BP) in the urine of patients with febrile illnesses or 
serum of patients with cancer (Seckinger et al. 1997; Gatanaga et al. 1990). Sequence 
analysis of TNFa-BP showed that the two proteins were the extracellular domains of 
the p55 and p75 receptors (Gray et al. 1990; Lantz et al. 1990a; Seckinger et al. 1990; 
Schall et al. 1990). Proteolytic cleavage of the membrane-bound receptors to produce 
soluble receptors (p55-sR and p75-sR) reduces both the level of cellular expression 
and the circulating levels of the active TNFa protein by the binding of the soluble 
receptors to TNFa, hence receptor shedding decreases the biological response by two 
mechanisms. In addition to this inhibitory effect, it is thought that the dissociation of 
bound TNFa from the soluble receptors may be capable of maintaining circulating 
TNFa at a biologically active level (Aderka et al. 1992; Bemelmans et al. 1993a; Van 
Zeeeta l. 1992).
1.1.5 Biological activity and disease pathogenesis
As described earlier during the cloning and purification of TNFa two diverse 
functions for the protein were discovered, these being the necrosis of tumours and 
regulating lipid metabolism during infection (hence the name cachectin). The 
production of the recombinant protein has lead to extensive studies of the activity of 
TNFa in in vitro and in vivo systems, the results from which have established a role 
for TNFa in the physiological and pathological state. It is believed that TNFa is 
important in a variety of normal physiological processes including embryogenesis 
(reviewed in Wride & Sanders, 1995), hematopoiesis (Jacobsen et al. 1992) and 
inflammation. However it is thought that the distinction between the physiological and 
pathological states may be due to the local TNFa concentration (Kunkel et al. 1989). 
At low levels TNFa acts to maintain/promote cellular and tissue homeostasis. By 
increasing the level, as in the case of a local tissue injury a controlled immune
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response is orchestrated to repair the tissue, but if the concentration is further 
increased a pathological state is reached.
With the wide distribution of receptors TNFa can stimulate virtually any cell 
type acting in an autocrine and paracrine fashion. Following activation TNFa induces 
a range of biological activities including the alteration of growth, differentiation and 
metabolism of a variety of cell types. These effects are cell dependent, for example 
proliferation is induced by TNFa in fibroblasts (Vilcek et a l 1986) but suppressed in 
endothelial and keratinocyte cell cultures (Pillai et al. 1989; Schweigerer et al. 1987). 
This broad range of actions is reflected in the diverse pathological conditions in which 
TNFa is implicated. One of the first documented pathological roles for TNFa was as a 
major mediator of the lethal metabolic effects of endotoxin-mediated (septic) shock 
(Beutler et a l  1985b). The administration of TNFa to rats induces shock syndrome 
symptoms, hypotension, tachypnea, metabolic acidosis, hyperglycemia followed by 
hypoglycemia, and multiple end-organ damage with death usually resulting from 
respiratory arrest . Latterly, the involvement of TNFa has been suggested in two 
extreme conditions of body weight: cachexia and obesity. TNFa can modulate the 
metabolic activities of adipocytes suppressing lipoprotein lipase activity, reducing 
adipose tissue lipid accumulation and leading to the wasting associated with cachexia, 
and the inhibition of insulin-stimulated glucose uptake observed in obesity-related 
insulin resistance (Hotamisligil et a l 1993).
TNFa has both peripheral and central effects. Although only low amounts of 
TNFa cross the blood-brain barrier (Beutler et a l 1985) cells within the central 
nervous system (CNS) are capable of producing the protein (Robbins et a l  1987). 
TNFa stimulation of the CNS can produce anorexia (Moldawer et a l 1988), changes 
in sleep patterns, pyrogenic responses (fever) (Dinarello et a l 1986), induction of the 
release of adrenocorticotropic hormone and prolactin from the pituitary (Milenkovic et 
a l  1989). Furthermore the overproduction of TNFa by cells within the CNS may be
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detrimental to the integrity of the blood brain barrier as TNFa is cytotoxic to 
oligodendrocytes, the myelin producing cells, which may facilitate demyelination 
(Selmaj & Raine, 1988) in, for example, multiple sclerosis.
Table 1.3: A partial list of the responses mediated by TNFa which may be 
involved in inflammatory responses.
Cell type Responses mediated by TNFa Reference
Endothelial
cell
Rearrangement of the cytoskeleton to increase vascular 
permeability
Coagulation (via down modulation of 
thrombomodulin) to generate thrombin and fibrinogen 
to induce cell contraction
Increased expression of adhesion molecules (E-, 
P-selectin, ICAM-1, VCAM-1)
Induction of bioactive mediators (e.g. IL-1, PAF, 
PGI2) and nitric oxide synthase
Induction of chemokine expression (e.g.IL-8, MCP-1)
(Brett etal. 1989) 
(Nawroth & Stem, 1986)
(Mantovani etal. 1992)
(Naworth et a l 1986; 
Camussiefa/. 1987; 
Kawakami et al. 1986) 
(Brown etal. 1994)
Increased cell surface antigen expression (Pober et al. 1986; Collins et 
al. 1986)
Leukocytes Induction of bioactive mediators (e.g. IL-1, PAF, 
TNFa, leukotrienes, prostaglandins, chemokines) 
Stimulates phagocytosis and cellular degranulation 
Increase MHC expression
Induced superoxide production, release of lysozyme 
and hydrogen peroxide
(Shalaby et al. 1985; 
Klebanoff et al. 1986) 
(Shalaby et al. 1985) 
(Perlmutter et al. 1986) 
(Tsujimoto et al. 1986; 
Klebanoff et al. 1986)
Resident 
tissue cells
Induction of bioactive mediators (e.g. EL-1, PAF, 
RANTES, MCP-1, IL-8) and nitric oxide synthase
Cellular proliferation 
Acute-phase protein synthesis 
Bone and cartilage resorption
(Lukacs et al. 1995a; Le et al. 
1984; Robson et al. 1995; 
Jordan et al. 1995; Jordan et 
al. 1996)
(Vilcek etal. 1986) 
(Perlmutter et al. 1986) 
(Saklatvala, 1986; Bertolini 
etal. 1986)
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Perhaps the most important role of TNFa is as a primary mediator of 
inflammation. It is widely hypothesised that an inflammatory response is initiated, 
maintained and resolved via the interplay of the cytokine network. TNFa, thought to 
be an integral part of this network, is capable of inducing many of the events which 
are associated with inflammation as described in table 1.3. In addition to the indirect 
recruitment of leukocytes via increased vascular permeability, enhanced adhesion 
molecule expression and the induced release of chemoattractants and inflammatory 
mediators, TNFa also influences tissue remodelling. Tissue remodelling may 
potentiate the inflammatory condition by stimulating bone and cartilage reabsorption 
(Saklatvala, 1986; Bertolini et a l  1986) or help resolve the damage incurred during 
the inflammatory response by acting as a growth factor (Vilcek et al. 1986) and 
inducing the production of other cytokines which stimulate matrix production (Hajjar 
et al. 1987). Raised TNFa levels in body fluids have implicated the involvement of 
the protein in the pathogenesis of many inflammatory disorders including rheumatoid 
arthritis (Saxne et al. 1988), congestive heart failure (Levine et al. 1990), allograft 
rejection (Maury & Teppo, 1987), bowel necrosis (Tracey et al. 1986; Sun & Hsueh, 
1988), multiple sclerosis (Selmaj.K et al. 1991) and bacterial meningitis (Leist et al. 
1988).
1.1.6 Distribution and clearance of TNFa
TNFa release into the circulation following the administration of LPS has been 
extensively studied. Within minutes of endotoxin delivery there is a burst of serum 
TNFa that peaks in 1-2 hours and is rapidly cleared from the serum becoming 
undetectable by 4-6 hours, exhibiting a kinetic profile which is similar in most species 
(table 1.4). In these studies the rapid decline in TNFa bioactivity was not attributed to 
the presence of soluble TNFa-BP (Brittain et al. 1985; Remick et al. 1989), however 
increases in TNFa levels have been associated with increases in TNFa-BP (Spinas et 
al. 1990; Lantz et al. 1990b; Bemelmans et al. 1993a; Bemelmans et al. 1993b). 
Repeat administration of LPS two hours following the first injection failed to induce a
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second serum TNFa peak and a state of tolerance was induced (Ulich et al. 1990). In 
accordance with earlier in vitro studies (Beutler et al. 1986a), in vivo studies 
demonstrated that dexamethasone was only effective at reducing serum TNFa levels if 
administered concomitant or prior to LPS (Remick et al. 1989). In studies monitoring 
TNFa production at ascites, where there was a ten fold increase in TNFa levels 
compared with plasma concentrations, dexamethasone if administered at the site of 
inflammation reduced both the local production and systemic (serum) appearance of 
TNFa protein. Both protein and mRNA levels at the ascites were reduced by 
dexamethasone, however administration 20 minutes following LPS did not reduce 
TNFa levels in the ascitic fluid or in the serum (Remick et a l 1989). The regulation 
of the decline of serum TNFa levels is believed to involve corticosteroids as serum 
levels in LPS challenged adrenalectomised animals remain at elevated levels. In this 
situation TNFa concentration is though to persist because the corticosteroid feedback 
loop, which normal reduces TNFa biosynthesis, is incomplete (Bertini et al. 1988).
Table 1.4: A comparison of kinetics of TNFa following in vivo LPS challenge.
CFA: complete Freunds adjuvant.
Species Time of peak Priming Resolved to Route of LPS Reference
serum levels agent basal levels administration
rabbits 2 hours none 4-6 hours intravenous (Beutler et al. 1985)
mice 2 hours BCG 4 hours ? intravenous (Carswell et al. 1975)
1 hour none 4 hours intraperitoneal (Brittain et al. 1985)
1 hour CFA 4 hours intraperitoneal (Remick etal. 1989)
rats 1-2 hours none 4 hours intravenous (Ulich et al. 1990)
1-2 hours C. parvum 4 hours ? intravenous (Ulich et al. 1990)
Studies injecting radio-labelled TNFa in mice provided evidence that the 
serum half-life of the protein is short, approximately 6  minutes in mice, and it is
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rapidly (within 10 minutes of TNFa injection) concentrated in liver, skin, 
gastrointestinal tract, kidney and lung when administered via a peripheral vein. With 
the exception of lung and skin this accumulation was shown to be via TNFa specific 
binding sites (Beutler et al. 1985). Although a large amount of the administered TNFa 
was detected in the kidney only a small amount was observed in the urine as degraded 
products. The clearance of TNFa is thought to be via the kidney and liver. 
Experiments using nephrectomised mice (Bemelmans et al. 1993b) showed that 
following the administration of LPS the semm levels of TNFa peaked at 2 hours but 
the decline was slower than that observed in sham treated animals, with 
immunologically detectable levels still present 6  hours following challenge. It was 
suggested that this increase was accompanied by an increase in TNFa-BP as the 
bioactivity of the serum was similar to the serum levels of the sham treated animals 
and chromatography studies identified an immunological protein of 95kDa (possibly 
TNFa bound p75-sR). Similarly, following the administration of TNFa the biological 
activity, but not the immunological detectability, was rapidly removed from the 
circulation of nephrectomised animals. It would appear from studies following 
unilateral nephrectomy in mice that one functioning kidney is sufficient for the 
maintenance of normal TNFa clearance. The study by Bemelmans et al. 1993b, in 
agreement with others (Lantz et al. 1990a), implicated the involvement of the kidney 
in the clearance of TNFa and TNFa-sR from the circulation. Studies by Bemelmans et 
al. 1993a stress the importance of considering the methods used to measure TNFa 
levels when interpreting data. Although immunological detectable levels of TNFa 
(e.g. measured by ELISA) following LPS administration remained high the levels of 
biologically active TNFa rapidly returned to the level observed in control animals. 
This is due to immunological assays not distinguishing between the active and inactive 
(TNFa bound to the soluble receptor or fragmented TNFa) forms of TNFa, unlike the 
TNFa bioassays (e.g. WEHI 164 clone 13 cytolytic assay) which only measure 
biologically active TNFa.
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1.2 Airway inflammation and asthma
Under normal physiological conditions an inflammatory reaction is an 
appropriate response by the body to rid the host of invading pathogens, but when the 
control on this system is in some way disturbed the inappropriate release of mediators 
from cells can lead to the destruction of healthy tissue, and the onset of a disease state.
Asthma, an inflammatory disease of the airways, displays reversible 
obstruction of the bronchi and bronchioles causing varying extents of dyspnea 
resulting from the much reduced airflow in the lungs. Asthmatics are often divided 
into one of 3 types; 1) extrinsic asthma, where the agent initiating the asthmatic attack 
originates outside the body, with initially a classical Type I hypersensitivity reaction 
occurring (atopic). 2) occupational asthma which is mainly atopic and 3) intrinsic 
asthma not being allergenic in nature (Corrigan & Kay, 1992). An asthmatic attack 
comprises of 2  main components: bronchial hyperreactivity, with the airways 
exhibiting increased sensitivity to a variety of non-allergenic stimuli and a localised 
inflammatory reaction occurring within the lung.
The allergic component of asthma was noted in the early 1900s and an 
extensive study by Huber & Koessler (Huber & Koessler, 1922) revealed increased 
eosinophil levels in the blood, sputum and lung tissue of asthmatic patients. The 
eosinophil has been shown to have a prominent role in asthma as: ( 1 ) asthmatic 
patients exhibit an increased number of eosinophils in the bronchial secretion and lung 
tissue and an increase in activated or hypodense eosinophils in the peripheral blood 
(which is often correlated with disease severity) (Bousquet et al. 1990; Fukuda et al.
1985), (2) increased eosinophil-derived toxic mediators including major basic protein 
(Frigas et al. 1981) and eosinophil cationic protein (Bousquet et al. 1990) are present 
in asthmatic sputum. Apart from lung eosinophilia histological studies show that the 
asthmatic patients’ airway walls exhibit abnormal features; a degraded epithelium, a 
thickened basement membrane, increased intraluminal secretions and smooth muscle
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hypertrophy and hyperplasia (Huber & Koessler, 1922; Laitinen et al. 1985; Jeffery, 
1993; Dunnill, 1960; Barnes et a l 1988).
1.2.1 Allergic asthma
The allergic asthmatic attack consists of an early and late phase response with 
the first early phase response occurring within minutes of contact with the antigen, the 
agent to which the individual is sensitised. On initial exposure to the antigen an 
immune response occurs with the inappropriate synthesis of IgE antibodies. The total 
IgE level is much lower than the levels of other antibodies (in human serum 50- 
300ng/ml compared with lOmg/ml of IgG) however, the response is amplified via 
receptor activation (Sutton & Gould, 1993). The Fc region of IgE molecule binds to a 
high affinity receptor (FceRI) present on the surface of mast cells, basophils, 
eosinophils and activated monocytes (atopic individuals) (Soussi Gounni et al. 1994; 
Maurer et al. 1994) and to a low affinity receptor (FceRII) on a variety of cells, 
including B lymphocytes, T lymphocytes, eosinophils, macrophages and platelets. The 
bound IgE molecules act as receptors for the antigen. Cross linkage between the 
antigen and the cell bound IgE - FceRI, principally involving mast cells and basophils, 
triggers cellular degranulation and mediator release from cellular granules by 
modifying the cell membrane permeability and activating a series of intracellular 
signalling pathways. Both mast cells, resident within the lung, and basophils contain a 
vast array of preformed mediators as well as the capacity to synthesise and secrete 
other mediators including cytokines, chemokines and biologically active lipids (Galli, 
1993; Wodnar-Filipowicz et al. 1989; Plaut et al. 1989).
The released mediators exhibit an array of bronchoconstricting and 
inflammatory activities. Prior to the recognition of the involvement of cytokines 
eicosanoids were thought to be one of the major mediators of inflammation. The 
arachidonic acid metabolites leukotrienes (LT) C4 , LTD4 , LTE4 (then called the slow 
reacting substance of anaphylaxis) were suggested, in the 1940’s, to be released from
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sensitised tissue following antigen challenge (Kellaways & Trethewie, 1940). Elevated 
eicosanoid levels have been detected in the bronchoalveolar lavage (BAL) of atopic 
asthmatics (Lam et al. 1988; Liu et al. 1990), especially LTE4  (a metabolite of LTC4  
and LTD4 ), prostaglandin (PG) D2  and thromboxane (Tx) A2  all of which induce 
bronchoconstriction. Unlike LTD4  and LTE4 , which induce bronchconstriction within 
5 minutes, the effect of LTC4  is delayed occurring after 10-20 minutes (Drazen, 1988). 
Apart from inducing acute bronchoconstriction eicosanoids also exhibit inflammatory 
activities, for example PGD2 increases vascular permeability and LTB4  is a neutrophil 
and eosinophil chemoattractant (Ford-Hutchinson et al. 1980) both of which in turn 
enhance leukocyte accumulation. In the development of anti-asthmatic drugs much 
attention has also focused on two other mediators released from mast cells which 
demonstrate bronchoconstricting and inflammatory activities and are elevated in BAL 
from asthmatics, these being histamine (Casale et al. 1987) and platelet activating 
factor (PAF) (Averill et al. 1991; Wardlaw et al. 1986). Although Hi receptor 
antagonists reduce anaphylaxis they have a limited role in the management of asthma, 
currently various approaches are under investigation and in clinical trials ranging from 
selective phosphodiesterase isoenzyme inhibitors to 5-lipoxygenase inhibitors, specific 
PAF and leukotriene antagonists to more specific muscarinic receptor antagonists. At 
present several of these new therapies relieve bronchospasm but their ability to prevent 
the underlying inflammatory damage to the lung is limited.
1.3 Evidence for the role of cytokines in asthma
The presence of cytokines in allergic airway inflammation has been 
demonstrated in the bronchial fluid and lung sections from asthmatic individuals and 
animal models of the disease. Changes in cytokine levels have been investigated at 
mRNA and protein levels using various techniques including polymerase chain 
reaction (PCR) and in situ hybridisation. Studies of bronchial fluid and biopsy 
specimens from asthmatic patients have shown elevated levels of several cytokines 
including IL-1, IL-6 , (Borish et al. 1992; Mattoli et al. 1991; Marini et al. 1992) and 
TNFa (Gosset et al. 1991; Krishnaswamy et al. 1993; Cembrzynska-Nowak et al.
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1993). In addition, recently three chemoattractant cytokines have also been identified 
in the BAL of antigen challenged asthmatics, lymphocyte chemoattractant factor 
(IL-16), macrophage inflammatory protein (MlP)-la and IL- 8  (Cruikshank et al. 
1997; Yousefi et al. 1995).
Although the involvement of TNFa in asthma is acknowledged, the majority 
of studies have focused on the interrelationship between T lymphocyte derived 
cytokines, especially IL-5, and eosinophils. The activation of T lymphocytes is thought 
to be important in the late phase asthmatic response together with the recruitment of 
leukocytes into the lungs. Mature T lymphocytes are (mainly) divided into CD4+ and 
CD8 + populations based on surface expression markers. CD4+ T lymphocytes are 
activated by processed antigen presented by antigen presenting cells (APC), in 
particular dendritic cells in the airway mucosa (Holt, 1993), in association with major 
histocompatibility complex (MHC) class II molecules. Less efficient APC active in the 
lung include macrophage/monocytes, epithelial cells, B lymphocytes and fibroblasts. 
The importance of CD4+ T lymphocytes in antigen-induced pulmonary eosinophilia 
was demonstrated in antigen-challenged CD4+ depleted mice where eosinophil 
accumulation was completely abolished (Gavett et al. 1994). CD4+ lymphocytes are 
further divided into at least two sub-types, Thl and Th2. This classification is based 
on the profile of cytokines released following activation (Mosmann et al. 1986), Thl 
cells produce IL-2, TNFp, and interferon (IFN) y  and Th2 cells produce IL-4, IL-5, and 
IL-10. Both subsets produce IL-3, IL-13 and granulocyte-macrophage colony- 
stimulating factor (GM-CSF) (Mosmann et al. 1986, Minty et al. 1993).
Recently, a Th2-like cytokine profile in allergy and asthma has been indicated, 
implicating a role for Th2 lymphocytes (Robinson et al. 1992; Robinson et al. 1993). 
Both the BAL and the supernatant from peripheral blood T lymphocytes collected 
from allergic asthmatics have been shown to contain higher levels of IL-4 and IL-5 
than samples from normal individuals (Walker et al. 1992; Walker et al. 1991). 
Furthermore, in situ hybridisation techniques have demonstrated increased IL-3,
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GM-CSF, IL-4 and IL-5 mRNA in BAL cells from atopic asthmatics (Robinson et a l 
1993). Asthmatic lung biopsies revealed that the IL-5 mRNA was localised to the 
inflammatory cells in the bronchial mucosa (Hamid et al. 1991). The Thl derived 
cytokines, IL-2 and BRNy, were unchanged or only marginally increased in asthmatic 
subjects at the mRNA and protein levels when compared with normal subjects 
(Robinson et al. 1992; Robinson et al. 1993; Walker et al. 1992). In addition, the 
expression of IL-3 and GM-CSF, hematopoietic growth factors which are linked to the 
activation and enhanced survival of eosinophils (Rothenberg et al. 1988; Owen et a l 
1987), is increased in asthmatic subjects (Robinson et al. 1992; Kato et a l  1992; 
Broide & Firestein, 1991). Figure 1.3 shows a diagrammatic representation of the 
potential central role of Th2 lymphocytes in the propagation of the inflammatory 
response following antigen stimulation. Furthermore the importance of Th2 
lymphocytes was indicated by the inhibition of antigen-induced BAL eosinophilia 
together with IL-4 and IL-5 production following the administration of IL-12 (Gavett 
et a l 1995), a cytokine which favours Thl expression by suppressing the production 
of Th2 lymphocytes and Th2 cytokines (Manetti et a l 1993). The role of IL-4 and 
IL-13 is unclear but these cytokines are believed to be of importance in allergic 
reactions. IL-4 is a regulating factor in the commitment of naive T lymphocytes to the 
Th2 phenotype, which favours the initiation of an immediate antibody reaction 
(Anderson & Coyle, 1994). In addition to promoting the Th2 phenotype, IL-4 and 
IL-13 also promote isotype switching increasing B lymphocyte production of IgE and 
IgG4 (Snapper & Paul, 1987; Punnonen et a l 1993). Furthermore, IL-4 and IL-13 
have demonstrated anti-inflammatory activities e.g. IL-4 and IL-13 inhibit monocyte 
/macrophage production of IL-1, TNFa and chemokines following LPS stimulation of 
the cells (Hart et a l 1991; Minty et a l 1993).
Once recruited to the lung tissue the eosinophils may then be primed by the 
eosinophil stimulating factors IL-3, GM-CSF and IL-5 released from the T 
lymphocytes. IL-5, a weak eosinophil chemoattractant (Wang et a l 1989), is of 
particular interest as unlike IL-3 and GM-CSF it promotes the selective differentiation
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of myeloid cells into eosinophils (Campbell et a l 1988). IL-5 is also of importance as 
it prolongs eosinophil survival (Tai et al. 1991) and following IL-5 priming of the 
cells eosinophil release of cytotoxic products is enhanced (Coeffier et al. 1991). 
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Figure 1.3: Diagram indicating the potential involvement of Th2 lymphocytes in the 
propagation of the allergic inflammatory response. Processed antigen is presented, 
by APC, in association with MHC class II molecule to Th2 lymphocytes. Released 
Th2-derived cytokines increase IgE production which promotes antigen-induced 
mast cell degranulation, and increase eosinophil activation and survival.
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eosinophilia. Several studies have provided evidence that the administration of 
anti-EL-5 antibodies in asthmatic models reduces antigen induced lung eosinophil 
infiltration and bronchial hyperreactivity (Nagai et al. 1993; Van Oosterhout et al. 
1993a; Gulbenkian et al. 1992; Chand et al. 1992; Mauser et al. 1993). Similarly, 
recombinant human IL-5 induces both lung eosinophilia and mild bronchial 
hyperreactivity (Fattah et al. 1990; Van Oosterhout et al. 1993b). Ohnishi (Ohnishi et 
al. 1993b; Ohnishi et al. 1993a) showed that following antigen challenge, the BAL 
from allergic subjects contained an activity which prolonged eosinophil survival in 
culture which was reduced by co-incubating the eosinophils with antibodies to IL-5 
and this activity was correlated with eosinophil recruitment, degranulation and lung 
injury. It is also possible that as the local IL-5 concentration rises within the lung, 
significant levels of IL-5 could enter the circulation and induce a transient blood 
eosinophilia which could account for the high tissue eosinophil numbers. In support of 
this theory Collins et al. (Collins et al. 1995) have shown that after administration of 
IL-5 there is an increase in blood eosinophil numbers but a decrease in bone marrow 
levels.
In addition to neutralising antibodies, receptor antagonists have also become a 
useful tool in establishing the role of specific cytokines in animal models. The 
administration of an IL-1 receptor antagonist (IL-lra) reduced antigen-induced lung 
eosinophil accumulation and bronchial hyperreactivity (Watson et al. 1993; Selig & 
Tocker, 1992). IL-lra is a naturally occurring member of the IL-1 family which 
competes with IL-1 for the IL-1 receptor (reveiwed by Lennard, 1995). Interestingly, 
following aerosol administration of IL-lra to antigen challenged guinea-pigs, TNFa 
bioactivity in the lung lavage was also reduced (Watson et al. 1993). This suggests 
that there is an interrelationship between these two pro-inflammatory cytokines and 




In order for cells to migrate from the post capillary venules to the inflammatory 
site a series of events is required; rolling, activation and firm adhesion, diapedesis, and 
migration. For initial binding between the leukocyte and the vascular endothelium the 
leukocyte velocity must be reduced allowing the cells to roll along the endothelium. 
The phenomenon of cellular rolling is mediated by a family of adhesion molecules, 
called selectins (Lasky, 1992), which form loose tethering bonds between leukocytes 
and endothelial cells. The family comprises of transmembrane glycoproteins 
characterised by an NH2 -terminal lectin-like domain, an epidermal growth factor-like 
region and a number of complement regulatory protein repeat sequences. To date, 
three selectins have been identified E- selectin (endothelial), P-selectin (platelet) and 
L-selectin (leukocyte), the cellular expression and ligands for these proteins are 
summarised in table 1.5. The formation of loose interactions reduces the leukocyte 
flow velocity allowing the leukocytes to adhere strongly to the endothelium.
Firm adhesion is mediated via the interaction between two families of adhesion 
proteins, integrins and their immunoglobulin supergene family ligands (Albelda & 
Buck, 1990; Hynes, 1987). The integrins are a large family of transmembrane 
heterodimeric glycoproteins consisting of two non covalently linked a  and (3 subunits. 
There are at least twelve different a  subunits and eight different p subunits which 
associate to form at least fourteen different integrins. The p2 integrins share a 
common P chain (CD 18) and their expression is restricted to leukocytes, hence they 
are also known as leukocyte integrins. Three a  subunits are associated with CD 18, 
namely CD 11a, CD lib  and CD 11c forming the integrins LFA-1, Mac-1 and pi 50,95 
respectively. Each a  subunit glycoprotein is similar in structure, having a NH2 - 
terminal signalling region, a relatively short cytoplasmic region and three putative 
divalent cation binding sites in the extracellular domain indicating the requirement of 
Ca2+ and Mg2+ for integrin function (Springer, 1990).
Table 1.5: A summary of the selectin adhesion molecules required for the rolling phenomena displayed in leukocyte-endothelium
adhesion.
Selectin Expression Expression Time Regulation Ligand Ligand
expression
Reference
L- leukocytes constitutively expressed receptor shedding following 
cellular activation
carbohydrate, e.g. 
sialyated Lewis a and x
endothelial
cells
(Kishimoto et al. 
1989)




rapid, transient expression, 
translocated to surface -10 
minutes, preformed and stored in 
endothelial Weibel-Palade bodies, 
platelet a  granules)















de novo synthesis induced by 
TNF, IL-1, and LPS
carbohydrate, e.g. 
sialyated Lewis a and x
leukocytes (Montgomery et al. 
1991)
(Bevilacqua et al. 
1985)




The pi (CD29) integrins are mainly receptors for extracellular matrix proteins 
including fibronectin and collagen. The principle pi integrin involved in leukocyte 
adhesion is very late antigen (VLA)-4 (a4/pi, CD49d/CD29) which mediates cell-cell 
interactions in addition to fibronectin binding. VLA-4 is of particular interest in 
diseases which exhibit eosinophilia, such as asthma, as it is expressed constitutively 
on all leukocytes with the exception of neutrophils (Elices et al. 1990).
It appears that integrins are indirectly associated with the cytoskeletal actin 
filaments via a linkage involving talin, vinculin and other cytoskeletal associated 
molecules (Burridge et al. 1988). Integrin-induced changes in the cytoskeleton may be 
involved in the conformational changes in the extracellular domains of the integrin 
resulting in firm adhesion and a high avidity state ligand (Pardi et al. 1992). 
Cytoskeletal activation requires the p subunit and is possibly regulated via a tyrosine 
phosphorylation site in the cytoplasmic domain of pi and P3 subunits (Tamkun et al.
1986). It has been postulated that phosphorylation results in the formation of a core of 
actin polymerisation and a polarised leading leukocyte edge which is in strong 
connection with the endothelial cell (Pardi et al. 1992). Integrin activation would 
therefore promote firm adherence to the endothelium by bond formation and by 
inducing leukocyte shape changes resulting in increased contact surface area of the 
cell.
The counter-ligands for the integrins are members of the immunoglobulin 
supergene family (Springer, 1990). Several members of this family are expressed by 
endothelial cells and are involved in leukocyte adhesion, these include intercellular 
adhesion molecule (ICAM)-l, -2 and vascular cell adhesion molecule (VCAM) -1. 
The interactions between integrins and their ligands are summarised in table 1.6. As 
VLA-4 binds to VCAM-1 this provides an alternative pathway for firm leukocyte 
adhesion which does not utilise CD ll/CD 18. The presence of eosinophils and 
mononuclear leukocytes, but not neutrophils, in inflamed tissue from patients
Table 1.6: A summary of integrin-immunoglogulin superfamily adhesion molecules required for firm leukocyte-endothelium adhesion.
Ligand Ligand expression Expression Time Regulation Integrin Expression reference












ICAM-2 monocytes, endothelial 
cells
constitutive LFA-1 (Staunton et al. 1989)
VCAM-1 endothelial cells, 
monocytes
6 hours-1 week 
peak 24 hours
induced by TNF, IL-1, LPS 
selectivley induced by IL-4
VLA-4 constitutively on 
leukocytes except for 
neutrophils (activatable)
(Osborn etal. 1989) 
(Elicesefa/. 1990) 
(Munoz etal. 1991)
Alternative names for integrin molecules: LFA- 1  CD 11 a/CD 18
Mac-1 CDllb/CD18 a M/p2
VLA-4 CD49d ai/p!
Introduction 29
suffering from leukocyte adhesion deficiency syndrome (LAD) type I (Anderson et al. 
1985), caused by a defected |32 subunit (Springer et al. 1984), reiterates the 
importance of this alternative pathway.
Once leukocytes have firmly adhered to the endothelium and diapedesed into 
the extracellular space by a process involving the cyclic modulation of integrin 
receptor avidity, they move to the inflammatory foci by chemotaxis. The leukocyte 
movement is directed by chemoattractants many of which are not leukocyte subtype 
selective, these include PAF, LTB4  and C5a. Recently much attention has focused on 
the low molecular weight, leukocyte selective chemotactic cytokines, chemokines. 
These chemoattractants can be divided into distinct supergene families, C-X-C, C-C, 
and the recently identified C and C-X-X-X-C families, designated by the position of 
the first cysteine amino acid residue (Westwick et al. 1991; Bazan et al. 1997). The 
C-X-C chemokines are primarily chemotactic for neutrophils and are typified by IL-8 , 
whereas the C-C family are principally chemotactic for mononuclear cells and 
eosinophils. Monocyte chemoattractant protein (MCP)-l, -2, -3, macrophage 
inflammatory protein (MIP)-lot/p and RANTES are all members of the C-C 
chemokine family. It has been proposed that chemokines use a hapatotactic 
mechanism by binding to glycosaminoglycan molecules present on endothelial cell 
surfaces (Rot, 1992). In vitro studies have suggested that the binding of chemokines to 
glycosaminoglycan molecules influences their effect on target cells. Webb et al. 
(Webb et al. 1993) demonstrated that the binding of IL- 8  to heparin/heparan sulphate 
enhanced neutrophil responses and Tanaka (Tanaka et al. 1993) provided evidence 
that the C-C chemokine MIP-lp when bound to proteoglycan induces T lymphocyte 
adhesion. In addition to the chemotactic properties chemokines also directly effect 
leukocyte adhesion, IL- 8  is capable of enhancing neutrophil adherence to endothelial 
cells by the upregulation of integrins (Carveth et al. 1989) and inducing the shedding 
of L-selectin (Detmers et al. 1990).
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Once recruited to the airways, the leukocytes may be activated by antigen (via 
FceRI/II) or agonist stimulation to induce the production of an array of inflammatory 
mediators. These substances can amplify the inflammatory response by promoting 
further leukocyte infiltration. Neutrophils, monocytes/macrophages (both phagocytic 
cells), and eosinophils are capable of generating numerous toxic substances, 
principally to remove foreign bodies but if inappropriately released these are often 
toxic to the surrounding tissue (Weiss, 1989; Gleich et al. 1988) and can destroy the 
architecture of the lung.
1.4 Animal model of airway inflammation
The OA sensitised guinea-pig demonstrates the characteristic features of 
asthma: bronchial hyperreactivity to a non-allergenic agent and lung inflammation 
with a pronounced lung eosinophilia. The guinea-pig is a classical model of allergic 
airway disorders which has been used by various workers since the early 1900’s 
(Samter, 1949; Popa et al. 1973; Lefort & Vargaftig, 1978; Sanjar et al. 1990a). 
During this time several guinea-pig models of asthma have been developed focusing 
on both the early and late responses (Hutson et al. 1988; Iijima et al. 1987), and on 
airway hyperreactivity (Ishida et al. 1989) and lung eosinophilia (Dunn et al. 1987) 
induced by antigen or environmental / occupational stimuli. However, controversy 
about the realistic nature of the model arose as the primary antibody in guinea-pigs is 
IgGi whereas in man it is IgE. Andersson produced evidence that guinea-pig IgE 
levels could be increased by sensitising the animals using low antigen concentration in 
combination with aluminium hydroxide via intraperitoneal injection (Andersson, 
1980a; Andersson & Bergstrand, 1981; Andersson & Brattsand, 1982; Andersson, 
1982). He and others later demonstrated that this effect could be further enhanced by 
repeat administration of sensitisation solution over a period of weeks and by the 
administration of cyclophosphamide prior to the initial sensitisation (Andersson, 
1980b; Andersson, 1981; Graziano et al. 1981). Ishida (Ishida et al. 1989) produced 
high IgE titers by incorporating Bordetella pertussis vaccine into the sensitisation 
solutions.
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Various protocols have been used to produce antigen-induced airway 
inflammation, but important differences exist between individual models, in particular 
the routes of allergen sensitisation and challenge i.e. depot injection (as used by 
Andersson) or aerosol inhalation (Boichot et al. 1991; Ishida et al. 1989). Whereas in 
humans, inhalation of airborne allergens is a natural route for both sensitisation and 
challenge, delivery of aerosol antigen to guinea-pigs presents a problem as they are 
obligate nose breathers. It is predicted that 80% of the aerosol inhaled by conscious 
free breathing guinea-pigs is deposited in the nose with less than 1 2 % being 
demonstrable in the lungs (Varley et a l 1991). Despite the methodological variations 
the antigen (notably OA) sensitised guinea-pig has been used extensively to assess the 
efficacy and mechanisms of action of potential anti-asthmatic drugs (Sanjar et al. 
1990a; Havill et al. 1990; Sanjar et al. 1990b; Schellenberg et al. 1991; Manzini et al. 
1993). In addition to the antigen sensitised guinea-pig, recently several other species 
have been used as models of antigen-induced airway inflammation including mouse 
(Lukacs et al. 1995c), rat (Sertl et al. 1988), rabbit (Marsh et al. 1985), sheep 
(Abraham et al. 1994), dogs (Chung et al. 1985) and primates (Wegner et al. 1990).
1.5 Aims of this project
The aim of this project was to assess the activity of TNFa in vivo and to 
investigate the role of TNFa in airway inflammation. Throughout this project guinea- 
pig models were used hence, in order to eliminate species selectivity, recombinant 
guinea-pig TNFa (gpTNFa) was produced. gpTNFa cDNA was cloned into E. coli 
and gpTNFa expressed and purified. gpTNFa was administered to non-sensitised 
(naive) animals and lung leukocyte accumulation characterised. Changes in bronchial 
hyperreactivity, airway leukocyte accumulation, the production of chemokine-like 
activity in the lung and airway TNFa levels in antigen-sensitised animals were 
investigated. Finally the effects of administering inhibitory cytokines and a TNFa 
antibody to animals, which were either antigen-sensitised or treated with gpTNFa, 
were examined.
2. Materials & 
Methods
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2.1 Materials
All items were purchased from Sigma Chemical Company Ltd., Poole, Dorset UK. 
unless otherwise stated.
2 -mercaptoethanol 
Aluminium hydroxide (F2200) 
anti DIG-AP Fab fragments 
Antibodies:
Monoclonal Hamster anti murine 
TNFa (IgG)
Polyclonal Goat anti murine TNFa 
(IgG)
Polyclonal Rabbit anti murine TNFa 
(sera)















BDH Laboratory Supplies Ltd., Lutterworth, UK 
Reheis Ireland, Dublin, Ireland 
Boehringer Mannheim Uk Ltd., Lewes, UK
gift from Celltech, Slough, UK
gift from Celltech, Slough, UK
gift from S. Kunkel Ann Arbor, USA
gift from DAKO Ltd., High Wycombe, UK
Calbiochem Novabiochem Ltd., Nottingham, UK 
Wellcome Foundation, Bechenham, UK 
Solvay -Duphar Veterinary, Southampton, UK 
Fisons Pharmaceuticals, Loughborough, UK 
BOCLtd., Guildford, UK 
Bio-Rad Laboratories, Hemel Hempstead, UK 
Bio-Rad Laboratories, Hemel Hempstead, UK 
Boehringer Mannheim Uk Ltd., Lewes, UK 
Boehringer Mannheim Uk Ltd., Lewes, UK 
BDH Laboratory Supplies Ltd., Lutterworth, UK 
Boehringer Mannheim Uk Ltd., Lewes, UK 
University of Bath, UK 
Novex Experimental Technology, San Diego,










HBSS without calcium, magnesium
and phenol red












Polymyxin B columns 
Platelet activating factor 
pMAL™-2 protein fusion and 
purification system 
PolyScreen PVDF transfer 
membrane 
Protogel
USA (distributed by R&D systems)
Fisons Pharmaceuticals, Loughborough, UK 
New England Biolabs Ltd., Hitchin, UK 
Gibco Life Technologies Ltd., Paisley, UK 
Calbiochem Novabiochem Ltd., Nottingham, UK 
May and Baker Ltd., Dagenham, UK 
Fisons Pharmaceuticals, Loughborough, UK 
Fisons Pharmaceuticals, Loughborough, UK 
Gibco Life Technologies Ltd., Paisley, UK 
Gibco Life Technologies Ltd., Paisley, UK
Gibco Life Technologies Ltd., Paisley, UK 
Gibco Life Technologies Ltd., Paisley, UK 
Fisons Pharmaceuticals, Loughborough, UK 
BDH Laboratory Supplies Ltd., Lutterworth, UK 
ECACC, Wiltshire, UK 
R. A. Lamb Laboratory Supplies, London, UK 
Fisons Pharmaceuticals, Loughborough, UK 
Premier Brands UK Ltd., Stafford, UK.
Fisons Pharmaceuticals, Loughborough, UK 
Miles Inc. Diagnostic Division, Elkhart, USA 
Gibco Life Technologies Ltd., Paisley, UK 
Pharmacia Biotech Ltd., St. Albans, UK 
Pierce & Warriner, Chester, UK 
Bachem UK Ltd., Saffron Walden, UK 
New England Biolabs Ltd., Hitchin, UK
DuPont NEN Research Products, Boston,
Massachusetts, USA
National Diagnostics, Atlanta, USA
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Recombinant human IL-1 a/p gift from Glaxo, Stevenage, UK
Recombinant human IL- 8 gift from Glaxo, Stevenage, UK
Recombinant human IFNy Boehringer Mannheim Uk Ltd., Lewes, UK
Recombinant human MIP-la Preprotech, London, UK
Recombinant human MIP-1 p Preprotech, London, UK
Recombinant human RANTES gift from Glaxo, Stevenage, UK
Recombinant human TNFa gift from Bayer UK, Slough, UK
Recombinant human TNFa NIB SC, Potters Bar, UK
standards
RNAozl B Tel-Test, Friendswood, Texas, USA
RPMI1640 Gibco Life Technologies Ltd., Paisley, UK
Saline Steripak, Runcorn, UK
Sodium chloride Fisons Pharmaceuticals, Loughborough, UK
Sodium hydroxide Fisons Pharmaceuticals, Loughborough, UK
Sodium pentobarbitone Rhone Merieux, Dublin, Ireland
Sodium phenobarbitone BDH Laboratory Supplies Ltd., Lutterworth,
Sterile distilled water Steripak, Runcorn, UK
Sterile sodium bicarbonate (7.5%) Gibco Life Technologies Ltd., Paisley, UK
Streptomycin Gibco Life Technologies Ltd., Paisley, UK
WEHI164 clone 13 NIBSC, Potters Bar, UK
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2.2 Expression of gpTNFa
The expression and purification system used to produce recombinant gpTNFa 
from cDNA is summarised in figure 2.0 and detailed in sections 2.2.1-2.3.4. The 
cDNA was cloned and sequenced by Dr T. Yoshimura, NCI-FCRDC, Frederick, MD, 
USA, as described in section 2.2.1. The cDNA, provided inserted in pBluescript 
SK(-), was amplified by polymerase chain reaction (PCR) and used to express 
gpTNFa (sections 2.2.2-2.3.4).
2.2.1 cDNA for gpTNFa
gpTNFa cDNA was cloned from guinea-pig spleen cells essentially as 
described for guinea-pig IL- 8  (Yoshimura & Johnson, 1993). Briefly, poly(A) RNA 
was prepared from guinea-pig splenocytes stimulated with concanavalin A (5|ig/ml, 4 
hours). A modification of the Gubler and Hoffman method (Gubler & Hoffman, 1983) 
was used to synthesis cDNA. This was used to prepare a library in a X ZAP II vector 
(Short et al. 1988), and phages were probed with a 33 base oligo 32P labelled probe 
based on a human TNFa cDNA using a sequence which was conserved between 
human and murine TNFa. Positive phagemids were rescued with helper phage and 
subcloned into pBluescript SK(-). cDNA was sequenced by the dideoxynucleotide 
triphosphate chain termination method (Sanger et al. 1977).
2.2.2 Transfection of gpTNFa cDNA into XLl-Blue
A 1 in 10 sub-culture of XL-1 Blue cells, from an overnight (37°C) culture, 
was grown for 2 hours in 40ml LB Broth (1% bacto-tryptone, 0.5% bacto-yeast 
extract, 1% NaCl, pH 7.0),with tetracycline (10|ig/ml) at 37°C. The cells were 
harvested by centrifugation (3000g, 15min, 4°C), washed in 0.5 volume Milli Q H2 O 
and resuspended in a minimum volume of ice cold 10% glycerol (approx. 250|xl). A 
40|il aliquot of cells was placed in a cold 0.5ml tube and kept on ice. The gpTNFa
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Figure 2.0: (please see next page).
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1. gpTNFa cDNA encoding the mature 









2. A T4 polymerase and Hind III were used to 
enzymatically cleave cDNA in order to 
create cDNA with one blunt and one 
cohesive end.
during PCR the cDNA with one
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pM AL-p2  plasmid






2. Plasmid DNA is double digested with 
Xmn\ and Hindlll to create an insertion 
site which has a blunt end and a cohesive 
end corresponding to the cohesive end of 
the gpTNFa cDNA.
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3. Ligation o f  gpTNFa cDNA and pMAL-p2 plasmid. 
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4. pMAL-p2 - gpTNF vector was cloned into the host T B 1 cells 




5. Transfected cells were induced by IPTG to express the fusion protein (MBP-gpTNFa).
•A
6. MBP-gpTNFa was isolated from E. coli lysate by passing over an amylose column.
Eluate: M B P-gpTN Fa
7. The fusion protein was cleaved with factor Xa. 
M B P-IEG R-gpTN Fa
Factor Xa cleavage site
8. Cleaved gpT N Fa was purified by a series o f affinity chromatography columns.
1) hydroxy apatite column 2) amylose column 3) polymixin B column
Figure 2.0: A simplified diagram to show the expression and purification of gpTNFa. 
(MBP; maltose binding protein, the methodology is detailed in section 2.1-2.2)
Materials and Methods 39
supplied cDNA inserted in pBluescript SK(-) was washed twice in cold 70% ethanol, 
pelleted by microfugation, and vacuum dried before resuspending in 50jll1  Milli Q 
H2 O. cDNA template (2-5|il) was added to the 40 pi aliquot of XL-1 Blue cells and 
stored on ice. The remaining template was frozen at -20°C for future use. Cell-cDNA 
mixture (42-45|il) was transfered to a sterile electrophoresis cuvette. Electroporation 
was performed at 2.5kV, 200 Ohms, 25pFD with a electroporation time constant of 
approx. 5 ms. Immediately after electrophoresis 1ml of conditioned culture media (LB 
Broth + ImM Mg2+) was added, the cuvette was mixed and contents were transfered to 
a conical culture flask containing 2ml LB Broth. The cells were agitated at 37°C for 
1 hour.
Following incubation, lOOjul of XL-1 Blue cell culture was plated out on an 
agar LB Broth plate (LB Broth, 1.5% agarose) containing ampicillin (100|ig/ml) and 
tetracycline (12.5p,g/ml) which had been over dried to remove surface moisture. 
Inverted culture plates were incubated at 37°C overnight. Since XLl-Blue cells are 
tetracycline resistant and ampicillin sensitive, whereas the cDNA template pBluescript 
SK(-) are tetracycline sensitive and ampicillin resistant, only cultures which contain 
the template will grow in media containing tetracycline and ampicillin.
2.2.3 Storing bacterial cultures at -70 °C
A stable frozen stock of cDNA was generated by freezing the XLl-Blue 
colonies which contained the Bluescript /  cDNA template, to ensure a continued 
supply of non-contaminated template which is readily accessible. Bacterial cultures 
were prepared for storage by adding 0.75ml LB Broth to the agar surface and 
suspending the cultures in the media by gentle scraping. The cells were removed, 
placed in a 2ml screw capped sterile tube and an equal volume of LB Broth containing 
30% glycerol added. The tube was vortexed to ensure that the glycerol was completely 
dispersed and cultures were stored at -70°C.
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2.2.4 Preparation of oligo nucleotide primers
A putative start site for mature gpTNFa was determined from the base 
sequence of gpTNFa cDNA, provided by Dr T. Yoshimura, and the published start 
sequences of human, murine and guinea-pig TNFa. Oligonucleotide primers were 
designed to amplify the region of cDNA encoding the putative mature protein. Primer 
sequences are shown in figure 2 . 1 .
Forward primer 5’ T C A G C T T C T C A A A A C G A T A A T
Reverse primer 3’ G T G A G T C A G G A A G G C C A A T  T C G A A C C C
Figure 2.1: The primers used for the amplification of gpTNFa cDNA. The 
reverse primer has a Hind HI cleavage site incorporated at the 5’ end 
(underlined).
The primers (Biochemistry, Bath University) were supplied attached to resin 
columns and displaced using concentrated ammonia solution (8 8 %). Ammonia 
(0 .2 ml) was applied to the column every 2 0  min with a 1 ml syringe and the eluted 
primer collected in a 5ml syringe. The eluted primer was transferred to a screw capped 
1.5ml tube and sealed with polythene film. This was then placed in a glass bottle 
containing 0.5ml ammonia solution, the bottle was capped, double sealed and 
incubated overnight at 55°C. Samples were cooled to room temperature, excess 
moisture removed by vacuum drying the samples for 1.5-2 hours. The dried primers 
were precipitated by the addition of 2 0 0 jll1  Milli Q H2 O, 20|xl 3M sodium acetate and 
4 0 0 j li1  cold ethanol (-20°C) followed by microcentrifugation (12,000g, room 
temperature, 10 min). The above precipitation was repeated then the single stranded 
DNA was washed in 1ml 70% cold ethanol and repelleted by microcentrifugation. The
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ethanol was removed and the pellet vacuum dried for 5-10 min before solubilising in 
300p,l Milli Q H2 0 .
Oligonucleotide concentration was ascertained by optical density (OD) at 
260nm, assuming an OD2 6 o 1.0 = 37jig/ml for single stranded RNA/DNA. Since the 
average molecular weight of a nucleotide is 350 the molarity of each primer was 
calculated.
2.2.5 Plasmid vector generation
A plasmid vector is a small circular molecule of double-stranded DNA used to 
transport the cDNA of interest into a host cell, which upon replication produces large 
quantities of cDNA. The plasmid, pMAL-p2 (New England Biolabs Ltd., Hitchin, 
UK), was used since it encodes a maltose binding protein (MBP) which is coexpressed 
with the gpTNFa enabling simple purification of the MBP-gpTNFa fusion protein 
using a MBP affinity column.
As the gpTNFa primers were designed to only amplify the region of gpTNFa 
cDNA sequence required, it was not necessary to excise the cDNA template from the 
pBluescript SK(-) prior to amplification by PCR. The concentration of the cDNA 
template previously prepared and stored at -20°C was determined by OD at 260nm, 
assuming OD2 6 o 1.0 = 50pg/ml double stranded DNA.
2.2.5./ Amplification of gpTNFa cDNA
The cDNA template was amplified using PCR, to minimise contamination the 
reagents were added to the PCR vials in the order stated in table 2.1. Nujol mineral oil 
(7 5 jll1 )  was layered on the top of the reaction mixture to prevent evaporation during the 
heating cycles. cDNA was amplified in a Crocodile II thermal cycler (Appligene, 
Pleasanton, California) using an initial 2 min at 95°C followed by 30 cycles of
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denaturation (95°C, 60 s), annealing (55°C, 60 s) and extension (72°C, 60 s) followed 
by a final extension at 72°C for 5 min. The expected PCR product, a low molecular 
weight fragment of 540 base pairs, was visualised by running on a 1.5% agarose gel 
containing 0.5|ig/ml ethidium bromide (2.2.5.2).
Table 2.1: PCR-amplification protocol detailing the order in which the reagents 
were added to minimise contamination.
Order to add reagents Final concentration
Milli Q H20
MgCl 2.5mM





TEMPLATE lOng/ml - lOpg/ml
Total volume 1 0 0 |il
2.2.5.2 Tris-Borate EDTA (TBE) agarose gels
Briefly, agarose (1.5% w/v) was solubilised in 30ml TBE buffer (45mM Tris- 
borate, ImM EDTA) by heating in a microwave oven for 1-2 min. The solution was 
allowed to cool to room temperature and Milli Q H2 O added to compensate for liquid 
lost by evaporation during heating. Ethidium bromide was added to a final 
concentration of 0.5|Xg/ml. The cooled solution was poured into a gel plate (15cm x 
6 cm) containing an 8  lane comb (0.5cm/lane) and allowed to set. The gel was 
immersed in a running tank containing TBE buffer.
Materials and Methods 43
An aliquot of PCR sample (1 OjllI) was mixed with 2pl 5x sample buffer 1 
(0.25% bromophenol blue, 0.25% xylene cyanol, 15% Ficoll-type 400), and the 
samples loaded into the gel wells. Hind IE molecular weight standards (2 jll1 ) were run 
in an outer lane to ensure the product was of the correct size. The gel was 
electrophoresed at 200V for 15-20 min. Following visualisation using a UV light 
source the product from the optimal PCR reaction (i.e. maximum product obtained 
using the minimum template concentration) was immediately excised from the agarose 
gel and ‘cleaned’ (see 2.2.5.3).
2,2.5.3 ‘Cleaning’ DNA recovered from agarose gels or in solution
The DNA was ‘cleaned’ using a Geneclean kit (BIO 101 Inc., La Jolla, CA) 
according to manufacturer’s instructions. Briefly, the slice of agarose gel containing 
the cDNA was weighed and incubated with 4.5 volumes sodium iodide (6 M) and 0.5 
volume TBE modifier at 50°C for 10 min. Once the gel had melted, glassmilk (5|LLl) 
was added, the solution mixed and incubated on ice for 10 min. The DNA was 
pelleted by microcentrifuging for 30 s, the supernatant removed, and the pellet washed 
three times in 0.5ml NEW Wash. On the last wash the supernatant was removed, the 
pellet was then re-spun and any remaining supernatant removed to obtain a dry pellet. 
Milli Q H2 O or low salt buffer (5|il) was added to the dry pellet and incubated at 50°C 
for 10 min. During this step the DNA disassociates from the glass particles into the 
low salt solution. The glass particles were pelleted by microcentrifugation and the 
supernatant, containing DNA, was transfered to a sterile 500fxl tube. The volume of 
DNA was restored to lOjxl with Milli Q H2 O and a ljil sample was electrophoresed on 
a 1.5% agarose gel to ensure that the DNA has dissociated from the glassmilk. 
Remaining DNA was stored at -20°C.
To ‘clean’ DNA which is in solution, 3 volumes sodium iodine (6 M) and 5|xl 
glassmilk were added to the DNA, the solution mixed and incubated on ice for 10 min. 
The DNA was then pelleted and washed in NEW Wash as described above.
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2.2.S.4 Preparing gpTNFacDNA for insertion into pMAL-p2 plasmid
When using PCR to amplify a length of cDNA a phenomenon of 
‘overshooting’ often occurs whereby a series of adenosine residues are added to the 3’ 
end of the template. This overshoot is removed by performing T4 polymerase 
digestion. T4 polymerase has a potent 3'—>5' exonuclease activity which removes 
protruding 3' termini from double stranded DNA to create a blunt ended fragment.
The ‘cleaned’ cDNA was added to the T4 polymerase digestion buffer (50mM 
Tris hydrochloride pH 8.0, 5mM MgCl2, 5mM DTT, lOOjig/ml BSA, lOmM dNTPs, 
final volume 49jil). The reaction was started by the addition of ljxl T4 polymerase 
(3U/|il) and the mixture incubated at 11°C (optimum temperature for T4 polymerase 
enzymatic activity) for 20 min. The reaction was stopped by denaturing the enzyme at 
75°C for 10 min. A 5|xl sample was run on a 1.5% agarose gel to ensure that the DNA 
was not fragmented during digestion. The DNA in solution, was ‘cleaned’ using 
geneclean kit detailed in 2.2.5.3, and finally resuspended in 10|il Milli Q H2 O.
In order to create a cohesive end which will orientate the cDNA when it is 
inserted into the pMAL-p2 plasmid the cDNA must be treated with Hind IE. A 
Hind IQ cleavage site had been incorporated into the primer sequence (figure 2.2).
5’ At A G C T T 
3’ T T C G ”A1A
Figure 2.2:. Hind HI cleavage site. The enzyme recognises the 6  bp and cleaves 
along the black line.
The T4 polymerase treated cDNA was incubated at 37°C for 2-3 hours with 
10U Hind HI in lOmM Tris.Cl, lOmM MgCl2, 50mM NaCl, ImM DTT (final volume
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20JJ.1). Hind HI was inactivated by incubating at 7 5 ° C  for 2 0  min. A sample of reaction 
product ( 2 jll1) was run on a 1 .5 %  agarose gel to ensure the cDNA had not been 
fragmented. DNA was ‘cleaned’ using the Geneclean kit ( 2 . 2 . 5 . 3 )  and resuspended in 
10|il Milli Q H2 O. The amplified gpTNFa cDNA was now suitable for cloning into 
the plasmid, and was stored at - 2 0 ° C  until required.
2.2.6 Preparation of pMAL-p2 plasmid
2.2.6.1 Isolation of pMAL-p2 plasmid DNA
Plasmid DNA was isolated using a Qiagen kit (Qiagen, Hilden, Germany). A 
500ml secondary culture of E.coli containing the correct plasmid (pMAL-p2) was 
grown overnight at 37°C in LB Broth containing ampicillin (50pg/ml). The cells were 
pelleted by centrifugation (4000g, 15 min, 4°C) and resuspended in 10ml ice cold 
buffer PI (50mM Tris hydrochloride, lOmM EDTA pH 8.0, 100|Lig/ml RNase A). The 
suspension was transferred to a sterile ultracentrifuge tube containing 1 0 ml 
prewarmed (37°C) buffer P2 (200mM NaOH, 1% SDS) and gently mixed by inverting 
the tube 5 times, producing a viscous lysate. After 4 min 10ml chilled buffer P3 (3.0M 
potassium acetate pH 5.5) were added and the mixture gently mixed by inverting. The 
mixture was incubated on ice for 30 min prior to ultracentrifugation (25,000g, 90 min, 
4°C). The clear, yellow, supernatant was carefully removed, promptly transferred to a 
50ml tube and placed on ice.
A Qiagen Tip 500 column was washed with 10ml QBT buffer (750mM NaCl, 
50mM MOPS, 15% ethanol, 0.15% Triton X-100, pH 7.0) by gravity induced flow. 
The collected supernatant was added to the column and washed through with 2 x 30ml 
QC buffer (1.0M NaCl, 50mM MOPS, 15% ethanol, pH 7.0). DNA was eluted with 
15ml QF buffer (1.25M NaCl, 50mM Tris hydrochloride, 15% ethanol, pH 8.5) and 
the eluate collected in a sterile glass ultracentrifuge tube.
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Isopropanol (10.5ml) was added to the eluate and ultracentrifuged (25,000g, 
60 min, 4°C) to precipitate the DNA. Supernatant was carefully removed from the 
pelleted DNA, which resembled a fine spray on the glass, the pellet was washed with 
15ml 70% cold ethanol and ultracentrifuged (25,000g, 45 min, 4°C) to repellet. The 
supernatant was discarded and the DNA pellet was air dried for 10 min before being 
redissolved in 200-500jil TE buffer (lOmM Tris hydrochloride, ImM EDTA pH 8.0).
DNA was quantified by measurement of OD at 260nm and 280nm and the 
260:280 ratio was calculated to assess the amount of background contamination in the 
preparation. The ratio obtained was >1.8 indicating low contamination with proteins. 
The DNA content was determined assumming OD2 6 0  1 = 50jig/ml double stranded 
DNA.
In order to produce a MBP fusion protein, the gpTNFa cDNA must be 
incorporated into the circular plasmid structure in the same translational reading frame 
as the plasmid’s malE gene. To create an insertion point for gpTNFa cDNA a section 
of the plasmid’s malE gene was enzymatically removed using Xmnl to create the blunt 
end and Hind HI to create a sticky end which will adhere to the sticky (Hind HI 
cleaved) end of the gpTNFa cDNA. Xmnl and Hind in were chosen as both enzymes 
have unique cleavage sites in the malE gene (figure 2.3) preventing fragmentation of 
either the plasmid or gpTNFa cDNA.
2.2.6.2 Double digestion of pMAL-p2 with Xmnl and Hind HI
pMal-p2 plasmid DNA (lOjLLg) was incubated with Xmnl 12U, 2|ig BSA, in 
lOmM Tris.Cl, lOmM MgCh, 50mM NaCl, ImM DTT (final volume 20jil), at 37°C 
(the optimum temperature for Xmnl enzymatic activity) for 2-3 hours. The enzyme 
was heat inactivated by incubating the mixture at 75°C for 20 min. To assure Xmnl 
digestion had occurred digested pMal-p2 DNA ( 2 jll1) and an equal amount of DNA
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from control non-digested pMal-p2 DNA was run and visualised on a 1.5% agarose 
gel. The digested plasmid had fewer base pairs, hence ran further on the gel than the 
non-digested fragment. The remaining digested fragment was ‘cleaned’ (2.2.5.3) and 
resuspended in 10|il Milli Q H2 O. Hind IE digestion was performed by incubating 
lOpl digested plasmid with 10U Hind HI in lOmM Tris.Cl, lOmM MgCh, 50mM 
NaCl, ImM DTT (final volume 20|il), at 37°C for 2-3 hours. The enzyme was heat 
inactivated (75°C, 20 min) prior to running 2 jll1 samples of, control non-digested, 
single digested, and double digested DNA on a 1.5% agarose gel which was visualised 
to ensure that each sample contained only a single band and that the double digested 
product had fewer base pairs than the non-digested control. The double digested 
product was ‘cleaned’ (2.2.5.3), resuspended in Milli Q H2 O to a final volume of 10|il 
and stored at -20°C.






2752 Xmn I Hind III
ATCGAGGGAAGGATTTCAGAATTCGGATCCTCTAGAGTCGACCTGCAGGCAGCAAGCTTG 
^  Factor Xa cleavage site
Figure 2.3: A map of the pMAL-p2 plasmid. The plasmid contains the inducible 
Ptac promoter, positioned to transcribe a malE-lacZa gene fusion. The laclq 
gene encodes the Lac repressor, which turns off transcription from Ptac until 
IPTG is added. The polylinker provides restriction endonuclease sites to insert 
the gene of interest, fusing it to the malE gene. The unique Xmn I  and Hind El 
cleavage sites are located in the polylinker. Nucleotide numbering starts at the 
beginning of the laclq fragment. (Adapted from pMAL-p2 map, New England 
Biolabs, Hitchin, Hertfordshire).
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2.2.7 Cloning of gpTNFa cDNA into pMAL-p2 plasmid
Ligation of the plasmid and cDNA was performed using T4 DNA ligase which 
catalyses the formation of phosphodiester bonds between adjacent 3’-hydroxyl and 
5’-phosphate termini in DNA. Briefly, double digested plasmid (4pl) was added to the 
reaction mixture containing 1200U T4 DNA ligase, 5pl gpTNFa cDNA in 50mM 
Tris.Cl (pH 7.5), lOmM MgCk, 0.75jig BSA, lOmM dithiothreitol, ImM ATP (final 
volume 30|il). The reaction mixture was left at room temperature overnight to ligate 
(T4 DNA ligase optimal ligation temperature is 16°C) and the reaction stopped by heat 
inactivation (75°C, 20 min). The ligation mixture was ‘cleaned’ (2.2.5.3) and 
resuspended in a final volume of 10pl in Milli Q H2 O. The ligated plasmid-gpTNFa 
cDNA construct, the vector, was stored at -20°C.
2.2.8 Preparing the host cell
To prepare the host cell, competent E. coli (TB1) cells were cultured from 
frozen stocks (-70°C). LB Broth (20ml) was innoculated with TB1 cells and cultured 
overnight at 37°C. A 1 in 20 sub-culture was grown in 10ml prewarmed LB Broth for 
a further 2-3 h, at 37°C, until the cell density was approximately 2xl0 8 cell/ml, OD 
600nm of 0 .2 .
2.2.9 Cloning of vector into host cell
Electroporation of the vector (pMAL-p2-gpTNFa) and host cell (TB1) was 
performed as previously described (2.2.2). Briefly, 40|il TB1 cells was mixed with 
either 2-5juil vector or 2 - 5 jll1 Milli Q H2 O and subjected to electroporation. Cells were 
incubated in 1ml conditioned culture media (1 h, 37°C, shaking). Control and vector 
containing-cells (100(il/plate) were plated on agar plates containing 100|Lig/ml 
ampicillin and agar plates containing 100|ig/ml ampicillin, 80pg/ml Xgal, 0.16mM
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IPTG. Plates were incubated, inverted, at 37°C overnight before assessing the colour 
of the colonies on the plates visually.
The presence of white colonies on the plate containing Xgal and IPTG 
indicated the disruption of the malE-lacZa gene which results in the inactivation of 
the p-galactosidase a  fragment, hence the cells were unable to metabolise Xgal into 
the blue product bromochloroindole, table 2 .2 .
Table 2.2: The expected growth of TB1 cells on agar plates containing 
ampicillin.






Blue + White colonies
A master plate (agar + lOOpg/ml ampicillin) and an agar plate containing 
100|ig/ml ampicillin, 80fig/ml Xgal, 0.16mM IPTG were prepared for sub-culturing 
the vector inserted colonies. Identical guideline grids with numbered squares were 
placed under each plate and the start position marked on the plates. Using sterile 
toothpicks colonies from the overnight culture plate without Xgal + IPTG were 
randomly picked by touching the surface of a single colony with the toothpick and 
then pricking identical squares on the master and Xgal/IPTG plate (figure 2.4), this 
was repeated until all the squares had been innoculated with a single colony. Both 
plates were incubated, inverted, 37°C overnight.
Five white colonies and 1 blue colony on the plate containing Xgal + IPTG 
were selected, randomly, and the corresponding colonies on the master plate i.e. 
colonies that have not seen IPTG were picked and streaked onto separate agar plates 
(containing 100|ig/ml ampicillin) and cultured overnight. The blue colony was used as 
a control since it contained cells which had not incorporated the vector. The white 
colonies contained a disrupted malE-lacZa gene, but the vector may still not have
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been inserted correctly. Due to the strength of the Ptac promoter, transformants taken 
from a plate containing IPTG can contain mutant plasmids that have either 1) lost part 
or all of the fusion gene or 2) no longer express it at high levels, thus colonies selected 
for sub-culturing should have had no contact with IPTG.
Overnight culture Master Plate Plate + Xgal + IPTG
toothpick
Figure 2.4: Selection of individual colonies to identify those containing the 
vector. A toothpick was used to select a colony from the overnight culture plate 
and seed onto the master (1) and a corresponding Xgal/IPTG plate (2).
Aliquots (20ml) of LB Broth containing ampicillin (100pg/ml) were inoculated 
with single colonies from each plate and cultured overnight in a shaking water bath at 
37°C. A 1.5ml aliquot from each flask was sub-cultured into 20ml pre-warmed LB 
Broth containing ampicillin (lOOpg/ml) and incubated at 37°C for 2-3 h, until the cell 
density was approx. 2 x 108 cells/ml.
2,2.10 Screening for the presence of vector insertion
A 1ml aliquot was removed from each culture prior to induction of the fusion 
protein, samples were microcentrifuged, the pellets were resuspended in 50|il SDS-
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sample buffer (see section 2.5.1) and retained on ice until required (these were the 
uninduced samples). IPTG (0.3mM) was added to each of the cultures incubated for a 
further 2 hours to induce fusion protein expression. Following induction, a 0.5ml 
sample of each culture was removed, microcentrifuged and the pellets resuspended in 
100p,l SDS-sample buffer (these were the induced samples). The uninduced and 
induced samples (15|l i 1) were run on two 10% SDS polyacrylamide gels which were 
used for protein staining and western blotting respectively (see section 2.5). The 
relative molecular mass of gpTNFa is ~17kDa, the MBP-p-galactosidase fusion 
protein has a mass of ~51kDa and the gpTNFa-MBP fusion protein is ~60kDa. 
Hence, the culture which demonstrated the most predominant protein band shift, 
corresponding with the incorporation of the gpTNFa gene, following IPTG induction 
was chosen for the production of gpTNFa. This culture was referred to as C/MBP- 
gpTNFa.
A pilot experiment was carried out to assess which cellular fraction contained 
the MBP-gpTNFa fusion protein. An aliquot (0.8ml) of an overnight culture of 
C/MBP-gpTNFa was use to innoculate 80ml rich media (1% bacto-tryptone, 0.5% 
bacto-yeast extract, 0.5% NaCl, 0.2% glucose, 100|ig/ml ampillicin). The culture was 
grown at 37°C for 2 hours prior to removing a 1ml sample of the uninduced culture, 
this was microcentrifuged and the cell pellet resuspended in 50|xl SDS-sample buffer. 
The sample was vortexed and stored at -20°C. Following the addition of 0.3mM IPTG 
the remaining culture was incubated for a further 2 hours when a 0.5ml sample was 
removed. This induced sample was microcentrifuged, the cell pellet resuspended in 
lOOpl SDS-sample buffer and stored at -20°C.
The cellular fraction of the culture was collected by centrifugation (4000g, 
10 min, 4°C) and the pellet resuspended in 10ml column buffer (20mM Tris pH 7.4, 
200mM NaCl, ImM EDTA). The suspension was frozen (-20°C) for at least 18 hours. 
Once thawed, the cells were lysed by sonication (10 cycles of 30 s sonication, 30 s
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rest) in an ice-water bath. The lysed cells were pelleted (9000g, 20 min, 4°C), the 
supernatant decanted and placed on ice, this was called the ‘soluble crude extract 
fraction’. The pelleted cellular debris was resuspended in 10ml column buffer, this 
was the ‘insoluble crude extract fraction’. Samples of the soluble (10pl) and insoluble 
(10|il) crude extract fractions were each added to lOjil SDS-sample buffer, and stored 
at -20°C.
To ensure that during expression the fusion protein had not lost the ability to 
bind to the amylose resin a small volume was tested. Amylose resin (200|il) from the 
amylose affinity column (see 2.3.1) was washed twice in 1.5ml column buffer and 
resuspended in 200jxl. 50pl of amylose resin slurry was mixed with 50|il crude extract 
and incubated on ice for 15 min. The sample supernatant was discarded after 
microcentrifugation and the pellet washed with column buffer and resuspended in 
50pl SDS-sample buffer. This was called the ‘protein bound to amylose’ fraction. 
Pilot experiment SDS samples (table 2.3) were boiled for 5-10 min, microcentrifuged 
for 1 min, run on a 15% polyacrylamide gel and stained with Coomassie blue.
Table 2.3: Volume of each pilot experiment/SDS sample loaded onto an SDS
gel.
Sample Volume sample/gel lane
Uninduced cells 2 0 |il
Induced cells 2 0 (xl
Soluble crude extract lOpl
Insoluble crude extract 1 0 pl
Protein bound to amylose 2 0 |il
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2.2.11 Production o f gpTNFOrMBP fusion protein
The pilot experiment demonstrated that the fusion protein was expressed as a 
soluble protein in the crude extract fraction hence, the pilot experiment was scaled up. 
Rich media (11) was inoculated with 10ml of an overnight culture of C/MBP-gpTNFa 
and grown at 37°C for 2 hours shaking. The culture was induced with IPTG (0.3mM) 
and incubated for a further 2 hours. The culture was centrifuged (4000g, 20 min, 4°C), 
and the pellet resuspended in 50ml cold lysis buffer (20mM Tris pH 7.4, 200mM 
NaCl, ImM EDTA 40U/ml aprotonin, ImM phenyl methyl-sulfonyl fluoride, lng/ml 
leupeptin, 4°C). The cells were frozen at -20°C for at least 18 hours.
Protein degradation during harvesting and cell lysis was minimised by 
performing all steps at 4°C and in the presence of protease inhibitors. The suspension 
was thawed, placed in an ice-water bath and sonicated in short pulses ( 1 0  cycles of 
30 s sonification, 30 s rest). The insoluble material was pelleted by centrifugation 
(9000g, 20 min, 4°C), the supernatant decanted off and retained on ice. The 
supernatant, which was the soluble crude extract containing the fusion protein, was 
diluted 1 in 5 with column buffer and applied to the amylose resin column.
2.3 Purification of gpTNFa
2.3.1 Affinity chromatography over amylose
Amylose resin (New England Biolabs Ltd., Hitchin, UK) was poured in a 2.5 x 
10cm glass chromatography column and allowed to settle. All subsequent steps were 
performed at 4°C. The column was washed with 200ml column buffer (20mM Tris.Cl, 
200mM NaCl, ImM EDTA) and the flow rate adjusted to 1 ml/min. The diluted 
soluble crude extract was applied and the column washed overnight with a further 
300ml column buffer.
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The fusion protein was eluted with 60ml column buffer containing lOmM 
maltose and collected in 3ml fractions. Fractions containing protein, assessed by 
measuring the OD at 280nm, were pooled (fractions 1-8) and the sample was stored at 
-20°C. The amylose column was regenerated by washing with 25ml distilled water, 
75ml 0.1% SDS, 75ml distilled water, 75ml column buffer, 50ml column buffer 
0.05% NaN3 , and stored at 4°C. The column was reused up to 5 times.
2.3.2 Cleavage with factor Xa
Cleavage of the MBP from gpTNFa was performed by factor Xa cleavage 
using the specific amino acid recognition sequence, IEGR, incorporated into the vector 
design (see figure 2.5). As thrombin cleaves at the arginine-serine (R-S) bond and 
there are no other R-S bonds in the amino acid sequence of gpTNFa, cleavage of the 
fusion protein with thrombin was also attempted.
MBP gpTNFa
—I—E--G—R- -S--A--S—
factor Xa and thrombin 
cleavage site
Figure 2.5: The factor Xa and thrombin cleavage site, in the MBP-gpTNFa 
fusion protein. Factor Xa recognises the amino acid sequence IEGR and cleaves 
at the next bond (R-X).
To determine that factor Xa and thrombin were able to cleave the fusion 
protein an inital pilot experiment was carried out. Fusion protein (20|il at a 
concentration of ~1 mg/ml) was incubated at room temperature with factor Xa (ljil, 
200|ig/ml) or thrombin (l|il, 2mg/ml) for 2, 4, 8 , 18 or 24 hours. To stop the reaction 
SDS-sample buffer was added and the samples were boiled for 5-10 min. Samples
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(20jxl) were run on 15% SDS polyacrylamide gels, for protein staining and western 
blotting. A sample of uncleaved fusion protein boiled in SDS-sample buffer was run 
as a negative control and human TNFa (10pg/ml) as a positive control.
The pilot study indicated that optimum conditions for cleavage were 18 hours 
at room temperature with factor Xa (lOjig/ml). These conditions were used in 
subsequent preparations to cleavage the MBP-gpTNFa fusion protein.
2.3.3 Removal of MBP
MBP was removed from the cleaved fusion protein mixture by passing over a 
hydroxyapatite column followed by an amylose column. Binding to hydroxyapatite 
caused maltose to be displaced from the MBP. The high affinity of the maltose-free 
MBP for amylose enabled it to be separated from gpTNFa by passage over an amylose 
column.
2.3.3.1 Hydroxyapatite column
Hydroxyapatite (lg) was allowed to swell in 30ml column buffer, the fines 
were removed by washing the resin in column buffer 3 times. The resin was poured 
into a 1 x 10cm polyproylene column (Bio-rad Laboratories, Hemel-Hampstead, UK) 
and allowed to settle at room temperature.
The cleaved fusion protein mixture was loaded onto the column and the 
column washed with 80ml column buffer, under gravity flow, to remove the maltose. 
Proteins were eluted from the column by 0.5M sodium phosphate buffer (1.61% 
NaH2 P0 4 'H2 0  10.26% Na2HP0 4  7 H2 O, pH 7.2) and collected in 2ml fractions. Protein 
containing fractions, assessed by OD at 280nm, were pooled.
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2.3.3.2 Amylose column
A 15ml amylose column was prepared as described previously (section 2.3.1). 
The proteins eluted from the hydroxyapatite column were run over the amylose 
column and washed with 75ml column buffer. Eluate was collected in 5ml fractions 
and protein content assessed by OD 280nm. Samples were removed for SDS-PAGE 
and proteins were detected by silver staining and western blotting (section 2.5). 
Western blotting was performed using antibodies against gpTNFa and factor Xa.
2.3.4 Removal of endotoxin
A polymixin B column (detoxi-gel, Pierce Chemical Company, Chester, UK) 
was used to remove endotoxin contamination from the purified protein. Under sterile 
conditions the column was regenerated by washing with 5ml 1% sodium deoxycholate 
and rinsed with 3ml H2 O. The column was equilibrated with sterile PBS and the 
protein sample applied. Eluate was collected in 1ml fractions and TNFa bioactivity of 
the samples assessed (2.4).
The purified recombinant gpTNFa was concentrated prior to storage at -20°C 
using centriplus-10 concentrators (Amicon Ltd., Stonehouse, UK, molecular weight 
cut-off 10,000 Da) and the buffer was replaced with PBS 0.1% BSA.
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2.4 TNFa cytotoxicity bioassay and immunological activity
2.4.1 TNF bio assay
TNF bioactivity was assessed using a mouse fibrosarcoma cell line, WEHI164 
clone 13 (supplied by Dr A. Meager, NIBSC, Potters Bar, UK) cytotoxicity assay 
(Espevik & Nissen-Mayer, 1986). WEHI 164 cells were rountinely cultured in RPMI 
1640 medium supplemented with 10% FCS, lOU/ml penicillin and lOpg/ml 
streptomycin. Cells were passaged twice weekly, when confluent, and split 1:20.
Aliquots (180|ll/well) of WEHI cell suspension (2 x l0 5/ml) in RPMI 1640, 
10% FCS, lOU/ml penicillin, 10|ig/ml streptomycin were dispensed into a 96 well 
microtitre plate (NUNC, Gibco Life Technologies Ltd., Paisley, UK) and incubated 
(37°C in a humidified, 5% CCVair environment) for 4 hours. Samples (including 
gpTNFa [2.3], BAL supernatant [2.6.4], lung homogenates [2.4.2]) or human TNFa 
(lpg/ml-lOng/ml) standards (20}il), diluted in the appropriate buffer, were added to 
the wells in triplicate and the cells incubated for a further 24 hours. The supernatant 
was carefully removed and the adhered cells fixed with 50pl/well 95% methanol for 
30 s. The methanol was removed and the cells were stained with crystal violet stain 
(lOOpl/well) for 15 min, then the plate was extensively washed with distilled water. 
To solubilize the remaining cell associated dye 33%v/v glacial acetic acid (200pl/well) 
was added and the optical density of the wells read at 540nm in a microtitre plate 
reader (MR5000, Dynatech Laboratories, Chantilly, Virginia).
2.4.2 Whole lung tissue sample preparation
Frozen (-70°C) peices of lung tissue were ground in liquid nitrogen using a 
mortar and pestle over dry ice. The lung powder was transferred to a glass 
homogeniser and frozen tissue (200mg/ml) homogenised in PBS containing 0.05%
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Triton X-100, 1% FCS and lOOU/ml aprotinin on ice. Homogenates were transferred 
to sterile tubes, microcentrifuged and the supernatant was stored at -20°C.
2.4.3 Neutralisation of TNF a  cytolytic activity
In neutralisation experiments TNFa containing samples were incubated with 
rabbit anti murine TNFa antiserum or rabbit anti murine TNFa IgG (2.4.4) for 30 min 
at room temperature prior to testing in a WEHI bioassay.
2.4.4 Preparation of rabbit anti murine TNF a  IgG fraction
Rabbit anti murine TNFa antiserum was a gift from Dr S .L. Kunkel, 
University of Mitchigan, Ann Arbor. An IgG fraction was produced using a 1ml 
protein A affinity column. The column was washed with 10ml PBS followed by 10ml 
1M Tris buffer pH 8.0 under gravity flow. A 1ml sample of antiserum was added to 
the column prior to washing with 10ml lOOmM Tris buffer pH 8.0 and 10ml lOmM 
Tris buffer pH 8.0. The IgG fraction was eluted from the column using lOOmM 
glycine (pH 3.0) and 1.5ml fractions were collected in tubes containing 50jil 1M Tris 
buffer (pH 8.0). The protein content of the fractions was determined by OD at 280nm. 
Protein containing fractions were pooled and concentrated using Centriplus-10 
concentrators (Amicon Ltd., Stonehouse, UK, molecular weight cut-off 10,000 Da) to 
approx lmg/ml (1 OD is approx. 0.8mg/ml for IgG fractions).
The column was reused once after residual antibodies were stripped off the 
column by washing sequentially with 2M urea, 1M lithium chloride and lOOmM 
glycine pH 2.5. The column was equilibrated by washing with PBS before applying 
1.5ml whole rabbit serum to obtain a control IgG fraction.
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2.4.5 ELISA for gpTNFa
In order to detect gpTNFa in biological samples, a murine TNFa ELISA 
(enzyme linked immunosorbent assay) known to cross react with rat TNFa was 
investigated. This ELISA was developed in co-operation with by Dr W. A. Buurman, 
University of Limburg, Maastricht, The Netherlands.
A 96 well plate (Immunoplate Maxisorb, NUNC, Gibco Life Technologies 
Ltd., Paisley, UK) was coated with monoclonal hamster anti murine TNFa (IgG) 
diluted 1 in 200 in PBS (lOOpl/well) and incubated at 4°C overnight. The wells were 
emptied, 1 5 0 jll1 1%BSA (Sigma A-7906) in PBS was added to block non-specific 
binding sites, and the plate incubated at room temperature, covered, for 1 hour. The 
plate was then washed 5 times in wash buffer (Milli Q H2 O 0.1% Tween 20).
The standard murine TNFa samples (0.03-30ng/ml) and gpTNFa samples 
(0 .1 - 1 0 0 ng/ml) were diluted in murine serum 2 0  min prior to addition to the plate. 
Samples (lOOpl/well) were added in duplicate to the plate, the plate was covered, and 
incubated for 1 hour at room temperature. The plate was then washed 5 times in wash 
buffer. The secondary antibody, rabbit anti murine TNFa, was diluted 1 in 10 in PBS 
containing 0.1%BSA and 100|xl/well added to the wells. The plate was incubated for a 
further 1 hour at room temperature prior to washing 5 times in wash buffer.
Goat anti rabbit IgG peroxidase conjugate (100|xl/well) was diluted 1 in 1000 
in PBS 0.1%BSA and added to the plate which was covered and incubated for 1 hour 
at room temperature. The plate was washed for a further 5 times in wash buffer and 
lOOpl/well 3,3’,5,5’-tetramethylbenzidine (TMB) detection substrate was added. The 
reaction was incubated in the dark for 10-15 min before stopping with lOOfxl/well 3M 
H 2 S O 4 .  The OD at 450nm was measured on a microtitre plate reader (MR5000 
Dynatech Laboratories, Chantilly, Virginia.). The murine TNFa standards were used 
to as a positive control and murine serum as the vehicle control.
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2.5 SDS-PAGE and western blotting
To avoid protein contamination all SDS-PAGE equipment was thoroughly 
cleaned with alcohol prior to use.
2.5.1 Sample preparation for PA GE gels
2.5.1.1 Protein containing solutions
Protein containing solutions for SDS-PAGE or western blotting were prepared 
by boiling with an equal volume of SDS-sample buffer (2% SDS, 20% glycerol, 
160mM Tris pH 6 .8 , 9% 2-mercaptoethanol, 0.2% bromophenol blue) for 5-10 min. 
The samples were then cooled prior to use or frozen at -20°C.
2.5.1.2 Whole lung tissue
Lung tissue was ground as described in section 2.4.2 and homogenised in PBS 
containing 0.05% Triton X-100, 0.1% BSA, lmMEDTA, 2|LLg/ml leupeptin, 
l|ig/ml pepstatin A, lOOjLig/ml PMSF and 2pg/ml aprotinin on ice. An aliquot (200jxl) 
of homogenate supernatants was retained to determine the protein content (2.5.1.3) 
and the remainder boiled with SDS-sample buffer as described above (2.5.1.1). Lung 
homogenate supernatants were run on 15% PAGE gels, loading equal amounts of 
protein for each sample.
2.5.1.3 Protein assay
The protein content of samples was calculated using a Bio-Rad Bradford-based 
protein assay. BSA protein standards (l-40jig/ml) or supernatant samples were added 
in triplicate to a 96 well microtitre plate (200|il/well). Dye reagent concentrate (50jLtl) 
was added to each well, the samples mixed thoroughly and incubated at room 
temperature for 30-50 min. OD at 595nm was measured on a microtitre plate reader
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(MR5000, Dynatech Laboratories, Chantilly, Virginia). Protein content of the samples 
was calculated following the generation of a BSA (standard) protein calibration curve.
2.5.2 SDS gel preparation
SDS-PAGE was carried out essentially as described by Laemmli (Laemmli, 
1970) using Bio-Rad mini gel system (Bio-Rad Laboratories, Hemel Hempstead, 
Hertfordshire, UK) with 1.5mm thick gels. The resolving gel of the appropriate 
acrylamide percentage was prepared as descibed in table 2.4 and poured to 
approximately 0.5cm below the point where the bottom of the combs would reach. 
The poured gel was overlaid with water, to reduce contact with air, and left to 
polymerise. Once set, all the liquid was removed from the top of the resolving gel. 
This was overlaid with stacking gel and the plastic comb carefully inserted. When the 
stacking gel had set, the comb was removed and the running chamber assembled. 
Electrophoresis was carried out in running buffer containing 0.25M Trizma base, 
1.92M glycine, 0.1%SDS.
Samples (10-20|il) were added to individual lanes and molecular mass protein 
standards (4-250kDa) were included on each gel (3jil pre-stained for western blotting). 
When available, a control sample which was known to cross react with the primary 
antibody used in western blotting was included. Electrophoresis was carried out at a 
constant voltage of 100V through the stacking gel (~ 20 min) and 150V through the 
resolving gel (1-1.5 h). The gels were removed and a selected comer was marked for 
orientation/identification. The gels were either stained to indicate the position of the 
proteins, with Coomassie blue (2.5.3.1) or silver stain (2.5.3.2), or used for western 
blot transfer (2.5.5).
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Table 2.4: Protocol for 10% and 15% SDS polyacrylamide gels.
Components 1 0 % polyacrylamide gel 15% polyacrylamide gel
(in order of addition) (optimal resolution (optimal resolution
~30-60kDa proteins) ~5-30kDa proteins)
Running gel Stacking gel Running gel Stacking gel
30% Acrylamide Stock 5.0ml 1.67ml 7.5ml 1.67ml
Tris Buffer 1.0M pH 8 . 8 5.6ml - 5.6ml -
Tris Buffer 1.0M pH 6 . 8 - 1.25ml - 1.25ml
Water 4.35ml 6 .0 ml 1.85ml 6 .0 ml
10% SDS 150|xl 1 0 0 jnl 150pl 1 0 0 pl
10% AMPS lOOpl 50|il lOOjil 50pl
TEMED 6 .6 M lOfxl lOjxl lOpl lOpl
Total volume required 15.21ml 9.08ml 15.21ml 9.08ml
for 2  mini gels
2.5.3 Detection of proteins in SDS-PAGE gels
2.5.3.1 Coomassie blue staining
The gel was submerged in Coomassie blue stain (table 2.5) and shaken for 30- 
45 min allowing the proteins to be both fixed and stained simultaneously. The gel was 
then placed in destain to remove background colouration for 3-4 hours.
Table 2.5: Protocol for comassie blue stain and destain.
Components Gel stain Gel destain
Coomaissie Brillant Blue R-250 0.25% -
Methanol 40% 40%
Acetic acid 7% 7%
Water 53% 53%
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2.5.3.2 Silver staining
All containers used were washed extensively prior to use and reserved 
exclusively for silver staining to prevent background artefacts. Solutions were made 
using sterile, double distilled water in sterile vessels.
Silver staining was performed essentially as described by Johnstone and 
Thorpe (Johnstone and Thorpe, 1987). Proteins in the gel were fixed by agitating the 
gel in 50% methanol for 1-1.5 hours. The methanol was replaced with the staining 
solution (0.0756% w/v NaOH, O.2 IMNH4 OH, 0.8% w/v silver nitrate) and the gel 
agitated for 15 min. The gel was washed 3 x 10 min in water, then developed in 
0.005% w/v citric acid, 0.019% w/v formaldehyde. The stain was developed until 
protein bands were visible on the gel (approx. 10 min). The reaction was stopped by 
rinsing in water and the gel stored in 45% methanol / 5% acetic acid. For longer 
storage gels were dried using a Bio-Rad gel dryer (Bio-Rad Laboratories, Hemel 
Hempstead, UK) in accordance to manufacturers instructions. The gel was placed on 
dampened filter paper, covered with a piece of soaked cellophane membrane and air 
bubbles carefully removed. The gel was dried for 70 min at 80°C under vacuum.
2.5.4 Electrophoretic transfer of proteins to nitrocellulose membrane
Proteins were transfered using a Tris-glycine system and mini Trans-blot cells 
(Bio-Rad Laboratories, Hemel Hempstead, UK). The transfer sponge pads, 2 pieces of 
filter paper/gel (cut slightly larger than the gel size) and the gel were soaked for 5 min 
in transfer buffer (0.25M Trizma base, 1.92M glycine). The PVDF nitrocellulouse 
membrane (NEN Research Products, Boston, MA, USA), cut to match the size of the 
gel, was activated by immersing in methanol (3 s), distilled water (1 min) and transfer 
buffer (1-2 min). A “western sandwich”, figure 2.6, was then assembled under transfer 
buffer. A transfer pad was placed on the transfer cell, then a piece of filter paper 
followed by the gel. A glass pasteur pipette was used to roll out air bubbles. The 
membrane was placed on the gel, air bubbles again carefully removed, and the filter
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and remaining transfer pad positioned. The transfer cell was closed, placed in the 
Trans-blot and then in the transfer tank with the gel nearest to the cathode.. The tank 
which contained an ice pack and magnetic stirrer was filled with transfer buffer. The 
blot was transfered at a constant current of 250mA for 1 hour whilst being stirred.




Black side Red side
of transfer Sponge Filter Gel Nitrocellulose Filter Sponge of transfer
cell membrane cell
Following transfer the membrane was ready for immunoblotting. Alternatively, 
the membrane was stored overnight in PBS, 0.1% NaN3 , 4°C or carefully placed 
between filter paper, wrapped in tin foil and stored at -20°C. The gel was then stained 
with Coomassie blue to ensure the protein transfer was complete.
Efficiency of protein transfer was checked by staining with Ponceau S stain 
(0.2% PonceauS, 3% trichloroacetic acid, 3% sulfosalicylic acid) for 5-10 min. 
Ponceau S staining was non-permanent and was removed during immunoblotting 
wash procedures.
2.5.5 Blocking and antibody probing of membranes
All stages were carried out on an orbital shaker at room temperature with 
1 membrane/container. Each membrane was covered with blotting buffer (170mM 
NaCl, lOmM Tris, pH 7.4) containing 5% non-fat milk protein for 1.5-2 hours to 
reduce non-specific protein binding. This was removed and the membrane washed
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twice in blotting buffer (10 min/wash) and once in wash buffer (0.05% Tween 20, 
blotting buffer).
The primary antibody, diluted as detailed in table 2.6 in wash buffer, 0.02% 
NaN3 was incubated with the membrane for 2 hours. After probing the antibody was 
stored at 4°C and reused up to 5 times. The membrane was washed 3 times in wash 
buffer ( 1 0  min/wash) prior to incubating with the secondary antibody alkaline 
phosphate conjugate for 1-1V4  hours. After discarding the secondary antibody the 
membrane was washed once in wash buffer for 1 0  min and twice in a high salt wash 
buffer (500mM NaCl, 170mM Tris, 0.05% Tween 20) for 15 min/wash.
Protein-antibody complexes were detected using nitro blue tetrazolium (NBT) 
and 5-bromo-4-chloro-3-indolyl phosphate (BCIP). The membrane was surmerged in 
detection solution of NBT (330pg/ml), BCIP (166|ig/ml) dissolved in Tris/magnesium 
buffer (lOOmM Tris, lOOmM NaCl, 50mM MgCk, pH 9.5). Bands were allowed to 
develop and the reaction was stopped by covering the membrane in cold blotting 
buffer (4°C). The membrane was then rinsed twice in blotting buffer, air dried and 
sealed in polythene bags for storage.




Primary antibody Dilution Secondary antibody Dilution
TNFa goat anti murine 
TNFalgG
1 in 1 0 0 0 anti goat IgG alkaline 
phosphate conjugate
1 in 2 0 0 0
TNFa rabbit anti murine 
TNFa sera
1 in 1 0 0 0 anti rabbit IgG 
alkaline phosphate 
conjugate
1 in 2 0 0 0
Factor Xa rabbit anti human 
Factor Xa
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2.6 Northern blot analysis of mRNA
To minimise degradation of RNA, by RNases, all solutions were prepared 
using RNase and pyrogen free Milli Q H2 O or distilled water was treated with 0.1% 
diethylpyrocarbonate (DEPC), overnight at 37°C, followed by autoclaving. Sterile 
equipment was used and gloves were worn throughout. Whenever possible the 
samples were kept on ice.
2.6.1 Extraction of total RNA from samples
Frozen (-70°C) pieces of lung tissue were ground (2.4.2) and homogenised in 
RNAozl B (5ml/g lung tissue) whereas cell pellets were mixed, using a plastic pasteur 
pipette, with 1ml RNAzol B, samples were kept on ice or stored at -70°C until 
required. Each sample was vortexed with lOOjil chloroform for 15 s, placed on ice for 
5 min, and centrifuged at 12500g, 4°C for 15 min. The aqueous (upper) layer of the 
sample was transfered into a sterile tube containing 0.5ml ice cold propan-2-ol, taking 
care not to transfer or disturb the aqueous/organic interface which contained proteins 
including RNases. The tube was inverted several times to mix and placed on ice for 
15 min before pelleting the RNA (12500g, 15 min, 4°C). The supernatant was 
removed and the pellet washed with 1ml 75% ethanol (at -20°C), the pellet was 
vortexed breifly to resuspend and then repelleted by centrifugation at 7500g, 4°C for 
8  min.
Supernatant was removed and the pellet was air dried for 30-45 min. The dry 
pellet was resuspended in 22pl water, vortexed and heated for 10-15 min at 60°C. The 
samples were then kept on ice. To quantify the amount of total RNA present the OD at 
260nm of a small sample was measured in 0.1% NaOH (equation 2.1).
OD 260 x dilution factor x 40 x volume sample (ml) = p,g total RNA.
Equation 2.1: Measurement of RNA concentration.
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2.6.2 Agarose/formaldehyde gel electrophoresis
A 1% agarose gel was prepared by dissolving agarose (3g) in 230ml water/gel, 
by microwaving for 2-3 min. Once dissolved 15ml of 20 x MOPS pH 7.0 (0.4M 
morpholinopropansulfonic acid [MOPS], 0.02M EDTA, 0.2M sodium acetate pH 5.2) 
and 54ml formaldehyde solution (38%) were added. The gel was allowed to cool 
before pouring into a gel holder with the combs already positioned. The gel was 
placed in a tank containing cold running buffer (lx  MOPS) in an ice bath.
RNA samples were prepared in RNA loading buffer (2.34 x MOPS, 303|ig/ml 
ethidium bromide, 60% formamide, 8.1% formaldehyde solution), 5-10pg RNA per 
30|il buffer per well. The samples were vortexed, heated at 80°C for 20 min, and 
quenched on ice. 2jxl/well bromophenol blue solution (0.25% bromophenol blue, 30% 
glycerol) was added to the RNA samples and microcentrifuged to mix. RNA samples 
were loaded into the wells and the power pack connected with the samples migrating 
towards the anode. Electrophoresis was carried out at 100V for 1.5-2 hours until the 
bromophenol blue had migrated 3-5cm from the wells.
The completed gel was visualised under UV light (Hoefer mighty bright 
UVTM 25), and photographed. The 18S and 28S ribosomal RNA bands were visible 
and could be used to demonstrate equal loading of the lanes.
2.6.3 Transferring RNA from the gel to nitrocellulose membrane
The RNA was transferred from the gel onto a nylon membrane by capillary 
action. The gel was cut to the desired sized and 1 peice of nylon membrane 
(Boehringer Mannheim, Lewes, Sussex, UK) and 3 pieces of 3mm filter paper cut to 
the same size. A length of filter paper was cut and placed in the blotting tank with 
each end in a reservoir of 20 x SSC transfer buffer (3M NaCl, 0.3M sodium citrate,
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pH 7.0), and the central platform area above this level so that the filter paper acts as a 
wick. The platform region was dampened with 20 x SSC and air bubbles were rolled 
out using a glass pipette. The gel was inverted on the platform such that the lower with 
the surface previously touching the gel tray was now uppermost. The gel was covered 
with nylon membrane and 3 pieces of filter paper taking care to exclude air bubbles. A 
stack (~8 cm) of absorbant paper (paper hand towels) cut to match the gel size were 
placed on top of the filter paper and weighted down with a glass plate and 500g 
weight, at least 2 0  hours was allowed for transfer to be completed.
Following transfer, the appropriate comer of the membrane was marked for 
orientation/identification purposes, the membrane was baked for 20 min at 120°C. The 
18S and 28S ribosomal RNA bands were visualised by exposure to UV light and their 
position marked on the edge of the membrane. The membrane was sealed in a 
polythene bag and stored ready for probing.
2.6.4 Digoxigenin (DIG)-labelled probes for northern analysis
p-actin and eotaxin mRNA were detected using DIG-labelled oligonucleotide 
probe cocktails (3 x 30mers) purchased from R&D Systems, Abingdon, Oxon, UK. 
The p-actin probe was designed to hybridise with human p-actin mRNA but it was 
found to detect guinea-pig mRNA (E. Campbell, University of Bath). The eotaxin 
probe was designed to in accordance to guinea-pig eotaxin nucleotide sequence (Jose 
e ta l  1994).
Guinea-pig IL- 8  and gpTNFa mRNA were detected using DIG-labelled double 
stranded cDNA probes. PCR was utilised to incorporate the DIG label into the cDNA. 
By using a 1:4 digoxigenin-11-dUTP (DIG-dUTP):dTTP ratio during amplification of 
the cDNA the DIG-dUTP randomly replaced dTTP, hence labelling the cDNA. PCR 
was performed as described in section 2.2.5.1 using the reagents in table 2.7. Primers 
were designed based on the cDNA sequences (table 2.8). Guinea-pig IL- 8  cDNA was
Materials and Methods 70
supplied by Dr T. Yoshimura supplied in pBluescript SK(-) (Yoshimura & Johnson, 
1993), the primer was based on the sequence registered with Genbank, accession no. 
L04986.
Table 2.7: PCR protocol for the synthesis of DIG-labelled cDNA probes.
Order to add reagents Final concentration
Milli Q H20
MgCl2 2.5mM









DNA was amplified in a GeneAmp 2400 thermal cycler (Perkin-Elmer, 
Warrington, UK) using an inital 2 min at 95°C followed by 30 cycles of denaturation 
(95°C for 60s), annealing (55°C for 60 s) and extension (72°C for 60 s) and a final 
extension at 72°C for 5 min. Following amplification a sample of each reaction 
mixture was run on a 1.5% agarose gel containing ethidium bromide, to ensure a 
single product was obtained. DIG incorporation was verified by immunoblotting. 
Briefly, 1 in 10 dilutions of the sample were dotted onto a nylon membrane and DIG 
was detected as described in section 2 .6 .6 .
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Table 2.8: Primers used for synthesis of DIG-labelled cDNA probes.
Primers Forward Reverse
guinea-pig IL- 8  
guinea-pig TNFa




5 ’ CCC AAGCTTCC AATTCC 
TGAAGTAGA
5 ’ CCC AAGCTT AACCGG AA 
GGACTGAGTG
2.6.5 Hybridisation of northern blots with DIG labelled probes
Membrane was prehybridised with 10-20ml of hybridisation solution 1 
(5 x SSC, 0.1% sarcosyl, 0.02% SDS, 1% blocking buffer), for oligonucleotide probes, 
or solution 2 (5 x SSC, 0.1% sarcosyl, 7% SDS, 2% blocking buffer, 50mM sodium 
phosphate pH 7.0, 50% formamide) for cDNA probes. The hybridisation solution was 
added to the membrane in the polythene bag and the bag resealed removing all air 
bubbles. The membrane was incubated at 42°C (oligonucleotide probes) or 50°C 
(cDNA probes) for 1 hour.
The top comer of the polythene bag was cut and the hybridization solution 
drained out. The oligonucleotide and cDNA probes, diluted in hybridization solution 
to a final concentration of lOng/ml was added to the membrane (2.5ml/50cm2) and the 
polythene bag was resealed removing air bubbles. At this stage it was important not to 
allow the membrane to dry out. The membrane was hybridised overnight at the 
prehybridisation temperature.
2.6.6 Immunodetection of DIG-labelled probes for northern analysis
The membrane was removed from the polythene bag, placed in a suitable wash 
tank, and washed at the prehybridisation temperature twice in stringency wash buffer 1
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(2 x SSC, 0.1% SDS) for 5 min and twice in stringency wash buffer 2 (0.1 x SSC, 
0.1% SDS) for 5 min.
All washes and incubations for the following stages, unless otherwise stated, 
w'ere performed at room temperature with shaking. The membrane was washed for 
5 min in wash buffer, 0.3% Tween 20 in maleic acid buffer (0.1M maleic acid, 0.15M 
NaCl), before incubating for 30 min in blocking buffer (1% blocking reagent in maleic 
acid buffer). The blocking buffer was removed and the membrane incubated with anti- 
DIG Fab fragments conjugated to alkaline phosphatase, diluted 1 in 10,000 in 
blocking buffer, for 30 min. The antibody solution was discarded and the membrane 
washed 3 x 1 0  min in wash buffer. The wash buffer was poured off and the membrane 
equilibrated in detection buffer (0.1M Tris.Cl, 0.1M NaCl, 50mM MgCb, pH 9.5) for 
2-5 min.
Chemiluminescent alkaline phosphate substrate, disodium 3-(4- 
methoxyspiro {1,2-dioxetane-3,2’ -(5 ’ -chloro)tricyclo[3.3.1.13 ,7 ]decan} -4-yl) phenyl 
phosphate (CSPD), was used for detection. CSPD (25mM) was diluted 1 in 100 in 
detection buffer. The membrane was removed from the detection buffer, excess buffer 
shaken off, placed on a polythene sheet and 1ml CSPD was evenly pipetted over the 
membrane. The membrane was covered with a top polythene sheet, the CSPD gently 
spread over the membrane surface and the membrane incubated for 5 min in the dark. 
The membrane was sealed in a new polythene sheet and incubated for 30 min at 37°C 
in the dark.
The membrane, in the sealed bag, was initially exposed to X-ray film for 1- 
1.5 hours. If necessary longer exposures of upto 12 hour were performed subsequently.
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2.7 Induction o f chemokine-like activity by TNFa
2.7.1 Guinea-pig peritoneal macrophage and eosinophil collection
Dunkin-Hartley guinea-pigs (500-650g, male and female) were each given a 
minimum of 4 injections of Horse Serum (0.5ml, i.p., 2 injections/week). A final 
"booster" injection was given the day before cell collection. The guinea-pigs were 
asphyxiated with CO2 , the lower abdominal fur was removed and the skin washed 
with methanol. An incision was made along the mid-ventral line and the peritoneal 
cavity lavaged with HBSS containing 0.1% BSA and ImMEDTA (4x10ml). The 
lavage was centrifuged at 400g for 10 min and the supernatant discarded. 
Contaminating red blood cells in the pellet were lysed by hypotonic shock, distilled 
H2 O (250|il, 4°C) was mixed with the pellet for 10-15 s before resuspending the cells 
in 25ml HBSS containing 0.1% BSA (buffer A). The collected cells were washed 
twice in buffer A, centrifuging for 10 min at 400g. The cells were resuspended at 
5x10 /ml in Percoll (1.070g/l) containing 1% BSA and carefully layered over a 
discontinuous isotonic Percoll gradient with densities 1.070, 1.080, 1.085, 1.090 and 
1.100g/l (Gartner, 1980), table 2.9. The gradient was centrifuged for 25 min at 1500g 
and the cell layers were removed sequentially from the top. The relevant leukocyte 
population (figure 2.7) was collected and washed twice in buffer A (400g, 10 min).







1 . 1 0 0 1.60 0.41
1.090 2.74 1.26
1.085 1.25 0.75
1.080 1.14 0 . 8 6
1.070 0.91 1.09
fLight Percoll = 9 parts Percoll with lpart 10 x HBSS with calcium and magnesium, 
pH 7.2-7.4. *HBSS+ = 1 x HBSS with calcium and magnesium, pH 1.2-1 A.
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Percoll 
gradient (g/1) 
















Figure 2.7: Layering of the Percoll Gradient.
2.7.2 Production o f gpTNFa by stimulated macrophages
A crude preparation of guinea-pig TNFa was prepared from guinea-pig 
macrophages as described by Tamatani et al. 1989. Briefly, guinea-pig peritoneal 
macrophages ( l x l 07/ml) were stimulated with 10pg/ml LPS for 1 hour (37°C in a 
humidified, 5% CCVair environment) in RPMI 1640, 10% FCS, lOU/ml penicillin, 
10|Lig/ml streptomycin. The cells were washed twice in PBS and cultured for 12 hours 
in 5ml RPMI 1640, lOU/ml penicillin, 10pg/ml streptomycin. The cells were pelleted 
(400g, 10 min) and the supernatant aliquoted and stored at -20°C. This supernatant 
was shown to contain TNFa by WEHI bioassay.
2.7.3 Stimulation o f guinea-pig spleen cells, peritoneal macrophages 
and JH-4 cells with gpTNF a  and recombinant human cytokines
JH-4 clone 1 are a guinea-pig lung fibroblastic cell line, obtained from 
European Collection of Animal Cell Cultures (Wiltshire, UK), which were derived
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from the lung of a young guinea-pig strain 13 and subsequently cloned. The cells were 
routinely cultured in Hams F12 medium supplemented with 10% FCS, lOU/ml 
penicillin and 10|ig/ml streptomycin. Cells were passaged when confluent using 
0.25% trypsin and seeded at a density of 3 x 104  - 4 x 104  cells/cm2  (splitting 1:3 - 
1:4). Cells were cultured until passage 39 (the cells were passage 34 when supplied).
Spleen cells were collected by removing the spleens from naive Dunkin- 
Hartley guinea-pigs (500-650g, male and female) and sieved through a fine wire mesh 
with saline. The resulting suspension was centrifuged (400g, 10 min), the red blood 
cells in the pellet were lysed with 150mM NH4 CI (5ml) for 15 min at 4°C and made 
up to 25ml with RPMI 1640 medium, 10% FCS, lOU/ml penicillin, lOpg/ml 
streptomycin. The cells were pelleted by centrifugation at 400g, 20°C for 10 min then 
rewashed twice and resuspending in medium at 5xl0 5cells/ml.
Cells were plated in 24 well plates (Gibco Life Technologies Ltd., Paisley, 
UK) at a density of 2xl0 5cells/well (JH-4 cells were grown to confluence and the 
medium replenished prior to stimulation) in their respective medium containing 1 0 % 
FCS, lOU/ml penicillin, 10|Ag/ml streptomycin. Cells were stimulated and then 
incubated at 37°C in a humidified, 5% CCVair environment for the duration of the 
experiment. Experiments were designed to incorporate cellular stimulation with 
macrophage derived gpTNFa, recombinant gpTNFa, recombinant human cytokines, 
TNFa antibody neutralisation and time course studies. The supernatants were 
collected, stored at -20°C prior to assessing the bioactivity (2.7.4) and in some 
experiments the adhered cells were scraped into 1ml RNAozl B and stored at -70°C 
for northern blot analysis (2 .6 ).
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2.7.4 Elevations in intracellular free calcium concentration [Ca2+]iin  
guinea-pig peritoneal leukocytes
Guinea-pig peritoneal macrophages and eosinophils were prepared as 
described previously in section 2.7.1 and peritoneal neutrophil collection is described 
in section 2.7.4.1.
2.7.4.1 Guinea-pig peritoneal neutrophil collection
Dunkin-Hartley guinea-pigs (430-620g, male and female) were injected with
0.1% glycogen in saline (15-20ml/animal, i.p.). After 2-4 hours animals were 
sacrificed by inhalation of carbon dioxide and peritoneal lavage performed as 
described above (2.7.1). The red blood cells were lysed as described previously, the 
cells were repelleted by centrifugation (400g for 10 min) and the pellet resuspended in 
5ml buffer A. Cell viability and percentage purity was determined by Trypan Blue 
exclusion and staining of cytospin preparations respectively (2.8.4).
2.7.4.2 Measurement of [Ca f  in fura-2 loaded guinea-pig peritoneal 
leukocytes
Leukocytes were loaded with the fluorescent dye by incubating the cells 
( lx l0 7/ml in buffer A) with fura-2-acetoxymethyl ester (2.5p,M) at 37°C for 30 min. 
The loaded cells were washed twice and resuspended in HBSS containing 0.1% BSA, 
ImM Mg2+ and lOOpM Ca2+ at 2xl06cells/ml.
Measurements of [Ca2+]i were obtained by using a dual excitation 
spectrophoto-fluorimeter (PTI Inc., NJ, USA, Deltascan) with excitation wavelengths 
of 340nm and 380nm and an emission wavelength of 510nm, the slit width was 5nm. 
The fluorescence signals from both excitation wavelengths were automatically 
recorded by the computer with the ratio of these being used to calculate [Ca2+]i as 
described by Grynkiewicz and co-workers (Grynkiewicz et al. 1985) (see section
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2.1 A3). The apparatus was calibrated at least twice (at the start and end) of each 
experiment to reduce any time induced cellular variations. Fura-2 loaded leukocytes 
(lml, 2xl06cells) and 1ml buffer A containing ImM MgCk, 2mM CaCb (to restore 
the extracellular calcium concentration to ImM), were added to a quartz cuvette and 
placed in the fluorimeter. The cuvette was maintained at 37°C and a magnetic stirrer 
was used to ensure thorough mixing. Once the fluorescence signal stabilised the 
maximum [Ca2+]i fluorescence (Fmax) was measured by lysing the cells with 80|xl 
digitonin (4mg/ml). After 20 s 40|il NaOH (2M) and 80|xl EDTA (500mM) were 
added to the cells to establish a minimum background fluorescence value ( F m i n ) .  
Following calibration the cuvette was soaked in 95% ethanol for 5 min to remove any 
remaining digitonin.
To monitor the effect of agonists on [Ca2+]i, fura-2 loaded cells (lml, 
2xl06cells) and lml buffer A containing 2mM CaCl2 , ImM MgCh were placed in the 
cuvette and allowed to equilibrate in the fluorimeter for 4 min at 37°C. The basal 
fluorescence signal was measured prior to agonist addition (lOOpl) and any 
fluorescence changes during the next 120 s were recorded.
2.7.4.3 Calculating [Ca2+]i
The binding of calcium ions to fura-2 causes an increase in fluorescence 
intensity and a hypsochromic shift in absorption and excitation spectra, such that 
maximum absorption of free fura-2 anion is 380nm and the Ca -fura-2 complexed 
state is 340nm. A ratio of absorption at 340/380nm was used to calculate [C a2+]i as 
this method minimised variability due to apparatus efficiency and the effective 
concentration of dye (Grynkiewicz et al. 1985).
From the calibration response the values for Fmax and Fmin were obtained from 
the 380nm measurements. Fmax and Fmin are equivalent to So and Sb2  the 
proportionality coefficients for free and bound Fura-2 at 380nm. Using the
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340nm/380nm ratio measurements Rmax and Rmin, the maximum and minimum
fluorescence ratios between the wavelengths, were evaluated. The apparent Kd for
<■»
fura-2 binding calcium at 37°C is equal to 2.24x10' M, hence, by applying equation
2.2 the [Ca2+]j at any one time is calculated. Once calibrated the computer 
automatically calculated [Ca2+]i. Changes in [Ca2+]i, following agonist stimulation, 
were measured as the difference between basal [Ca2+]i and the maximum [Ca2+]i.
[Ca2+], = Kd x (R-Rmin) x (S B)
(Rmax“R) (Sb2)
Equation 2.2: To determine the [Ca2+]i of fura-2 loaded cells.
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2.8 In vivo studies of airway inflammation in the guinea-pig
The effect of instilling cytokines and/or antibodies into the airways of both 
antigen sensitised and non-sensitised (naive) animals was examined and is 
summarised in figure 2.8.
2.8.1 Antigen sensitisation procedure and antigen challenge
Dunkin-Hartley guinea-pigs (200-400g, male and female) were sensitised over 
a period of 4 weeks to an antigen, ovalbumin (OA), via a series of intraperitoneal (i.p.) 
injections according to the method described in table 2.10. Aerosol challenge was 
performed by restraining the animal by the neck whilst the snout of each animal was 
placed in a nose-cone attached to a nebulizer. Animals were exposed to an aerosol of 
OA (0.1% in saline 10ml) using a compressed air (71/min) nebuliser until dry. To 
prevent anaphylactic shock animals were injected with mepyramine (lOmg/kg i.p.) 
15 min prior to challenging. In some studies lung function tests (2.8.3) were 
performed 2-48 hours following aerosol challenge.
2.8.2 In vivo cytokine and murine anti TNFa antibody challenge
Naive (non-treated) or sensitised Dunkin-Hartley guinea-pigs (200-400g, male 
and female) were challenged with recombinant cytokines (TNFa, IL-13, IL-4) or 
rabbit anti-murine TNFa antibody. Inital studies compared 3 methods of administering 
the agents, as detailed below, but tracheal instillation (2.8.2.3) was used for the 
majority of the studies as this method allowed a known amount of agent to be 
delivered to the airways.
2.8.2.1 Aerosol challenge using a nose-cone
Naive guinea-pigs were restrained by the neck whilst the snout of each animal 
was placed in a nose-cone attached to a nebulizer. Animals were exposed to an aerosol
OA sensitisation 
(28-42 days)
Instillation via trachea 










OA aeorosol challenge 
20 min after instillation
Bronchial reactivity
B AL - differential cell counts 
TNFa content 
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Figure 2.8: A flow diagram to show the sequence of the 
in vivo and in vitro methodologies used.
a) OA sensitised animals







Table 2.10: Protocol for guinea-pig sensitisation methodology.
BV; Bordertella bronchisepetica vaccine.
All injection solutions were incubated for 1 hr at room temperature prior to use, to allow adjuvant (aluminium hydroxide) - antigen (OA) 
binding.
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of 5ml agent using a compressed air (7 1/min) nebuliser until dry. Lung function tests 
were performed 2 or 6 hours following challenge (2.8.3).
2.8.2.2 Tracheal aerosol challenge
Naive guinea-pigs were anaesthetised, ventilated via the trachea cannula and 
prepared for lung function analysis, as described in 2.8.3. Bronchial reactivity in 
response to i.v. histamine (l-10|ig/kg) was measured (2.8.3). The ADC nebulizer 
(PMS, Mumed, London, UK) was then attached between the trachea cannula and the 
flow transducer. Inspiration by the animal activated the ADC nebulizer to generate an 
aerosol for 50% of the inspiration time. The animal was exposed to the aerosol on 
alternate breaths for 60 min during which time approx. 1.2ml of the agent was 
dispensed. A resting period of 30 min was allowed prior to reassessing bronchial 
reactivity.
2,8,23 Tracheal instillation
Guinea-pigs (male and female, 200-550g) were anaesthetised (ketamine 
40mg/kg, xylazine 5mg/kg, i.m.) and kept on warming blankets until the desired 
degree of anaesthesia was achieved. Animals were positioned prone and any food 
particles removed from the inside of the mouth using cotton buds. The mouth was 
opened and an adapted pediatric laryngoscope used to depress the tongue so that the 
glottis and vocal cords were visible. Agents were adminstered using an elongated-gel 
loading pipette tip which was passed between the vocal cords before expelling the 
agent. Animals were maintained on the warming blanket until fully recovered and lung 
function tests and/or bronchoalveolar lavage (BAL) was performed at set times 
following instillation.
To ensure the agents were entering the lungs, inital studies were performed by 
instilling 50jil Evans’ blue dye (lmg/ml) into the airways. The animals were allowed
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to recover before sacrificing, by an overdose of pentobarbitone, and removing the 
intact lungs to determine the distribution of the dye visually.
In neutralisation experiments gpTNFa was incubated with anti TNFa antibody 
at room temperature for 30 min prior to instillation. To examine the effect of 
co-instilling 2 cytokines, both were mixed immediately prior to instillation.
The instillation of sensitised animals, with rabbit anti murine TNFa antibody 
or IL-13, was performed 20 min prior to aerosol OA challenge. Mepyramine (lOmg/kg
i.p.) was administered 15 min before the animals were OA challenged.
2.8.3 Measurement of guinea-pig lung function in vivo
Dunkin-Hartley guinea-pigs (300-500g, male and female) were anaesthetised 
with sodium phenobarbitone (lOOmg/kg) and sodium pentobarbitone (30mg/kg) i.v. 
The animals were placed supine on a heated bed and their body temperature 
maintained at 37°C. Once in the state of surgical anaesthesia, a 3cm incision was 
made, the trachea exposed and cannulated. The trachea cannula was connected to a 
pneumotachograph (Fleish 0000) attached to a differential pressure transducer (MP45-
14-871; Validyne, Northridge, CA) (See figure 2.9). The animal was ventilated 
(7ml/kg/breath) with a mixture of air and oxygen (1:1 v/v) at 60Hz using a small 
animal ventilator (Sandoz, Basel, Switzerland). The right carotid artery was 
cannulated with a heparinised saline filled cannula (1.02mm outside diameter, Portex 
Ltd., Kent, UK) connected to a pressure transducer (Washington PT400 Elcomatic 
Ltd.) to allow the measurement of blood pressure. The left jugular vein was 
cannulated, using a saline filled cannula with a volume of > 0.2ml, and attached to a 
saline containing infusion pump (B.Braun Melsungen AG). Transpulmonary pressure 
was assessed using a differential transducer (MP45-24-871; Validyne) connected to 
the trachea cannula and a blunt intrathoracic cannula inserted between ribs 6 and 8 
(figure 2.9). Air introduced into the pleural cavity was removed via a 3-way tap
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leaving approx. lml residue for pulmonary measurements. Changes in the lung 
function (lung resistance and dynamic compliance) were calculated via a computerised 
respiratory analyser (PMS, Mumed, London, UK). The animal was paralysed with 
gallamine (lOmg/kg i.v.) and allowed to stabilise for 15 min.
To assess the airway responsiveness, 0.2ml of a spasmogen (e.g. histamine, 
metacholine at concentrations between l-56|ig/kg) was administered at 10 min 
intervals via the jugular vein, each dose was infused into the vessel with saline 
(0.4ml). The lung resistance and dynamic compliance were measured for lmin prior to 
and 3 min following spasmogen administration.
2.8.4 Bronchoalveolar lavage (BAL) cell accumulation
Immediately after the assessment of lung function the animal was sacrificed 
with an overdose of anaesthetic (sodium pentobarbitone 200mg/kg i.p.). The lungs 
were lavaged with 2 x 10ml PBS containing 0.1% BSA and ImM EDTA, the BAL 
was centrifuged at 400g for 10 min and the supernatant stored at -20°C. The lavage 
was repeated and combined with the cell pellet from the first lavage. Total BAL 
leukocyte numbers were assessed using a haemocytometer and Trypan blue exclusion. 
Aliquots of BAL were cytospun (500rpm for 5 min) onto poly-lysine coated slides 
using a Shandon II cytospin (Life Sciences, Ireland). Slides were either wrapped in foil 
and stored at -70°C for subsequent immunohistochemical analysis or stained with 
Leishman's (1.5g/l methanol) or Diff-Quik stain. Differential leukocyte percentages, 
based on counting 700-1000 stained cells/sample, were used to determine the BAL 
leukocyte population numbers.
2.8.5 Storage of lung tissue
Lungs which had been lavaged were dissected from the carcase, washed in 
saline and chopped into small pieces. The lung pieces were frozen in iso-pentane for
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Figure 2.9: Diagram to show the basis lung function apparatus. (PMS; pulmonary 
monitoring system, red lines represent the guinea-pig)
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15-30 s and samples stored in air-tight bags at -70°C. Fresh lung tissue, stored in 10% 
formaldehyde fixative solution following dissection, was cryostat sectioned and 
haeamatoxylin and eosin stained by Pathology, Royal United Hospital, Bath.
2.9 Measurement of TNFa and chemokine protein content and 
bioactivity in BAL and lung tissue
Biologically active TNFa in BAL and lung tissue was assessed using a TNFa 
cytotoxicity assay (2.4), and the presence of antigenic TNFa was determined by 
western blot analysis (2.5) for lung tissue and immunohistochemistry for BAL cells. 
The ability of BAL to induce mobilisation of intracellular calcium in leukocyte 
subtypes (2.7.4) was used as an indication of chemokine-like bioactivity. Changes in 
gpTNFa and chemokine mRNA levels in lung tissue were determined by northern blot 
analysis (2.6).
2.9.1 Immunohistochemical analysis of BAL cell TNFa content
BAL cell cytospins were thawed at room temperature, the cells fixed in 1:1 
methanol:3% hydrogen peroxide for 30 min and the slides rinsed twice in TBS pH 7.6. 
Non specific binding was blocked by incubating the slides in blocking buffer (TBS 
pH 7.6, 5% rabbit serum) for 15 min at 37°C. The slides were drained, but not rinsed, 
and the primary antibody (goat anti murine TNFa Ig G) diluted 1 in 500 in blocking 
buffer was added to the cells. A control antibody, goat IgG, was included for each 
BAL cytospin. Slides were incubated at 4°C overnight in a humidified chamber.
The slides were washed three times in TBS pH 7.6 on an orbital shaker for 
5 min at room temperature. Rabbit anti goat Ig G peroxidase conjugate, diluted 1 in 
100 in blocking buffer, was added and incubated at room temperature for 30 min. The 
secondary antibody was removed by washing the slides three times in TBS pH 7.6 for 
5 min at room temperature. The peroxidase conjugate was detected by
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diaminobenzidine (DAB) peroxidase substrate using a tablet substrate kit. The DAB 
solution was applied to the slides for 5-10 min before counterstaining with Mayer’s 
haematoxylin for 3-7 min and rinsing the slides in distilled water.
Slides were allowed to air dry before being examined under a microscope in a 
blind fashion. Positive staining was scored using a quantal scoring scale (table 2.11) 
for the number of cells stained in 5 fields of view.
Table 2.11: The quantal scale used for scoring the percentage of stained cells.
Scale Percentage of cells stained positive




2.10 Measurements of eosinophil peroxidase (EPO) activity in lung 
tissue
Frozen (-70°C) pieces of lung tissue were ground in liquid nitrogen (2.4.2) and 
homogenised in PBS 0.5% hexadecyltrimethylammonium bromide (HTAB) on ice, 2g 
lung tissue/8ml buffer. The homogenate was sonicated for 1 min prior to 
ultracentrifugation at 40,000g ,4°C for 5 min. The supernatant was decanted and 
repelleted at 48,000g, 4°C for 60 min. The pellet was resuspended in 3ml of ImM Tris 
pH 7.4, centrifuged for 5 min at 12,000g, 4°C, the supernatant was aliquoted and 
stored at -20°C overnight. The aliqouts were thawed, heated for 2 hr at 60°C and 
stored on ice prior to use.
Horseradish peroxidase standards (l-100ng/ml) or test samples were added to a 
96 well microtitre plate in triplicate (100p,l/well). An equal volume of 
o-phenylenediamine (OPD) detection substrate was added. OPD solution was freshly
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prepared by dissolving lOmg OPD in 25ml 0.05M phosphate citrate buffer pH 5.0 
containing lOpl H2 O2 . The reaction was incubated in the dark for 30 min before 
stopping with 50|il/well of 3M H 2 S O 4 .  The OD at 450nm was measured on a 
microtitre plate reader (MR5000 Dynatech Laboratories, Chantilly, Virginia.). A 
protein assay (2.5.1.3) was used to determine the amount of protein per sample and 
hence, the EPO activity (horseradish peroxidase equivalents) per mg protein was 
calculated.
2.11 Statistical analysis
The data is expressed as mean ± SEM. One-way analysis of variance 
(ANOVA) was performed on log transformed data (normalised) to determine 
significance between groups, unless otherwise stated. If significance was found 
Dunnett’s test was used to assess differences between means. A value of p < 0.05 was 
considered significant. Statistical analysis was performed using Minitab for Windows 
(version 10).
3. Expression & 
purification of
gpTNFa
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3.1 Predicted protein sequence of gpTNFa
The sequence of gpTNFa cDNA, provided by Dr T. Yoshimura, and predicted 
amino acid sequence, are shown in figure 3.1. The gpTNFa cDNA is 77.8% and 
74.7% homologous with human (Wang et al. 1985) and murine (Pennica et al. 1985) 
TNFa over the 1071 bp obtained. The amplified region encoded a 154 amino acid 
protein of 17 kDa which is approximately 80% identical with other mammalian 
sequences at the amino acid level, figure 3.2.
3.2 Expression of gpTNFa
cDNA was amplified using a forward primer corresponding with the NH2  
terminus of the secreted form of gpTNFa (Tamatani et a l 1989) to yield a DNA 
fragment of 540 bp (figure 3.3). This fragment was inserted into the pMAL-p2 
plasmid to generate the vector which was subsequently cloned into TB1 cells. The 
cloning of the vector, using the electroporation conditions described, resulted in the 
disruption of the malE-lacZcc gene in the colonies which had incorporated the vector 
(approximately 30% of the colonies). IPTG induction of cultures containing the 
disrupted gene promoted MBP-gpTNFa fusion protein expression in one of the five 
cultures randomly selected. SDS-PAGE and western blot analysis of the bacterial 
lysate indicated TNFa immunoreactivity at approximately 60 kDa, representing the 
fusion protein, figure 3.4. The fusion protein was isolated from the soluble crude 
bacterial extract by MBP-affinity chromatography using an amylose column. Factor 
Xa cleavage of the fusion protein resulted in the release of MBP (43 kDa) and 
gpTNFa (17 kDa), which was optimal following 8-24 hours incubation as shown in 
figure 3.5. Only limited cleavage was obtained by incubating the fusion protein with 
thrombin at room temperature for 24 hours.
Expression and purification of gpTNFa 91
- 8 9  - 8 0  - 7 0  - 6 0  - 5 0  - 4 0  - 3 0
GAAATAAGCCCAGACAATCCAGACAGGCAGGTTTGGTCCCTCTCACACACACCACCCCAGACTC
- 2 0 -10 1 10 20 30
CAGAGGTCCCTCTGCAGAAGACGCC ATG AGC ACA GAA AGC ATG ATC CGG GAC GTG
Met H e r T h r  G lu H e r M e t T i e A r g A s p V a l
40 50 60 70 80
GAG CTC GCA GAG GAG CAG CTC CCC AAG AAG GCA GGG GGC CCC CAG GGC TCC
Glu L e u A la Glu Glu Gin Leu P r o L y s  L y s A l a G ly G ly P r o G in G ly S er
90 100 110 1 2 0 13 0
AGG CGG TGC TGG TGC CTC AGC CTC TTC TCC TTC CTG CTG GTG GCA GGG GCC
A rg A rg Cys Trp Cys L e u S er Leu P h e S er P h e L e u L e u V a l A l a G ly A la
1 4 0 15 0 1 60 1 7 0 1 8 0
ACC ACG CTC TTC TGC CTG CTG CAC TTT GGG GTG ATC GGC CCC CAG CGG GAA
T h r Thr Leu Phe Cys L e u L e u H i s P h e  G ly V a l H e G ly P r o G in A r g  G lu
19 0 2 0 0 2 1 0 2 2 0 2 3 0
GAG CAG TTC TCC AGT GGC CCC CCC TTC AGA CCC CTG GCC CAG ACG CTC ACA
Glu Gin Phe S e r S er G ly Pro P r o P h e A rg P r o L e u A l a G in T h r L e u Thr
2 4 0 2 5 0 2 6 0 2 7 0 2 8 0
CTC AGA TCA GCT TCT CAA AAC GAT AAT GAC AAG CCG GTG GCT CAT GTT GTG
Leu Arg'AS e r  A la S er G in A sn A sp A sn A s p L y s P r o V a l A l a H i s V a l V a l
2 9 0 3 00 31 0 3 2 0 3 3 0
GCA AAC CAG CAA GCA GAG GAG GAG CTG CAG TGG CTC AGC AAG CGT GCT AAC
A la Asn Gin G in A la G lu G lu G lu L e u G in T r p L e u H e r L y s A r g A l a Asn
3 4 0 35 0 3 60 3 7 0 3 8 0
GCC CTC CTG GCC AAT GGC ATG GGC CTG AGC GAC AAC CAG CTG GTG GTG CCT
A la Leu Leu A la Asn G ly Met G ly L e u H e r A s p A s n G in L e u V a l V a l Pro
3 9 0 4 0 0 4 1 0 4 2 0 4 3 0
TCG GAT GGG CTG TAC CTC ATC TAC TCC CAG GTC CTC TTC AAG GGC CAA GGC
S e r A sp G ly  Leu T yr L e u J l e Tyr S e r G in V a l L e u P h e L y s G ly G in G ly
4 4 0 4 50 4 6 0 4 7 0 4 8 0
TGC CCC TCC TAC CTG CTT CTC ACC CAT ACC GTC AGC CGC TTG GCC GTC TCC
Cys Pro S e r  T yr Leu L e u L e u T h r H i s T h r V a l H e r A r g  L e u A l a V a l H e r
4 9 0 5 0 0 5 10 5 2 0 53 0 54 0
TAC CCG GAA AAG GTC AAC CTT CTC TCT GCC ATC AAG AGT CCC TGC CAG AAG
T yr Pro Glu L ys Val A s n L e u L e u S er A l a T i e L y s H e r P r o C y s G in L ys
5 5 0 56 0 570 58 0 5 9 0
GAG ACC CCA GAA GGG GCT GAG CGC AAG CCC TGG TAT GAA CCC ATC TAC CTG
Glu Thr Pro Glu G ly A la G lu A rg L y s P r o  T r p T y r G lu P r o T i e T yr Leu
60 0 610 62 0 6 30 6 40
GGA GGC GTC TTC CAG CTG CAG AAG GGT GAC CGG CTC AGC GCT GAG GTC AAC
G ly G ly Val Phe Gin L e u G in L y s G ly A s p A rg L e u H e r  A l a G lu V a l Asn
6 50 660 6 70 680 6 9 0
CTG CCT CAG TAC CCT GAC TTT GCC GAT TCC GGG CAG ATC TAC TTT GGG GTC
Leu Pro Gin T yr P r o Asp Phe A la A sp H e r G ly G in l i e  T y r P h e G l y  V a l
7 0 0  7 1 0  7 5 0
ATT GCC CTG TGA GAAGGACGGACGTCTCCATCCATCCCTTCTCCTTCCCCCACCAGTTCCTT 










Fieure 3.1: The nucleotide and deduced amino acid sequence of gpTNFa. The A 
symbol between bases 240-241 denotes the position of the cleavage site to release the 
mature protein. The sequence is available from GenBank under accession number 
U77036.
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Figure 3.2: The amino acid sequence alignment of secreted gpTNFa with human 
(Wang 1985), rabbit (Ito 1986), murine (Pennica 1985) and rat (Shirai 1989) TNFa. 
Amino acids identical to guinea-pig are boxed.
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Figure 3.3: gpTNFa cDNA was amplified by PCR, using specific primers, to yield 
a single PCR product.
lane 1: X base pair ladder, 2: control, no cDNA in PCR reaction 3: gpTNFa cDNA









Figure 3.4: gpTNFa-MBP fusion protein expression following IPTG-induction of TB 1 cells. 
Samples were run on a 10% SDS-PAGE gel and stained with coomassie blue (A) or transferred 
to nitrocellulose membrane and TNFa detected by western blotting (B). Molecule weight markers 
(MWt, kDa) were run in lane 1 and TB 1 cell samples run in lanes 2-9, lane 2 and 3 :uninduced 
and induced cells without pMal-p2 insertion, lanes 4/5, 6/7 and 8/9 uninduced/induced cells, 
respectively, which exhibited inactive p-galactosidase activity (pMal-p2 inserted), but IPTG only 
induced significant fusion protein expression in one of the colonies (lanes 8 and 9) which was 
detected by anti murine TN Fa antibody.
"gpTNFa-MBP fusion protein
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Figure 3.5: Western blot detection of gpTNFa by anti murine TNFa following cleavage of 
the MBP-gpTNFa fusion protein by Factor Xa (a) or thrombin (b).
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3.3 Purification of gpTNFa
gpTNFa was purified by a series of affinity chromatography columns 
(amylose, hydroxyapatite, 2nd amylose and polymixin B) to yield a single band on a 
silver stained SDS-PAGE gel (figure 3.6) at 17 kDa. The purified protein was 
positively immunoblotted with goat and rabbit anti murine TNFa antibodies. The 
immunoblotting of gpTNFa with an anti factor Xa antibody was negative (figure 3.7) 
indicating that the factor Xa had been removed, although an affinity column had not 
been incorporated in the methodology to specifically remove factor Xa.
In initial experiments reverse phase HPLC, barium sulphate precipitation and 
heparin binding columns were used in attempts to isolate gpTNFa from the cleaved 
fusion protein mix, but these proved unsuccessful (not shown).
3.4 Cytolytic activity of gpTNFa
The WEHI 164 clone 13 cytotoxicity assay was used to determine the 
bioactivity of gpTNFa. Both the precleaved fusion protein and the purified gpTNFa 
exhibited cytolytic activity detailed in figure 3.8. The cytotoxic effect of 0.25ng/ml 
gpTNFa on WEHI 164 cells was dose dependently neutralised by increasing the 
concentration of rabbit anti murine TNFa sera (1 in 100 - 1 in 10000) pre-incubated 
with the protein, representative data is shown in figure 3.9. gpTNFa had an activity of 
160IU/ng, compared with 40IU/ng of human TNFa standard.
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Figure 3.6: Western blot (a) and silver stained SDS gel (b) to show the presence of gpTNFa 
at various stages of purification. The MBP-gpTNFa fusion protein, expressed in TB 1 E. coli, 
was cleaved with factor Xa and gpTNFa purified to a single band on a silver stained gel (b).
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Figure 3.7: Western blot to show to the removal of factor Xa during the purification 
of gpTNFa. Factor Xa, which under denaturing conditions is detected as 30kDa and 
20kDa proteins, was immunodetected using rabbit anti human factor Xa. The membrane 
was probed for a second time with goat anti murine TNFa to determine the presence of 
gpTNFa in the samples.
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Figure 3.8: Bioactivity o f gpTNFa was assessed various stages of purification by WEHI 
cytotoxicity assays.
A) The bioactivity o f MBP-gpTNFa fusion protein before (H i )  and after cleavage with 
factor Xa ( | H I  )• Factor Xa (200pg/ml) was incubated with the fusion protein for 18 h at room 
temperature. Cytotoxicity is expressed as cell viability with WEHI cells incubated with medium 
alone representing 100% viability, cells were incubated with factor Xa alone ( □  ) as a control. 
Bars represent mean +/- sem from triplicate determinations.
B) Purified gpTNFa had a specific activity o f 160IU/ng compared to recombinant human TNFa 
standards which had an activity o f 40 IU/ng.
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Figure 3.9: The effect on gpTNFa cytolytic activity by pre-incubating gpTNFa with 
anti TNFa antisera.
gpTNFa ( H  , 25ng/ml) was pre-incubated with rabbit anti murine TN Fa antisera 
1 in 1000 ( (5661), 1 in 1000 ( M S I ) or 1 in 10000 ( Y //X ) for 30 min at room temperature 
prior to addition to WEHI cultures. Cytotoxicity is expressed as cell viability with WEHI 
cells incubated with medium alone representing 100% viability, cells were incubated 
1 in 100 rb a  muTNFa alone ( □  ) as a control.
Bars represent the mean +/- sem from triplicate determinations.
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3.5 Detection of TNFa by ELISA
The murine TNFa ELISA detected murine TNFa over the range of l-30ng/ml 
but did not detect gpTNFa (lOOng/ml), data presented in figure 3.10. As the secondary 
antibody (polyclonal rabbit anti murine TNFa) is known to cross react with gpTNFa 
this suggests that the primary antibody (monoclonal hamster anti murine TNFa) did 
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Figure 3.10: Measurement o f gpTNFa using a murine T N Fa ELISA. 
gpTNFa (0.03-100ng/m l, —O —) and murine TN Fa (0.01-30ng/m l, — ■ —) standards 
were compared in the asssay. Points represent mean absorbance values, with basal 
vehicle absorbance subtracted, o f triplicates +/- sem.
Representative data for 2 experiments.
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3.6 Summary of expression and purification of gpTNFa
• gpTNFa cDNA exhibited a 77.8% and 74.7% homology with murine and human 
TNFa cDNA respectively.
• Mature gpTNFa was expressed as a 154 amino acid, 17 kDa, protein which was 
83.1%, 82.5%, 80.5 and 79.2% homologous with murine, rat, human and rabbit 
TNFa respectively.
• MBP affinity chromatography and purification using hydroxyapatite and 
polymixin B columns resulted in a single 17 kDa band on SDS-PAGE.
• Purified gpTNFa and the MBP-gpTNFa fusion protein was recognised by goat and 
rabbit anti murine TNFa antibodies.
• This recombinant gpTNFa has a cytolytic activity of 160IU/ng, compared with 
40IU/ng recombinant huTNFa standards.
• gpTNFa cytolytic activity was neutralised by rabbit a  murine TNFa antibodies.
4. Induction of 
chemokines by
TNFa
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4.1 The induction of chemokines by TNFa
The ability of gpTNFa (recombinant and macrophage derived) and human 
TNFa to stimulate the release of chemokine-like bioactivity from JH-4 cells was 
assessed by measuring cell culture-supernatant induced calcium mobilisation in 
guinea-pig peritoneal leukocytes. JH-4 IL-8 mRNA production following gpTNFa 
(recombinant) stimulation was also examined.
Supernatants from the incubation of JH-4 cultures with recombinant gpTNFa 
for 4-48 hours induced an increase in [Ca2+]i of peritoneal neutrophils. Maximum 
[Ca2+]i elevations were observed in supernatants from 18 hours incubation with 
gpTNFa. The ability of gpTNFa to stimulate JH-4 cells to produce calcium 
mobilising activity was reduced to control levels by coincubating with rabbit anti 
murine TNFa sera, examples of the experimental traces are shown in figure 4.1. 
Culturing cells with rabbit anti murine TNFa sera alone (control) did induce 
chemokine-like activity in the supernatants but for each time matched control the 
[Ca2+]i elevation was less than the rises induced by supernatants from incubating cells 
with gpTNFa alone. The supernatants from incubations of JH-4 with human TNFa 
only induced slight increases in [Ca2+]i in peritoneal neutrophils following 18 and 24 
hours incubation, shown in figure 4.1.
Guinea-pig IL-8 mRNA was detected in JH-4 cells incubated with gpTNFa for 
6 and 12 hours by northern blot analysis (figure 4.2). This mRNA expression was 
reduced by co-incubating with rabbit anti murine TNFa sera. IL-8 mRNA was not 
detected following the incubation of JH-4 with human TNFa at 6 or 12 hours.
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Figure 4.1 (please see next page):
Figure 4.1 (see facing pageV. Experimental traces to show the elevation of 
[Ca2+]i in fura2 loaded guinea-pig peritoneal neutrophils induced by JH-4 
culture supernatants. Confluent JH-4 cells were stimulated with human TNFa 
lOOng/ml, gpTNFa lOOng/ml (gpTNFa) or gpTNFa lOOng/ml + rabbit anti 
murine TNFa sera 1 in 100 (gpTNFa + rbamuTNFa) for 4 - 4 8  hours. Guinea- 
pig peritoneal neutrophils (lxlO6 cells/ml) were stimulated with lOOjil 
supernatant at approximately 25 seconds. Experimental traces are representative 
of 2 experiments.
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6  hours 1 2  hours
Figure 4.2: gpIL - 8  mRNA expression in stimulated JH-4 cells, measured by Northern blot analysis. 
JH-4 cells were incubated with gpTNFa (lOOng/ml), gpTNFa (lOOng/ml) +rabbit anti murine TNFa, 
sera (1 in 100), human TNFa (lOOng/ml) and antibody (1 in 100) or media alone as controls for 6  
and 12 hours. The top panel shows equal loading of the gel as denoted by the 18S and 28S bands.
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Experiments to determine the ability of human cytokines to induce chemokine 
release from guinea-pig cells were performed. Supernatants from cell cultures of 
guinea-pig spleen cells, peritoneal macrophages and JH-4 cell line, stimulated with 
human cytokines (TNFa, IL-la and IFNy either alone or in combinations) for 24 
hours were assayed for the ability to induce elevation of [Ca2+]i in guinea-pig 
peritoneal leukocytes. With the exception of the supernatant from JH-4 cells cultured 
with human TNFa, which elicited small amounts of IL-8-like (neutrophil stimulating) 
activity, none of the human cytokines, when added alone or in combination, were able 
to induce chemokine activity in the culture supernatants. All supernatants were 
assayed on peritoneal neutrophils, macrophages and eosinophils. For example, fura-2 
loaded peritoneal neutrophil, macrophage and eosinophil [Ca2+]i levels remained at 87 
± 5nM n=18, 72 ± 3nM n=14, 44 ± 2nM n=12, respectively, following the addition of 
cell culture supernatants collected 24 hours following the stimulation of the cell 
cultures with either a single human cytokine or cytokine combinations. However, 
increases in [Ca2+]i levels were observed when fura-2 loaded eosinophils were 
stimulated with supernatant from JH-4 cells incubated with guinea-pig macrophage 
derived gpTNFa (lfig/ml) for 24 hours. The addition of supernatant (100|il) induced 
elevations of [Ca2+]i in eosinophils by 76nM ± 21nM, n=3. In each case the fura-2 
loaded cells were shown to be responsive to lOnM human chemokine standards 
(human RANTES or human IL-8) or PAF (table 4.1).
Table 4.1: Agonist induced elevations of [Ca2+]i in fura-2 loaded guinea-pig
peritoneal leukocytes.
Leukocyte Purity of 
preparation
lOnM agonist Increase in [Ca2+]i 
(nM)
n
eosinophils 92%±3% PAF 265.1 ±24 12
neutrophils 82%±7% human IL-8 236.3 ± 23 18
macrophages 86%±5% human RANTES 184.2+19 14
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4.2 Summary of the induction of ILr8 and chemokine-like activity by 
TNFa
• Supernatants from JH-4 cells incubated with recombinant gpTNFa, for 4 - 48 h, 
induced an IL-8-like bioactivity which was maximal at 18 hours. This bioactivity in 
the supernatant was reduced by co-incubating the JH-4 cells with gpTNFa and 
rabbit anti murine TNFa antibody.
• IL-8 mRNA was detected in JH-4 cells following incubation with gpTNFa but not 
human TNFa.
• Supernatants from guinea-pig spleen cells, peritoneal macrophages and JH-4 cells 
incubated with human TNFa either alone or in combination with IL-1 and IFNy, for 
24 h, did not induce increases in [Ca2+]i in fura-2 loaded peritoneal leukocytes.
• Supernatants from JH-4 cells incubated with guinea-pig macrophage derived TNFa 
for 24 h, induced increases in [Ca2+]j in fura-2 loaded peritoneal eosinophils.
5. In vivo bioactivity 
of TNFa in the 
guinea-pig lung
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5.1 In vivo bioactivity o f gpTNFa
For all of the following in vivo studies tracheal instillation was used. The major 
advantages of this method were that a known amount of agent could be instilled 
directly to the trachea and as the animals were allowed to recover following 
instillation this enabled time course studies to be performed. To monitor the delivery 
and distribution of the instilled agents pilot experiments were performed using a 
protein dye, Evans Blue (50jig per animal), and an eosinophil chemoattractant, PAF 
(5nmoles per animal). Examination of the intact lungs following instillation of Evans 
Blue indicated that this method evenly distributed the instilled agents within the lung. 
Furthermore, the efficiency of the method was demonstrated by the instillation of PAF 
which induced a pronounced BAL eosinophil and neutrophil accumulation 24 hours 
post instillation as shown in figure 5.1.
Instillation of gpTNFa (50 -150ng per animal) induced a significant BAL 
eosinophil accumulation (p<0.01) at 24 hours (shown in plate 5.1 a and b) compared 
with vehicle instilled time matched controls. This response was dose dependent 
reaching significance at 50 and 150ng/animal, as shown in figure 5.2. BAL neutrophil 
numbers were variable within experiments. No increase in macrophage/monocyte 
numbers was observed at 15 or 50ng gpTNFa, compared to vehicle treated animals, 
although the higher dose of 150ng induced macrophage/monocyte infiltration. 
Lymphocyte numbers were not significantly altered in any of the test groups.
Pre-incubation of rabbit anti murine TNFa sera (1 in 100) with gpTNFa prior 
to instillation reduced the BAL eosinophil accumulation by 79.2%±9.4%, 24 hours 
after instillation, as detailed in figure 5.3. Heat treatment of 50ng gpTNFa abrogated 
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Figure 5.1: The effect o f the instillation o f PAF on BAL leukocyte accum ulation. 
Guinea-pigs were instilled with either vehicle PBS 0.1% BSA ( I I ) or PA F ( |  
5nm oles/anim al) 24 h prior to BAL. Bars represent the mean +/- sem, 
n=3 anim als/treatm ent. *p<0.05, **p<0.01 com pared to vehicle treated animals.




Plate 5.1 a: Photograph of gpTNFa (50ng) induced BAL eosinophil 
accumulation 24 hours after instillation of naive guinea-pigs, BAL from vehicle 
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Figure 5.2: The effect of the instillation of gpTNFa on BAL leukocyte accumulation. 
Guinea-pigs were instilled with either vehicle (PBS 0.1% BSAI I), 15 ( (*££>]),
50 ( H ) or 150ng ( Y / / X ) gpTNFa/animal 24 h prior to BAL. Bars represent the 
mean +/- sem, n=3 animals/dose. *p<0.05, **p<0.01 compared with vehicle treated animals.
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Figure 5.3: Neutralisation of gpTNFa induced BAL leukocyte accumulation by anti TNFa 
antibody. Guinea-pigs were instilled with either vehicle (PBS 0.1% BSA, I I),
50ng gpTNFa ( H ) or 50ng gpTNFa preincubated with 1 in 100 rabbit anti 
murine TNFa serum ( tNNN) 24 h prior to BAL. Bars represent the mean +/- sem, 
n=3 animals/treatment. ++p<0.01 compared with vehicle treated animals, **p<0.01 
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Figure 5.4: The effect of heat treating gpTNFa on BAL leukocyte accumulation. 
Guinea-pigs were instilled with either vehicle (PBS 0.1% BSA 1 1), gpTNFa
(50ng H  ) or heat treated gpTNFa (50ng, 80°C 1 h, Y / / X ). Bars represent 
the mean +/- sem, n=3 animals/treatment. **p<0.01, ***p<0.001 compared with 
vehicle treated animals.
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Time course studies of BAL leukocyte accumulation, presented in figure 5.5, 
following the instillation of gpTNFa (50ng) indicated that maximum leukocyte 
accumulation occurred 24 hours after instillation. A slight increase in total BAL 
leukocyte numbers occurred 6 hours after instillation which did not reach significance 
(p=0.051) possibly due to the small sample size (n=3). A pronounced BAL eosinophil 
infiltration was observed 24 hours and maintained significantly above vehicle treated 
time matched controls at 48 and 72 hours after instillation. In these time course studies 
significant increases in BAL macrophage/monocyte and neutrophil numbers was only 
observed at 72 hours after instillation. BAL lymphocyte numbers were not 
significantly elevated at any of the time points studied.
Further experiments were performed to assess the effect of the instillation of 
gpTNFa (50ng) on in vivo bronchial hyperreactivity 24 hours after instillation. As can 
be seen in figure 5.6, although gpTNFa did cause BAL leukocyte accumulation in 
these animals, bronchial hyperreactivity was not induced. Administration of either 1.8- 
10jig/kg histamine or methacholine 3.2 and lOjig/kg caused a dose response effect 
increasing lung resistance in both the control vehicle instilled animals and in the 
gpTNFa instilled animals but differences between the groups were not statistically 
significant.
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Figure 5.5: Time course of gpTNFa induced BAL leukocyte accumulation.
Guinea-pigs were instilled with either vehicle (PBS 0.1% BSA, —□—) or 50ng gpTNFa 
(—• —) at 6, 24,48 or 72 h prior to BAL. Points represent the mean +/- sem, 
n=3 animals/treatment at 6, 48, and 72 h, n=6 animals/treatment at 24 h.
*p<0.05, **p<0.01 compared with animals treated with vehicle treated animals. 
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Figure 5.6: The effect of instilling 50ng gpTNFa on in vivo bronchial responsiveness 
induced by histamine and methacholine. Guinea-pigs were instilled with either vehicle 
(PBS 0.1 % BSA □  ) or gpTNFa (50ng •  ) 24 h prior to lung function tests being
performed. Points represent the mean +/- sem, n=3 animals/treatment.
Figure 5.6 insert: The effect of instilling 50ng gpTNFa on BAL leukocyte accumulation, following lung 
function tests, indicating that the gpTNFa was biologically active. Guinea-pigs were instilled with either 
vehicle (PBS 0.1% BSA I I) or gpTNFa (50ng H ) 26 h prior to BAL. Bars represent the mean +/-sem, 
n=3 animals/treatment. *p<0.05 compared with vehicle instilled animals.
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5.2 In vivo bioactivity o f  human T N F a
In comparison with gpTNFa, the instillation of human TNFa (15-150ng) did 
not induce BAL eosinophil infiltration by 24 hours, figure 5.7. At the highest dose 
examined (150ng) human TNFa induced elevations in BAL macrophage/monocyte 
(which increased by approximately 2 fold) and neutrophil numbers, but only the 
increase in neutrophils reached statistical significance. A photograph of BAL 




Plate 5.2: Photograph of human TNFa (150ng) induced BAL neutrophil 
accumulation 24 hours after instillation of naive guinea-pigs. Magnification 
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Figure 5.7: The effect of instilling human TNFa on BAL leukocyte accummulation. 
Guinea-pigs were instilled with either vehicle (PBS 0.1% BSA, □  ,n=6),
15 ( Y //\  , n=3), 50 ( ■ ■  , n=3) or 150ng ( ES551, n=6) human TNFa/animal 
24 h prior to BAL. Bars represent the mean +/- sem for each treatment.
**p<0.01 compared with vehicle treated animals, where no symbols are indicated 
the differences were not significant (p>0.05) compared with appropriate controls.
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In addition, experiments were performed to assess the effect of administering 
aerosol human TNFa to naive guinea-pigs. The aerosols were delivered either via a 
nose-cone or via an in-line nebulizer connected between the ventilator and the trachea 
cannulae. As shown in tables 5.1 and 5.2 and figures 5.8 and 5.9, at the time points 
examined the administration of human TNFa, by either method, did not induce airway 
hyperreactivity or BAL leukocyte accumulation. Figures 5.8 and 5.9 show the effect of 
administering human TNFa, by aerosol challenge using a nose cone, on airway 
reactivity and BAL leukocyte infiltration 6 hours after challenge. Furthermore, visual 
observation of the basal lung resistance and compliance levels over the 30min TNFa 
(15|ig) challenge, using the in-line ultrasonic nebuliser, indicated that aerosol 
administration of human TNFa had no immediate overt effect on in vivo lung 
function.
Table 5.1: Changes in in vivo guinea-pig bronchial reactivity following the 
aerosol administration of human TNFa. When using the in-line tracheal 
nebuliser each animal served as its own control with the increase in lung 
resistance induced by 10pg/kg histamine assessed immediately prior to 
challenge (before TNFa) and 30 min after TNFa (15|ig) challenge. 50(ig human 
TNFa was administered via the nose-cone with vehicle challenged animals 
being exposed to an equal volume of saline 0.1% BSA.
Human TN Fa Time after Treatment Increase in lung resistance
administered via challenge (cm H jO .lL s1) induced by
(n) histamine (10|lg/kg)
in line ultrasonic 30 min beforeTNFa (3) 483.3±239
nebuliser after TNFa (3) 451.7+284
nose-cone jet 2 hours vehicle (4) 393.2±68
nebuliser TNFa (6) 405±67
nose-cone jet 6 hours vehicle (4) 612.6±196
nebuliser TNFa (4) 428.1±219
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Table 5.2: Human TNFa induced changes in BAL leukocyte numbers when 
administered via a nose-cone (50p,g) or an in-line tracheal nebuliser (15|Xg) 
Vehicle challenged animals were exposed to an equal volume of saline 0.1%
BSA.
Human Time Treatment BAL leukocyte numbers (millions)
TN Fa after
administered challenge (n) macrophages eosinophils neutrophils lymphocytes
via /monocytes
in-line 2 hours vehicle (3) 5.69±1.7 1.2810.7 1.0910.6 0.2110.06
ultrasonic TNFa (3) 8.40+0.9 1.7310.2 1.1810.3 0.2610.2
nebuliser
nose-cone jet 4 hours vehicle (4) 11.46±1.3 5.9311.5 0.3810.05 1.010.2
nebuliser TNFa (6) 7.98±1.7 4.2311.2 0.3010.08 0.6110.2
nose-cone jet 8 hours vehicle (4) 10.3112.5 4.1111.3 0.1710.04 0.4510.1
nebuliser TNFa (4) 11.4614.9 6.0511.9 0.2810.1 0.5110.1
Experiments were performed to determine whether aerosol generation affected the 
bioactivity of TNFa (table 5.3). TNFa WEHI cytolytic activity was assessed in 
samples before and after ultrasonic nebulisation. This treatment was found not to 
change TNFa bioactivity.
Table 5.3: The bioactivity of TNFa was assessed by WEHI bioassay. The 
cytolytic activity prior to aerosolisation was equated to represent 100% TNFa 
bioactivity.
TNFa treatment Cytolytic activity (%)
Before aerosol generation (n=3) 
After aerosol generation (n=3)
100 
94 ± 5
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Figure 5.8: The effect of aerosol huTNFa, administered using a nose cone, on in vivo 
airway responsiveness to histamine. Guinea-pigs were exposed to 5ml of either vehicle 
(PBS 0.1% BSA, —■ —) or huTNFa ; 50|ig) 6 h prior to lung function tests being
performed. Points represent the mean +/- sem, n=4 animals/treatment.
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Figure 5.9: The effect of aerosol huTNFa, administered using a nose cone, on BAL 
leukocyte accumulation. Guinea-pigs were exposed to 5ml of either vehicle (PBS 0.1% BSA, 
1 I) or huTNFa ( H U  I 50pg) 8 h prior to BAL being performed.
Bars represent the mean +/- sem, n=4 animals/treatment.
In vivo bioactivity of TNFa 125
5.3 Summary of the in vivo activity of TNFa in the guinea-pig 
gpTNFa
• gpTNFa (15-150ng) induced a dose dependent increase in BAL leukocyte 
accumulation which was maximum 24 hours after instillation and substained above 
control levels at 72 hours.
• 50ng gpTNFa induced a pronounced BAL eosinophil infiltration.
• gpTNFa induced BAL leukocyte accumulation was abrogated by pre-incubating 
gpTNFa with rabbit anti murine TNFa sera or by heat treating the gpTNFa prior to 
instillation.
• gpTNFa did not induce bronchial hyperreactivity 24 hours after instillation.
Human TNFa
• Human TNFa (150ng) induced a significant elevation in BAL neutrophil numbers 
24 hours after instillation. Macrophage/monocyte numbers were slightly enhanced, 
but eosinophil numbers were not increased.
• Aerosol delivery of human TNFa did not induce bronchial hyperreactivity or BAL 
leukocyte accumulation at 30 min - 8 hours after challenge.
© Following the instillation of human TNFa the leukocytes recruited to the airways 
were predominantly neutrophils. This was in contrast to the eosinophilic leukocyte 
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In order to investigate the involvement of TNFa in allergic airway 
inflammation an animal model was first established and characterised. The ovalbumin 
(OA) sensitised guinea-pig is a classical model of allergic inflammatory lung diseases. 
Before settling on the method used for the other studies shown in this chapter (method 
number 4) which demonstrated bronchial hyperreactivity and lung eosinophilia in the 
studies shown below, several variations of the sensitisation methods were tried. The 
bronchial reactivity and BAL eosinophil accumulation data from various sensitisation 
methods is shown in table 6.1.
Table 6.1: Increases in bronchial reactivity (induced by histamine i.v., 3.2|ig/kg 
and lOjig/kg) and BAL eosinophil infiltration 24 hours following antigen 
challenge of naive or sensitised guinea-pigs using various sensitisation 
protocols. * p<0.05, ** p<0.01, *** pcO.OOl compared with naive guinea-pigs, 
where no symbol is shown the difference was not statistically significant 
(p>0.05). PV: Bordetella pertussis vaccine, BV; Bordetella bronchoseptiemia 
vaccine.
Sensitisation Injected Aerosol Treatment Increases in lung BAL lung
protocols (1ml, i.p.) antigen resistance (cm ILO.l^.s'1) eosinophil
challenge induced by i.v. histamine numbers
No. on days: on days: (n) 3.2|ig/kg lOpg/kg (millions)
1 Cyclophosphamide -1 35-42 naive (6) 127± 99 180± 69 5.8±1.2
Al(OH)3 lmg 0 10ml 0.1%
OA lOflg 14 (no PV) OA sensitised (6) 138+ 16 388± 133 17.9+1.3 *
PV 0.25ml 28 (no PV)
2 Al(OH)3 lmg 0 44-51 naive (4) 319± 126 916±74 1.91±0.2
OA lmg 14 (no PV) 10ml 0.1%
PV 0.25ml 36 (no PV) OA sensitised (4) 456± 118 1244± 159 18.2+3.6**
3 Cyclophosphamide -1 42-52
Al(OH)3 lmg 0 10ml 0.1% naive (5) 200± 95 850± 208 4.67+0.8
OA 10|ig 14 (no PV) OA
PV 0.25ml 28 (no PV) sensitised (5) 805± 226 1305± 90 18.5+2.3**
4 Al(OH)3 2mg 0 28-40 naive (8) 12± 3 115± 38 6.2±2.3
OA lOpg 14 10ml 0.1%
BV 0.05ml OA sensitised (8) 180+ 72*** 836±152*** 26.7+0.5**
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6.1 The effect of antigen sensitisation on in vivo bronchial reactivity
An anti-histamine, mepyramine, was administered 15 min prior to challenging 
with aerosol antigen (OA) for a 60 min period. Changes in in vivo bronchial reactivity 
to known spasmogens was assessed at set time points after antigen challenge. 
Examples of experimental traces, 24 hours after antigen challenge, showing changes in 
lung resistance and dynamic compliance following the infusion of histamine in 
sensitised and naive animals are presented in figure 6.1 when the effects of 
mepyramine were assumed to be negligible. The sensitisation of animals per se had 
little effect on the basal lung resistance and dynamic compliance, as can be seen in 
table 6.2.
Table 6.2: Basal lung resistance and dynamic compliance measurements for 
sensitised and naive guinea-pigs. Animals were antigen challenged 2-48 hours 
prior to in vivo lung function tests, n=3 animals/time point.
time after lung resistance (cm F^O.I^.s'1) dynamic compliance (ml. cm H2O'1)
challenge naive sensitised naive sensitised
(h) challenged challenged challenged challenged
2 151.3±18 195.1±45 0.68±0.2 0.69±0.1
6 113.3±10 184.5±23 0.87±0.1 0.78±0.1
12 143.1±16 174.6±11 0.66±0.1 0.74±0.1
18 155.9±26 143.0±13 0.77±0.1 0.74±0.1
24 160.27±35 126.4±13 0.64±0.1 1.15±0.1
48 145.1±13 158.1±19 0.69±0.1 0.67±0.1
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Figure 6.1 (AV. Dose related increases in lung resistance and decreases in dynamic compliance 
induced by histamine. The experimental traces shown are from a sensitised antigen challenged, 24 h prior 
to assessment o f bronchial reactivity, guinea-pig administered histamine (0 - 5.6pg/kg, i.v.) at the 
60 second time point. 10 minutes was allowed between each infusion.
Figure 6.1 (B): Comparison o f  responses from a naive or sensitised guinea-pig infused with 5.6pg/kg 
histamine at the 60 second time point. Animals were antigen challenged 24 h prior to lung function tests 
being performed.
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Time course studies of histamine induced increases in lung resistance at 2 - 48 
hours after antigen challenge showed a biphasic pattern of hyperreactivity when 
comparing sensitised and naive animals as detailed in figure 6.2. Sensitised animals 
were hyperreactive to histamine (5.6 or 10|ig/kg) 6 hours after antigen challenge, but 
this resolved by 12 hours. The second phase of hyperreactivity occurred at 24 hours 
and was sustained to 48 hours after challenge (figure 6.2). In all cases sensitised 
animals were compared with naive time matched controls. This pattern of 
hyperreactivity was also seen using 10|ig/kg methacholine as the spasmogen, shown in 
figure 6.3, with hyperreactivity peaks at 6 hours (although this was not statistically 
significant, possibly due to the small numbers in the groups) and a sustained phase 24 
- 48 hours. It should be noted that the degree of hyperreactivity varied considerably 
between different batches of sensitised guinea-pigs.
6.2 Airway leukocyte recruitment following antigen challenge of 
sensitised guinea-pigs
The profile of antigen induced leukocyte recruitment to the lungs between 
2 - 4 8  hours is shown in figure 6.4. Total BAL leukocyte numbers were elevated by 6 
hours and remained above the levels of time matched naive antigen challenged 
controls over the time course studied, as shown in table 6.3. BAL neutrophil 
recruitment was transient with numbers significantly elevated by 2 hours, peaking at 
12 hours and returning to control levels by 24 hours. Increased recruitment of 
eosinophils was not observed until 12 hours after challenge of sensitised animals, with 
a maximum accumulation at 24 hours (plate6.1) which was sustained at 48 hours. 
Significant macrophage/monocyte recruitment was observed at 24 hours and sustained 
at 48 hours. Lymphocyte numbers remained very low throughout the time course.
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li Time course studies o f bronchial hyperresponsivness to histamine following antigen 
challenge o f sensitised (— • —) or naive (— □ —) guinea-pigs. Animals were aerosol antigen 
(0.1% OA; 10ml) challenged 2-48 h prior to lung function tests. Points represent mean +/- sem, 
n=3 animals/treatment for 2, 6, 12, 18 ,48  h and n=8/treatment 24 h.
*p<0.05, **p<0.01, ***p<0.001 compared with naive antigen challenged animals.
Panel A shows histamine (l-lO pg/kg) dose-response curves for individual time points post-challenge. 
Panel B shows increases in lung resistance induced by lOjig/kg histamine 2-48 h post-challenge 
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Figure 6.3: Bronchial hyperresponsiveness to methacholine (10pg/kg) following antigen 
challenge of sensitised (—• —) versus naive (— □ —) guinea-pigs. Animals were aerosol 
antigen challenged (0.1% OA; 10ml) 2-48 h prior to lung function tests. Points represent 
mean +/- sem, n=3 animals/treatment. *p<0.05, ***p<0.001 compared with antigen 
challenged naive animals.
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Figure 6.4: Time course of BAL leukocyte accumulation following aerosol antigen (OA) 
challenge o f sensitised (—• —) or naive (—□—) guinea-pigs. Animals were challenged with 
antigen (10ml 0.1% OA) 2-48 h prior to BAL. Points represent mean +/- sem; 
n=3 animals/treatment for 2,6 , 12 and 18 h, n=4 animals/treatment for 24 and 48 h.
*p<0.05, **p<0.01, ***p<0.001 compared with naive antigen challenged animals.
Data are representative of 6 experiments.
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Plate 6.1 a: Photograph of antigen induced BAL eosinophil accumulation 24 
hours after aerosol challenge of sensitised guinea-pigs, BAL from a time- 
matched control antigen challenged naive animals is shown in plate 6.1 b. 
Magnification 2000x.
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Table 6.3: The total BAL leukocyte numbers 2 -48 hours following antigen 
challenge of naive or sensitised animals. * p<0.05, ** p<0.01, *** pcO.OOl 


























6.3 TNFa generation in antigen challenged sensitised guinea-pigs
TNFa generation was measured at the protein and mRNA levels at various 
times after antigen challenge. TNFa levels in the BAL, measured by WEHI 
cytotoxicity assay, were similar in both sensitised and naive antigen challenged 
animals, figure 6.5 (assay sensitivity >0.1IU/ml TNFa). One problem often 
encountered during the assay was a potentiation of WEHI growth induced by BAL 
samples. Experiments were performed in the presence of actinomycin D (lpg/ml) to 
inhibit proliferation but this also reduced WEHI adhesion and cellular viability (-50% 
viable) and hence was not routinely used. In some experiments, FCS was added to the 
BAL samples prior to the addition to wells in order to “saturate” WEHI growth, but 
this did not enhance the sensitivity of the assay.
Whole lung TNFa protein content was measured by western blot analysis. In 
the sensitised animals, 2-24 hours after antigen challenge, there appeared to be a slight 
























48 hours6 hours 12 hours
Figure 6.5: Time course of BAL TNFa content following antigen challenge of 
sensitised (Sen, n=5-8) or naive (N, n=6-8) guinea-pigs. Animals were challenged 
with antigen 2-48 h prior to BAL, and BAL TNFa content was measured by WEHI 
cytotoxicity assay. Each ■  represents the TNFa content of lm l BAL from one 
animal. Data are expressed in cytolytic activity based on a human TNFa standards.
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table 6.4. However, TNFa protein was detected in both groups at all time points 
examined, an example of the western blots obtained is shown in figure 6.6.
Table 6.4: Whole lung TNFa content of sensitised or naive antigen challenged 
guinea-pigs. Lungs were removed 2-24 hours after challenging and TNFa 
content determined by western blot analysis. Scale: - no TNFa, + TNFa band 









2 (n=3) +, + +, +, +
6 (n=3) +, +, - +, +, +
12 (n=3) + +, +, -
18 (n=2) -»+ +,+
24 (n=2) + +,++
Immunohistochemical staining of BAL cytospins for each time point (2-48 h) 
following antigen challenge indicates TNFa in all samples. 50-75% of the BAL cells 
were stained positive (as shown in plate 6.2) but there was no observable difference 
between sensitised or naive animals and the staining was not specific for one 
leukocyte sub-type. However, this data does reflect an increase in overall TNFa 
expression, as the total BAL leukocyte numbers were increased in sensitised animals 
as shown in table 6.3. Due to the low number of animals in each group statistical 
analysis was not performed on these data. Control IgG antibody, used for each BAL 
sample, did not stain positive.
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148kDa ►  
60kDa ►
17kDa ►
Figure 6.6: Western blot to show the presence of TNFa in guinea-pig lung 
tissue homogenates. Naive (N) or sensitised (Sen) animals were antigen 
challenged 2-24 hours prior to BAL and the subsequent removal of the lungs. 
TNFa was detected using rabbit anti murine TN Fa antibody.
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Plate 6.2: Photograph of immunohistochemically detected TNFa in BAL 
leukocytes from an antigen challenged sensitised guinea-pig. TNFa is detected 
with a brown stain and the cells counter stained with Mayers’ hematoxylin 
(blue). BAL was collected 24 hours after aerosol challenging the animals. 
Magnification 2000x.
6.4 BAL induced elevation o f [Ca2+]i in guinea-pig peritoneal 
leukocytes
Elevations of [Ca2+]i in fura-2 loaded peritoneal leukocytes was used to assess 
the chemokine-like bioactivity present in the BAL following antigen challenge of 
sensitised and naive guinea-pigs. It should be noted that gpTNFa does not elevate 
[Ca2+]j in guinea-pig eosinophils, macrophages or neutrophils (M.L. Watson, 
University of Bath and personal observations)
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BAL from sensitised antigen challenged animals induced a rapid transient 
[Ca2+]i elevation in peritoneal eosinophils (eosinophil purity 93% ±5%, n=15), 
figure 6.7. Increased calcium mobilising activity in BAL from sensitised challenged 
animals compared with BAL from naive challenged animals was observed 2 hours 
after challenge but this was not statistically significant. This mobilising activity 
peaked at 6 hours (p<0.001) and was maintained above time matched controls at 12 
and 18 hours (p<0.001, p<0.01 respectively), returning to control levels 48 hours after 
antigen challenge. The [Ca2+]i elevation in eosinophils was reached 10-20s after 
addition of the BAL, with a lag time of ~5s.
BAL from naive challenged animals had weak macrophage (macrophage purity 
85%±4% n=12) stimulating activity, and this was not significantly elevated in time 
matched antigen challenged sensitised animals (e.g. BAL from sensitised animals 6 
hours after challenge induced a 52nM ± lOnM increase in [Ca2+]i compared with 
40nM ± 7nM increase with BAL from time matched controls, n=3 for each group). 
The profile of these [Ca2+]i elevations were similar to those induced in eosinophils. 
BAL from sensitised or naive animals did not induce elevation of [Ca2+]i above basal 
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Figure 6.7: BAL induced elevation of [Ca 2+] in fiira-2 loaded guinea-pig peritoneal eosinophils.
Eosinophils were stimulated with lOOpl BAL from either naive (—□ —, n=5-9) or sensitised (— # —, n=5-9) 
guinea-pigs. Animals were challenged with aerosol antigen 2-48 h prior to BAL. Points represent the 
mean +/- sem. **p<0.01, ***p<0.001 compared with elevations induced by BAL from naive animals. Inserts 
show typical experimental time courses o f [Ca2+]j elevations following BA L stimulation at approximately 
20 seconds (arrows). Only one experimental trace following the addition o f  BAL from a naive animal (B A L  collected  
2 h after challenge) is shown for clarity, this trace is shown superimposed on the 2 h trace.
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6.5 Effect of instilling anti TNFa antibody 20 min prior to antigen 
challenge on antigen induced BAL leukocyte accumulation
The instillation of rabbit anti murine TNFa IgG in sensitised guinea-pigs 
reduced the eosinophil accumulation by 69.4%±3.8% (n=6) and the neutrophil 
accumulation by 94.1%±3.5% (n=6) 24 hours after challenge (figure 6.8) compared 
with sensitised guinea-pigs instilled with rabbit IgG. BAL macrophage/monocyte 
numbers were not significantly reduced by antibody instillation. The instillation of 
rabbit anti murine TNFa IgG to naive animals had no significant effect on BAL 
leukocyte accumulation when compared with naive animals instilled with rabbit IgG, 



























Figure 6.8: The effect of anti TNFa antibody on antigen induced BAL leukocyte 
accumulation. Antigen sensitised animals were instilled with either rabbit anti murine 
TNFa IgG (1 in 100; IHBil) or control rabbit IgG (linlOO; H  ), and naive animals 
were instilled with either rabbit anti murine TNFa IgG (1 in 100; Y //X ) or rabbit IgG 
(linlOO; I I) as additional controls. All animals were instilled with 50pl antibody 
20 min prior to aerosol antigen challenge (10ml 0.1% OA) and BAL was performed 
24 h later.
Bars represent mean +/- sem, n=6 animals/treatment. +++p<0.001 compared with 
naive animals instilled with rabbit IgG. **p<0.01, ***p<0.001 compared with sensitised 
animals instilled with rabbit anti murine TNFa IgG. Where no symbols are indicated 
the differences were not significant (p>0.05).
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6.6 Summary of the effect of antigen challenge of sensitised animals
• Antigen challenge induced biphasic bronchial hyperreactivity: The initial period of 
hyperreactivity occurred at 6 hours and was resolved by 12 hours, with the second 
period maximal at 24 hours and sustained at 48 hours.
• Antigen challenge induced BAL leukocyte accumulation: Neutrophil infiltration 
was transient and rapid in onset (occurring by 2 h), with maximum infiltration 12 
hours after antigen challenge. The accumulation of eosinophils occurred at 12 
hours, was maximum at 24 hours and remained pronounced at 48 hours. 
Macrophage/monocyte infiltration was later in onset, occurring at 24 hours and 
sustained at 48 hours.
• TNFa, mRNA and protein, was expressed in both naive and sensitised animals.
• BAL from sensitised animals induced transient increases in [Ca ]i in fura-2 loaded 
peritoneal eosinophils. Activity was maximum in BAL 6 hours after challenge and 
returned to control levels by 48 hours after challenge. BAL from both naive and 
sensitised animals, 2 - 4 8  hours after challenge, induced similar increases in [Ca2+]i 
in fura-2 loaded peritoneal macrophages. BAL stimulation of fura-2 loaded 
peritoneal neutrophils did not increase [Ca2+] i .
• Instilling rabbit anti murine TNFa IgG 20 min prior to antigen challenge caused a 
marked reduction in BAL eosinophil and neutrophil accumulation, the latter being 
reduced to control levels 24 hours after challenge. Macrophage/monocyte 
accumulation was not affected.





In vivo effects ofIL-13 146
To determine the effect of IL-13 on airway inflammation two guinea-pig 
models were used 1) gpTNFa-induced inflammation and 2) antigen induced airway 
inflammation.
7.1 The effect of IL-13 and IL-4 on gpTNFa induced BAL leukocyte 
accumulation
Initial experiments demonstrated that the instillation of IL-13 (lOOng) alone 
did not induce increased BAL leukocyte accumulation. However, by co-instilling IL- 
13 (1-lOOng) with gpTNFa (50ng) there was a reduction in total BAL leukocyte 
accumulation 24 hours after instillation. gpTNFa induced macrophage/monocyte and 
eosinophil infiltration was reduced in a dose dependent manner by IL-13, as shown in 
figure 7.1. The gpTNFa induced BAL macrophage/monocyte and eosinophil 
recruitment was inhibited to near control (vehicle treated) levels by the co-instillation 
of the highest used dose of IL-13 (lOOng) with gpTNFa (50ng).
Measurements of total lung EPO performed following BAL indicated that the 
co-instillation of IL-13 caused a reduction in EPO levels (figure 7.2) compared to 
levels in lung tissue from animals instilled with gpTNFa alone. Statistical significance 
was not reached, probably due to the small number of animals (3/group) used in this 
study.
Following the co-instillation of gpTNFa (50ng) with IL-4 (lOOng) a slight 
reduction in BAL macrophage/monocyte and eosinophil numbers and a marginal 
increase in neutrophil numbers were observed at 24 hours, compared with the 
instillation of gpTNFa alone, but none of these changes were significant as shown in 
figure 7.3. The instillation of IL-4 (lOOng) alone induced a significant increase in BAL 
macrophage/monocyte and neutrophil numbers compared to vehicle instilled animals. 
No increase in BAL eosinophil or lymphocyte numbers was induced by IL-4.
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Figure 7.1: The effect of IL-13 on gpTNFa induced BAL leukocyte accumulation.
Naive guinea-pigs animals were instilled with either vehicle (PBS 0.1% BSA; I 1; n=5), 
lOOng IL-13 ( Y Z Z  ; n=6), 50ng gpTNFa ( W M  ; n=5), 50ng gpTNFa + lOOng IL-13 ( W M  ; n=< 
50ng gpTNFa + lOng IL-13 ( PS&5I; n=6) or 50ng gpTNFa + lng IL-13 ( H I  i n=6).
All animals were instilled (50pl) 24 h prior to BAL. Bars represent the mean+/- sem for each 
treatment. +++p<0.001 compared with vehicle treated animals *p<0.05, **p<0.01, ***p<0.001 
compared with gpTNFa treated animals. Where no symbols are indicated the difference 
was not significant (p>0.05) compared with the appropriate controls.
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Figure 7.2: The effect of gpTNFa and IL-13 on eosinophil peroxidase (EPO) activity 
in guinea-pig whole lung extracts following BAL. Naive guinea-pigs were instilled with 
vehicle (PBS 0.1% BSA), lOOng IL-13 alone, 50ng gpTNFa alone or 50ng gpTNFa + 100, 
10 or lng IL-13 24 h prior to BAL and the subsequent removal of whole lung tissue.
Bars represent the mean +/- sem, n=3 animals/treatment.
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Figure 7.3: The effect of instilling IL-4 on gpTNFa induced BAL leukocyte accumulation. 
Guinea-pigs were instilled with either vehicle (PBS 0.1% BSA, I I), lOOng IL-4 ( E99S1), 
50ng gpTNFa ( H ) or 50ng gpTNFa + lOOng IL-4 ( IflMBSl) 24 h prior to BAL.
Bars represent the mean +/- sem, n=3 animals/treatment, **p<0.01, ***p<0.001 compared 
with vehicle treated animals. Where no symbols are indicated the difference was not 
significant (p>0.05) compared with the appropriate controls.
In vivo effects of IL-13 150
7.2 Effect of IL-13, instilled 20 min prior to antigen challenge, on 
antigen-induced BAL leukocyte accumulation
The instillation of IL-13 (l-100ng/animal) 20 min prior to antigen challenge of 
sensitised guinea-pigs caused a dose dependent reduction in antigen induced BAL 
leukocyte accumulation as detailed in table 7.1. This reduced number of cells was 
principally accounted for by a reduction in eosinophil numbers (figure 7.4) with no 
significant change in macrophage/monocyte or neutrophil numbers. Lymphocyte 
numbers were reduced by instilling IL-13 prior to antigen challenge, which was 
significant at the dose of lOng IL-13. Although the instillation of lOOng IL-13 
significantly inhibited BAL eosinophil accumulation in response to antigen challenge 
of sensitised animals by 72% ±4% (n=6), this level was still 3 fold higher than the 
eosinophil numbers in naive animals instilled with IL-13.
Table 7.1: The effect of instilling IL-13 on antigen induced total leukocyte BAL 
accumulation. 11^13 (l-100ng/animal) or vehicle (PBS, 0.1%BSA) was instilled 
20 min prior to antigen challenge of sensitised or naive animals. BAL was 
performed 24 hours after challenge, t t t  p<0.001 compared with vehicle treated 




Total number of BAL 
cells (millions)
Naive (n=6) 0 14.43±2.7
Naive (n=6) 100 15.79±2.9
Sensitised (n=6) 0 87.47±5.2 t t t
Sensitised (n=5) 1 64.01 ±6.5 *
Sensitised (n=6) 10 51.69±4.0 ***
Sensitised (n=6) 100 48.67+3.7 ***
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Figure 7.4: The effect o f  IL-13 on antigen induced BAL leukocyte accumulation.
Antigen sensitised animals were instilled with either vehicle (PBS 0.1% BSA; H I ; n=6), 
lOOng IL-13 ( IfilgSl; n=6), lOng IL-13 ( RS&Sl; n=6) or lng IL-13 ( H I  i n=5) prior to aerosol 
antigen challenge (10ml 0.1% OA). Naive animals were instilled with vehicle ( I I ; n=6) 
or lOOng IL-13 ( Y / / \  ; n=6) as additional controls. All animals were instilled with 50pl 20 min 
prior to antigen challenge and BAL was performed 24 h later. Bars represent the mean +/-sem  
for each treatment. +++p<0.001 compared with naive-vehicle treated animals **p<0.0l, 
***p<0.001 compared with sensitised-vehicle treated animals. Where no symbols are 
indicated the difference was not significant (p>0.05) compared with the appropriate controls. 
Lymphocyte data inset shows enlarged scale.
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7.3 Effect of IL-13 on chemokine-like activity in BAL of antigen 
challenged sensitised guinea-pigs
The chemokine-like activity present in the BAL was assessed by measuring
9+changes in [Ca ]i in fura-2 loaded peritoneal eosinophils following the addition of 
BAL. BAL (IOOjliI) from vehicle instilled naive antigen challenged animals induced 
marginal increases in eosinophil [Ca2+]i (5.8±3.6 nM, n=6). However, transient 
increases in eosinophil [Ca2+]i were induced by BAL from vehicle instilled sensitised 
animals, as shown in the experimental trace in figure 7.5. Following the instillation of 
lOOng IL-13 prior to antigen challenging sensitised animals, the calcium mobilising 
activity in the BAL was reduced by 60%±13% (n=6/group, compared to vehicle 
instilled sensitised animals) which was statistically significant (p<0.05).
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Figure7.5: Inhibition o f the generation of BAL eosinophil stimulating activity by IL-13.
Fura-2 loaded guinea-pig peritoneal eosinophils were stimulated with lOOpl BAL
from sensitised animals instilled with either vehicle ( B ) or IL-13 (lOOng/animal) ( RS&Sl),
or control naive animals instilled with vehichle ( 1 I).
Animals were instilled 20 min prior to aerosol antigen challenge (10ml 0.1% OA) and BAL 
was performed 24 h later. Bars represent the mean +/- sem, n=6 animals/treatment.
***p<0.001 compared with elevations induced by BAL from vehicle instilled naive animals, 
+p<0.05 compared with elevations induced by BAL from vehicle instilled sensitised animals. 
Inserts show typical time courses o f [Ca2+]j elevations following addition o f BAL at the 
40 second time point (arrows).
vehicle-naive
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7.4 Summary of the in vivo activity of IL-13 in guinea-pig models of 
airway inflammation
gpTNFa induced airway inflammation
• Co-instillation of IL-13 with gpTNFa inhibited gpTNFa induced BAL leukocyte 
accumulation. IL-13 (1-lOOng) co-instillation dose dependently reduced the 
gpTNFa induced BAL leukocyte infiltration with lOOng IL-13 reducing the BAL 
leukocyte numbers to control levels.
• Co-instillation of IL-4 (lOOng) with gpTNFa did not significantly reduce gpTNFa 
induce BAL leukocyte accumulation.
Antigen induced airway inflammation
• The instillation of IL-13 (1-lOOng) 20 min prior to antigen challenge of sensitised 
animals caused a dose dependent reduction in BAL eosinophil accumulation 24 
hours after challenge.
• BAL from sensitised animals instilled with lOOng IL-13 prior to antigen challenge 




8.1 Initial aims of the project
At the outset of this project in vitro studies had provided evidence to implicate 
the involvement of TNFa in inflammatory diseases and this was combined with a 
number of clinical studies reporting elevated levels of TNFa in the asthmatic lung. 
However, the in vivo bioactivity of TNFa in the lung had been incompletely 
characterised. The purpose of this study was to express and purify recombinant 
gpTNFa and then to determine its activity in vitro using guinea-pig cells and in the 
guinea-pig airways in vivo. Furthermore, in order to investigate whether TNFa is 
expressed in antigen challenged sensitised guinea-pigs DIG-labelled DNA probes were 
developed and anti TNFa antibodies used. In addition, the effect on antigen-induced 
airway leukocyte accumulation and the generation of chemokine-like bioactivity 
following the administration of anti-inflammatory cytokines was examined. Agents 
which inhibit the actions of TNFa could be potential therapies in preventing allergic 
respiratory disorders.
8.2 Expression and purification of gpTNFa
The cDNA sequence predicted gpTNFa to be a 234 amino acid propeptide 
which, in order to correspond with the NH2  terminus of the sequence reported by 
Tamatani et al. (Tamatani et al. 1989), probably forms a 154 amino acid mature 
protein. gpTNFa exhibited high amino acid sequence homology with published 
mammalian TNFa sequences. The NH2  terminus of secreted TNFa has been predicted 
to result from the cleavage of the propeptide at one of two sites separated by 2  amino 
acid residues. In the majority of mammalian sequences there is a highly conserved area 
of the propeptide, shown in table 8 . 1  as a shaded area, in the region of the putative 
TNFa cleavage site. Studies of human TNFa (Pennica et al. 1984; Wang et al. 1985; 
Aggarwal et al. 1985) have identified the cleavage site to be between propeptide 
amino acids 76 alanine (A) and 77 valine (V), referred to as cleavage site a in the text 
and table 8.1. However, Shirai et a l (Shirai et al. 1985) predicted the cleavage site to
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be between amino acids 78 arginine (R) and 79 serine (S), referred to as cleavage site 
b in the text and in table 8.1, in accordance to the sequence of TNFa derived from 
rabbit serum (Ito et al. 1986). In this study I have assumed gpTNFa is cleaved at the 
R-S bond, as is the case for rat (Shirai et al. 1989) and rabbit TNFa (Ito et al. 1986), 
and indicated by the sequence data of Tamatani et al. (Tamatani et al. 1989). This R-S 
bond appears to be conserved in all mammalian sequences. Furthermore, as the amino 
acids at the predicted cleavage site a (A-V) are less conserved between species than 
the R-S bond at cleavage site b, this may be of relevance when designing inhibitors of 
TNFa secretion and their subsequent use in animal models. However, the removal of 
four amino acids (VRSS) from the NH2 terminus has little effect on the biological 
activity of human TNFa (Kirchesis et al. 1992; Gase et al. 1990). Gearing et al. 
(Gearing et al. 1994) and McGeehan et al. (McGeehan et al. 1994) have implicated a 
role for metalloproteinases in the processing of the propeptide and also that specific 
metalloproteinases inhibitors reduce in vitro TNFa secretion and circulating TNFa 
levels in rats and mice following LPS administration. A human metalloproteinase, 
TNFa converting enzyme (TACE), which acts at the A-V bond, has recently been 
cloned (Black et al. 1997; Moss et al. 1997).
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Table 8.1: Alignment of a region of the TNFa propeptide amino acid sequences 
of various mammalian species to show the highly conserved area surrounding 
the putative secreted TNFa cleavage site. Cleavage is predicted to occur at one 
of two sites either cleavage site a, between the first two amino acids in the 
shaded area, or cleavage site b, between the third and fourth amino acid residues 
in the shaded area.
species amino acid sequence for cleavage region of propeptide
i*>
reference
baboon SPLAQ AVRSSS RTPSDKPVAHWANPQAEGQLQWLNRRANALLANGV Sanjanwala, M.
Genebank P33620
bovine SPLVQ TLRSSS . QAS SNKPVAHWADINS PGQLRWWDS YANALMANGV (Cludts
1993)
et al.
equine NPLAQ TLRSSS RTPSDKPVAHWANPQAEGQLQWLSGRANALLANGV (Su et al. 1991)
feline NPLPQ TLRSSS RTPSDKPVAHWANPEAEGQLQRLSRRANALLANGV (McGraw
1990)
et al.
guinea- LAQTL TLRSAS QNDNDKPVAHWANQQAEEELQWLSKRANALLANGM this report
pig
human SPLAQ AVRSSS RTPSDKPVAHWANPQAEGQLQWLNRRANALLANGV (Pennica
1984)
et al.
murine MAQTL TLRSSS QN S S DK PVAHWANHQVEEQLEWL S QRANALL ANGM (Pennica
1985)
et al.
ovine RPLVQ TLRSSS QASNNKPVAHWANISAPGQLRWGDSYANALMANGV (Nash
1991)
et al.
porcine NPLAQ GLRSSS QT SDKPVAHWANVKAEGQLQWQSGYANALLANGV (Drews 
1990)
et al.
rabbit VAQMV TLRSAS RALSDKPLAHWANPQVEGQLQWLSQRANALLANGM (Ito et al.
rat MAQTL TLRSSS





The amplified gpTNFa cDNA was inserted into an expression system that 
resulted in the production of a MBP-gpTNFa fusion protein. The expressed fusion 
protein was shown to exhibit both cytolytic activity and TNFa immunoreactivity. 
Interestingly, the ability of the fusion protein to induce cytotoxicity in a WEHI
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bioassay suggests that the MBP did not hinder trimer formation which is required for 
bioactivity (Smith & Baglioni 1987).
gpTNFa was cleaved from the fusion protein by factor Xa. Although thrombin 
also cleaves at R-S bonds this was not found to be efficient under the conditions used. 
Pilot purification experiments using reverse phase HLPC (Tamatani et al. 1989) and 
heparin columns (Lantz et al. 1991) were disappointing as no active product was 
recovered. The protein was subsequently purified using a series of hydroxyapatite, 
amylose and polymixin B bound agarose columns. Purification of gpTNFa resulted in 
the production of a single 17kDa protein which was recognised by goat and rabbit anti 
murine TNFa antibodies. In agreement with the findings of (Tamatani et al. 1989) the 
specific activity of gpTNFa was found to be greater than that of human TNFa. Both 
human and gpTNFa bioactivity could be neutralised by co-incubating with anti 
murine TNFa antibodies.
8.3 The in vivo bioactivity of TNFa
Inflammation induced by TNFa has been previously studied in the guinea-pig 
with conflicting results. In vivo studies by Kings et al. (Kings et al. 1990) showed that 
intraperitoneal administration of recombinant murine TNFa induced lung 
eosinophilia, whilst Collins et al. (Collins et al. 1993) were unable to induce skin 
eosinophilia following intradermal administration of human TNFa. Endogenous 
TNFa could induce eosinophil accumulation in the guinea-pig skin as the response to 
intradermal LPS was reduced by administration of a soluble TNFa receptor : Ig 
construct (sTNFaR-Fc) (Weg et al. 1995). Further, in isolated perfused guinea-pigs 
lungs, human TNFa increased the sequestration of activated human neutrophils via the 
upregulation of pulmonary vascular endothelial cell ICAM-1 expression (Lo, K. et al.
1992). Previous reports of intratracheal administration of TNFa have utilised in vivo 
rat models, where again the data have been variable. Ulich et al. (Ulich et al. 1991)
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indicated that human TNFa induced a slight but reproducible lung neutrophilia which 
began 6  hours following instillation, peaked at 12-24 hours and subsided by 48 hours 
following intratracheal instillation in rats, whilst significant BAL neutrophil 
accumulation occurred 90 minutes following aerosol exposure human TNFa (Kips et 
al. 1992). However, Wesselius et al. (Wesselius et al. 1995) and Debs et al. (Debs et 
al. 1988) did not observe intra-alveolar neutrophil accumulation following 
intratracheal or lung-specific aerosol delivery of human TNFa respectively. These 
differences may reflect poor species cross-reactivity as none of the studies used TNFa 
from the host species.
The intratracheal instillation of gpTNFa induced a pronounced and protracted 
eosinophilia which was dose dependent. During the initial experiments gpTNFa 
appeared to selectively recruit eosinophils to the airways, however in later experiments 
there was also an increase in macrophage/monocyte numbers which had previously 
been masked by high macrophage/monocyte numbers in the control groups. The 
pre-incubation of rabbit anti murine TNFa sera with gpTNFa prior to instillation 
reduced the eosinophil accumulation, indicating this was a TNFa-driven effect. The 
possibility that the effect was due to LPS induced TNFa production was ruled out 
since both heat treatment and pre-incubation of gpTNFa with antibody abrogated the 
eosinophilia, in addition the gpTNFa was passed over a solid phase polymyxin B 
column prior to instillation. Time course studies indicated that the maximum 
eosinophilia was observed 24 hours following gpTNFa instillation, but significant 
eosinophilia was maintained at 72 hours.
The administration of human TNFa by various aerosol routes was unable to 
induce guinea-pig BAL leukocyte accumulation in this study, a finding also reported 
in a rat model (Debs et al. 1988). However, the administration of human TNFa by 
intratracheal instillation to the guinea-pig did induce an inflammatory cell recruitment 
which was weaker and exhibited different cellular characteristics than the
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gpTNFa-induced response. Unlike gpTNFa, human TNFa did not induce eosinophil 
accumulation but did promote significant neutrophil infiltration and a slight increase 
in macrophage/monocyte numbers 24 hours after the administration of the highest 
dose used. The difference in leukocyte sub-type accumulation might be due to both 
differences in the distribution of the two TNFa receptors and their affinity for the 
proteins. However, only a limited number of experiments were performed using 
human TNFa, and further studies using anti receptor antibodies may help to clarify 
this. In the murine system the two TNFa receptors bind TNFa from different species 
with varying affinities. Whereas the murine p55 receptor binds with similar affinity to 
both murine and human TNFa, the murine p75 receptor shows strong selectivity for 
murine TNFa (Lewis et al. 1991; Smith et al. 1986). Species selectivity resulting in 
reduced in vivo bioactivity of human TNFa, compared with gpTNFa, was also 
demonstrated in vitro. In vitro studies indicated that gpTNFa but not human TNFa 
induced the production of chemokine-like bioactivity from guinea-pig cells. The 
stimulation of guinea-pig spleen cells, peritoneal macrophages and the guinea-pig cell 
line, JH-4 with either human TNFa, or a combination of human TNFa plus human 
IL-1 and human IFNywas unable to induce chemokine production following 24 hours 
incubation. However, the incubation of JH-4 cells with either macrophage derived 
TNFa or recombinant TNFa induced the production of eotaxin-like bioactivity (the 
supernatants increased [Ca2+]i in eosinophils) and IL- 8  production, respectively. TNFa 
induced eotaxin and IL- 8  expression have previously been reported in various human 
cell types (Westwick et al. 1991, Garcia-Zepeda et al. 1996). Similarly, human TNFa 
was reported to be unable to induce guinea-pig eosinophil chemotaxis or prime the 
eosinophils with respect to PAF or LTB4  induced responses (Coeffier et al. 1991). 
These results further support in vivo studies where human TNFa did not induce skin 
eosinophil accumulation in the guinea-pig (Collins et al. 1993), suggesting species 
selectivity.
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8.4 Is TNFa involved in allergic airway inflammation?
In order to address this question an OA sensitised guinea-pig model of airway 
inflammation was utilised. The sensitisation protocols used were based on those 
described by Andersson (Andersson 1981) and Sanjar et al. (Sanjar et al. 1990). 
Several variations of the methods, which included the use of cyclophosphamide and 
Bordetella pertussis vaccine, were tried in order to establish a model which 
demonstrated consistent bronchial hyperreactivity and lung eosinophilia. Due to the 
toxic nature of cyclophosphamide and the difficulty in obtaining Bordetella pertussis 
vaccine, the sensitisation method was changed to incorporate Bordetella 
bronchiseptica vaccine (P. McCabe, Glaxo-Wellcome, personal communication) and 
this methodology was used in all sensitisation data shown. In order to avoid fatal 
anaphylactic shock during antigen provocation all animals were routinely administered 
an anti-histamine, mepyramine, prior to challenging.
The model exhibited airway hyperreactivity, with peak responsiveness 6  and 
24 hours following antigen challenge. Both an early and late phase airway 
hyperreactivity have previously been demonstrated in the OA sensitised guinea-pig 
however the time of onset of the early response is variable, reported to occur 
immediately (Ishida et al. 1989) or up to 4 hours after antigen challenge (Hutson et al. 
1988; Boichot et al. 1991). The differences in onset times are in part due to variations 
in sensitisation methods and the time of administration of an Hi-receptor antagonist. 
In addition to the biphasic increase in bronchial hyperreactivity, airway leukocyte 
infiltration was also observed in two phases, an early infiltration of neutrophils 
peaking by 1 2  hours was followed by a delayed and protracted eosinophil infiltration, 
which peaked at 24 hours and the plateau was maintained at 48 hours. Unlike lung 
inflammation, airway hyperreactivity was not consistently observed following antigen 
challenge of sensitised animals. This is in agreement with the concept that cellular 
influx may be important but is not sufficient to induce airway hyperresponsiveness 
(Folkerts et al. 1988; Chapman et al. 1993). In support of this theory the instillation of 
gpTNFa alone did not induce airway hyperresponsiveness although these animals did
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exhibit a pronounced airway eosinophilia. However, the administration of an 
anti TNFa antibody is reported to reduce LPS induced hyperreactivity in a rat model 
(Kipsefa/. 1992).
Increased TNFa levels in the airways of sensitised guinea-pigs have previously 
been demonstrated at 1-2 hours (Kelly et a l 1993) and 24 hours (Watson et a l  1993) 
after antigen challenge. Although no significant antigen-induced increases in TNFa 
expression were demonstrated in this report, the trends shown suggest that TNFa 
protein levels in whole lung tissue and BAL leukocytes were increased following 
antigen challenge. Pilot experiments indicated the presence of TNFa mRNA in lung 
tissue following antigen challenge. Unfortunately, repeating these experiments proved 
problematic due to RNA degradation during the extraction of message from the tissue. 
This may be due to high RNase activity of the infiltrating eosinophils. However, 
increased TNFa mRNA in murine lung tissue has been reported by others 1, 8 , and 24 
hours following antigen challenge (Lukacs et a l 1995b). Elevated TNFa levels in the 
BAL were variable, this may possibly have been due to the multitude of mediators 
collected in the BAL influencing the growth of the WEHI cells. These mediators may 
therefore have masked the cytolytic activity of TNFa present in the BAL. Additionally 
it is possible that these mediators were not released in the airways of naive animals 
and hence the apparent decrease in BAL TNFa levels following antigen challenge of 
sensitised animals compared to antigen challenged naive animals. In an attempt to 
resolve this problem a murine TNFa ELISA was tested using purified gpTNFa. The 
ELISA did not detect gpTNFa and the adaptation of the ELISA to measure the protein 
was hindered by the lack of specific monoclonal antibodies for gpTNFa.
Since the start of this project the involvement of TNFa in various models of 
inflammation has been demonstrated using anti TNFa antibodies or soluble receptors. 
The data presented show that the administration of an anti TNFa antibody prior to 
antigen challenge reduced both eosinophil and neutrophil airway inflammation 24
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hours after challenge. These results are in accordance with those of Lukacs et al. 
(Lukacs et al. 1995b) where the administration of sTNFaR-Fc in a murine model of 
allergic airway inflammation reduced both the early neutrophil and later eosinophil 
airway infiltration. Additionally, to assess the potential use of sTNFaR-Fc as a 
therapeutic agent it was administered to the mice 24 hours after antigen challenge and 
this inhibited subsequent eosinophil influx. In contrast to inhibiting eosinophilia, in a 
rat model of sephadex-induced lung injury the administration of sTNFaR-Fc reduced 
BAL neutrophilia but slightly increased eosinophil infiltration (Gater et al. 1996).
The complexity of the role of TNFa has been demonstrated in studies 
indicating that both cytokines and chemokines which are themselves induced by 
TNFa may also regulate TNFa expression. Our lab has reported that the in vivo 
administration of IL-lra reduced BAL TNFa levels and eosinophil infiltration in a 
guinea-pig model of antigen-induced airway inflammation (Watson et al. 1993). 
Furthermore, studies relating to the regulation of chemokine expression report that in a 
murine model of endotoxemia inhibition of TNFa reduced MIP-la expression by 
60% (Standiford et al. 1995), whilst administration of an anti MIP-la antibody 
decreased BAL TNFa levels in two neutrophil-dependent models of lung 
inflammation (Shanley et al. 1995).
The development of human TNFa mutants which bind selectively to one of the 
two receptors (Loetscher et al. 1993) has promoted further investigation into the 
mechanisms by which TNFa induces an inflammatory response. The subcutaneous 
administration of a p55 agonist in the baboon resulted in neutrophil accumulation 
which was not seen with p75 agonist (Welbom III et al. 1996). Here a p75 agonist was 
unable to elicit an inflammatory response but the authors did not establish if p55 alone 
is sufficient to mediate a full inflammatory response as the p55 agonist has been 
shown to induce endogenous TNFa release (Van Zee et al. 1994) which can activate 
both p55 and p75.
Discussion 165
8.5 Mechanisms by which TNFa induces airway inflammation.
The recruitment of leukocytes in response to TNFa is likely to result from a 
series of orchestrated events which includes increased adhesion molecule and 
chemokine expression. In vitro TNFa is a very weak inducer of eosinophil chemotaxis 
(Bittleman et al. 1996). gpTNFa does not induce eosinophil migration in chemotaxis 
chambers with artificial filters or induce changes in [Ca2+]i in fura-2 loaded guinea-pig 
peritoneal eosinophils (White et al. 1997). However, TNFa induces the expression of 
VCAM-1 on endothelial cells which would facilitate the recruitment of eosinophilic 
and mononuclear leukocytes. Further VCAM-1 expression might favour a protracted 
response as VCAM-1 mRNA persists for 72 hours following in vitro TNFa 
stimulation of endothelial cells (Osborn et al. 1989). In addition, the in vitro 
preincubation of 11 ^ -labeled guinea-pig eosinophils with anti VLA-4 antibodies 
reduces eosinophil accumulation in guinea-pig skin following LPS administration 
(Weg et al. 1993).
The migration of eosinophils from the microvasculature to the lung tissue is 
reported to be primarily via VLA-4/VCAM-1 interactions and to a lesser extent 
LFA-1, Mac-1 / ICAM-1, ICAM-2 interactions (Nakajima et al. 1994). Several studies 
have demonstrated that the inhibition of VLA-4 reduces antigen-induced BAL 
eosinophil accumulation and bronchial hyperreactivity (Pretolani et al. 1994; Milne et 
al. 1995; Abraham et al. 1994). In contrast, a previous study reported that the 
inhibition of ICAM-1 reduced antigen-induced eosinophil accumulation in the BAL of 
monkeys (Wegner et al. 1990). In addition, the administration of an anti CD 18 
antibody, the p2 integrin sub-unit of ICAM-1 ligands LFA-1 and Mac-1, also inhibited 
BAL eosinophil accumulation. However, the anti CD 18 antibody did not reduce the 
accumulation of eosinophils in the lung tissue (Milne et al. 1994), indicating that the 
subsequent migration into the airway lumen might involve LFA-1 or Mac-1 
interactions with ICAM-1 and ICAM-2. This theory is supported by the distribution of
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the adhesion molecules as, unlike ICAM-1 which is expressed on the endothelium and 
epithelium, VCAM-1 is not expressed on airway epithelial cells (Bloeman et al.
1993).
The identification of chemokines has helped to advance our understanding of 
the mechanisms underlying the accumulation of a predominant leukocyte sub-type in a 
disease condition. TNFa is a potent inducer of chemokine expression in vitro from 
both resident tissue cells e.g. fibroblasts and epithelial cells, and leukocytes (Lukacs et 
al. 1995a; Westwick et al. 1991; Cromwell et al. 1992). TNFa induced eosinophil 
migration involves, at least in part, the upregulation of chemokine expression (Watson 
et al. 1988).To date, one of the most potent chemokines with respect to eosinophil 
chemotaxis is eotaxin (Jose et al. 1994b), a C-C chemokine recently cloned from 
allergen-challenged guinea-pig lungs (Jose et al. 1994a). TNFa induces eotaxin 
expression in endothelial and epithelial cells (Garcia-Zepeda et al. 1996), and it is 
possibly a very important mediator of TNFa-induced eosinophil accumulation. In 
addition, the C-C chemokines RANTES, MCP-2, -3,-4 and the recently discovered 
peptide eotaxin-2 (Rot et al. 1992, Noso et al. 1994; White J. et al. 1997) are capable 
of stimulating human eosinophils. RANTES, although found to activate guinea-pig 
macrophages not guinea-pig eosinophils (Campbell et al. 1996), is increased in BAL 
from asthmatic subjects (Teran et al. 1996). A further C-C chemokine which activates 
eosinophils and regulates eosinophil accumulation is MIP-la (Rot et al. 1992). In a 
model of antigen-induced airway inflammation, MIP-la mRNA and protein 
expression was increased after challenge with mononuclear cells, eosinophils and 
airway epithelial cells expressing the protein. The inhibition of MIP-la reduced lung 
and airway eosinophil infiltration by 50% (Lukacs et al. 1997). In addition to the 
direct actions of MIP-la on eosinophil recruitment, MIP-la can potentiate the 
inflammatory response by modulating macrophage function, increasing TNFa and 
IL-1 production (Fahey et al. 1992), and inducing mast cell degranulation (Alam et al.
1994) and the release of preformed mediators including TNFa (Gordon et al. 1990).
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The incomplete inhibition of antigen-induced lung eosinophil accumulation 
following the blockade of MIP-la alone suggests that eosinophil recruitment is 
unlikely to be as a result of the expression of a sole chemokine. Eosinophils have the 
capacity to synthesis and release certain cytokines and chemokines including TNFa, 
eotaxin, IL- 8  and MIP-la (Costa et a l 1993; Finotto et al. 1994; Garcia-Zepeda et al. 
1996; Yousefi et al. 1995; Kita et al. 1995). IL- 8  is a potent neutrophil activator 
(Baggiolini et al. 1989) which induces lung eosinophilia following aerosol (Smith et 
al. 1991) or intraperitoneal administration (Burrows et al. 1990; Burrows et al. 1991a) 
and induces eosinophil accumulation in guinea-pig skin (Collins et al. 1993). The pre- 
incubation of eosinophils with priming agents influences the biological response, for 
example the weak IL- 8  chemotactic response is enhanced by pre-incubation with IL-3 
GMCSF and IL-5 (Burrows et al. 1991b; Schweizer et al. 1994). Furthermore, 
eosinophils from antigen-challenged allergic individuals display enhanced 
transendothelial migration, compared with non-allergic individuals, and the 
potentiated response is similar to that seen following the priming of eosinophils from 
non-allergic individuals (Ebisawa et al. 1994).
8.6 Effect of IL-13 on antigen and gpTNFOrinduced airway 
inflammation
IL-13, originally described as a cytokine derived principally from Th2 
lymphocytes, exhibits some anti-inflammatory properties (Minty et al. 1993). IL-13 is 
also expressed by activated B lymphocytes, basophils and mast cells (Krishnaswamy 
et al. 1993; Li et al. 1996; Burd et al. 1995). IL-13 inhibits the expression of mRNA 
for certain cytokines in LPS-stimulated monocytes, including IL-1, TNFa, IL- 8  and 
MIP-la (Minty et al. 1993; De Waal Malefyt et al. 1993; Cosentino et al. 1995), 
whilst it increases IL-lra expression (Vannier et al. 1996). The inhibition of TNFa 
and IL-1, and increased production of IL-lra by IL-13 have also been demonstrated 
using stimulated alveolar macrophages (Yanagawa et al. 1995). As IL-13 alters
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mRNA levels it acts at a pre-translational level. In the case of IL-lra, IL-13 enhances 
IL-lra mRNA steady-state levels by increasing transcriptional activation of the gene, 
but does not affect mRNA stability, conversely, IL-13 reduces IL-1 gene transcription 
and mRNA stability (Vannier et al. 1996). Many, but not all, of the biological 
activities of IL-13 are similar to IL-4, the exceptions include T lymphocytes 
stimulation by IL-4 but not IL-13 (Zurawski et al. 1994).
IL-13, like IL-4, also exhibits pro-inflammatory activities such as isotype 
switching in B lymphocytes increasing IgE and IgG4 production (Punnonen et al.
1993). Furthermore, IL-13 inhibits the production of IL-12 and IFNy by LPS 
stimulated monocytes (de Waal Malefyt et al. 1993). Inhibition of IL-12 could affect 
the regulation of Thl and Th2 development, since both IL-12 and IFNy have been 
shown to direct the generation of Thl lymphocytes (Manetti et al. 1993). Hence, this 
suggests that IL-13 would favour Th2 responses with the production of IL-4 and IL-5, 
which are both upregulated in asthma. In addition, IL-13 upregulates the expression of 
MHC class II antigens which may result in more efficient antigen-presentation. As 
summarised in figure 8.1 the net effect of IL-13 in an in vivo situation is dependent on 
a balance between the anti-inflammatory and pro-inflammatory activities.
The data presented in this thesis report a novel in vivo action of EL-13 which 
was not shown with IL-4. IL-13 inhibited gpTNFa-induced BAL eosinophil and 
macrophage/monocyte infiltration when co-instilled with gpTNFa. The inhibition of 
antigen-induced BAL eosinophil infiltration, following the instillation of IL-13 prior 
to antigen challenge, was pronounced although the numbers were not reduced to those 
of control animals. As IL-13 produced a dose-dependent reduction maximum 
inhibition may not have been achieved even with the highest dose of IL-13 used. 
Interestingly, a low dose of IL-13 (lng per animal) reduced antigen-induced eosinophil 
influx by >50%, suggesting IL-13 was an effective inhibitor of eosinophil 




T B cell proliferation 
T IgE and IgG4 production 
T VCAM- 1  expression 




Inhibits IL-1, TNFa, IL-8 , 
MCP-1 and RANTES 
production 
Inhibits nitric oxide 
production 
T IL-lra synthesis
Figure 8.1: IL-13, good or bad? IL-13 exhibits both anti-inflammatory and 
pro-inflammatory activites in vitro, in vivo the net effect of IL-13 is dependent 
on the balance between these properties.
To address whether IL-13 prevented the migration of eosinophils from the lung 
tissue into the airway lumen whole lung EPO measurements were performed as an 
indication of the relative eosinophil numbers. Lung tissue of animals co-instilled with 
IL-13 and gpTNFa contained lower EPO levels than animals instilled with gpTNFa 
alone. This indicates that the eosinophils were not retained in the lung tissue and
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prevented from migrating to the lumen which might be expected if IL-13 was 
increasing VCAM-1 expression (Bochner et al. 1995).
In addition to inhibition of BAL eosinophil accumulation, IL-13 also reduced 
the chemokine-like bioactivity in the BAL. The antigen-induced calcium mobilisation 
activity in the BAL was leukocyte specific, activating only eosinophils. The C-C 
chemokine RANTES is a major mediator of human eosinophil activation including 
chemotaxis and transient changes in [Ca2+]i (Kameyoshi et a l  1992; Rot et al. 1992; 
Bourne et al. 1995). However, neither guinea-pig nor human RANTES induce calcium 
mobilisation in guinea-pig peritoneal eosinophils, but both activate guinea-pig 
peritoneal macrophages (Campbell et al. 1996 and own observations). This 
chemokine-like activity is possibly due to eotaxin. Eotaxin induces calcium 
mobilisation and aggregation of eosinophils in vitro, and the administration of aerosol 
eotaxin in vivo induces the selective accumulation of BAL eosinophils (Griffiths- 
Johnson et al. 1993). The peak expression of eotaxin mRNA in lung tissue and 
bioactivity in BAL occurs 3-6 hours following antigen-challenge and returns to basal 
levels by 24 hours (Rothenberg et al. 1995; Jose et al. 1994b). The time course 
described is similar to the profile of eosinophil specific chemokine activity 
demonstrated in this thesis. Moreover the reduction in chemokine-like activity induced 
by IL-13 further suggests the involvement of chemokines such as IL- 8  and MIP-la, 
the synthesis of which may be inhibited by IL-13. To date, the effect of IL-13 on 
antigen- or TNFa-induced eotaxin expression have not been published. However as 
previously discussed others have demonstrated a significant increase in lung TNFa 
expression, and this report indicates enhanced TNFa levels, during antigen-induced 
airway inflammation, it is feasible that in the allergic model IL-13 inhibits both TNFa 
and chemokine expression. Furthermore, the enhancement of IL-lra by IL-13 is an 
additional pathway by which IL-13 may reduce antigen-induced eosinophil 
accumulation. In vivo studies have demonstrated that the administration of IL-lra prior 
to antigen challenge reduces BAL eosinophil accumulation, bronchial hyperreactivity 
and BAL TNFa levels 24 hours after challenge (Watson et al. 1993).
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Although IL-4 shares many biological activities with IL-13, including 
inhibiting the synthesis of certain cytokines and chemokines, it did not affect gpTNFa 
induced BAL eosinophil infiltration when co-instilled with gpTNFa. The instillation 
of IL-4 alone to naive animals did increase BAL macrophage/monocyte accumulation, 
which was not observed when IL-13 was administered to naive animals. The 
differences in the IL-13 and IL-4 responses may be due to variation in the expression 
and affinity of the IL-13 and IL-4 receptors for the ligands. In this study both cytokines 
were recombinant human proteins and as previously noted with TNFa species 
selectivity may favour the binding of either IL-13 or IL-4. At present the receptors 
have yet to be fully characterised. It is believed that there are multiple receptors and 
certain sub-unit(s) are shared by both 11^13 and IL-4 receptors (Callard et al. 1996). 
One of the IL-4 receptors is independent of the IL-2 receptor y sub-unit and this sub­
unit is not the shared IL-13/IL-4 receptor component (He et al. 1995). Furthermore, 
the expression of the human eosinophil chemoattractant RANTES by endothelial cells 
was inhibited by both IL-13 and IL-4 (Marfaing-Koka et al. 1995), but only IL-4 
reduced RANTES expression in human airway epithelial cells (Berkman et al. 1996), 
indicating that the effects of IL-13 and IL-4 may be cell type dependent. In addition, 
our group has recently shown that IL-13 is a potent inhibitor of MCP-1 and RANTES 
but not 1 1 ^ 8  in colonic epithelial cells, further indicating cell type dependant effects of 
IL-13 (Kolios etal. 1997)
It is clear that in order to understand the mechanism by which IL-13 inhibits 
antigen-induced eosinophil accumulation further research is required. Recent findings 
by members of the group have demonstrated that IL-13 can modulate not only 
chemokine expression but also reduce inducible nitric oxide synthase (iNOS) and 
nitric oxide production (Jordan et al. 1996; Kolios et al. 1996b; Kolios et al. 1996a). 
Exhaled nitric oxide levels are increased in asthmatic patients, suggesting that nitric 
oxide may have a pro-inflammatory role in asthma (Kharitonov et al. 1994). In 
addition, epithelial cells in the asthmatic, but not normal, lung express iNOS (Hamid
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et al. 1993). The effects of nitric oxide on airway function have been reviewed by 
Barnes (Barnes, 1995), and include increased airway blood flow and plasma 
exudation. Nitric oxide has an inhibitory action on Thl but not Th2 lymphocytes 
(Taylor-Robinson et a l 1994), which would favour Th2 proliferation.
To my knowledge this is the first report of IL-13 inhibiting airway 
inflammation and these results are contrary to the reported involvement of IL-4. 
Inhibition of IL-4 in a murine model of antigen-induced airway inflammation reduced 
BAL eosinophil accumulation (Lukacs et al. 1994) and IL-4 transgenic mice exhibited 
eosinophilia (Tepper et al. 1993). However IL-10, which exhibits anti-inflammatory 
properties similar to that of IL-13 (Fiorentino et al. 1991), reduces antigen-induced 
eosinophil infiltration and IL-5 generation in the peritoneal cavity of mice (Zuany- 
Amorim^fll. 1996).
8.7 Cytokine networking in allergic lung inflammation
TNFa is released at an early stage of the allergic response following antigen 
activation of mast cells (Plaut et al. 1989). The potential central role for TNFa in 
allergic lung inflammation is summarised in figure 8.2. The upregulation of adhesion 
molecules is a crucial step in leukocyte accumulation. TNFa is a potent non-selective 
inducer of adhesion molecule expression increasing E-selectin, ICAM-1 and VCAM-1 
(Kyan-Aung et al. 1991), whereas IL-4 and IL-13 selectively increase VCAM-1 
expression on endothelial cells. Concomitantly, TNFa induces the production of 
chemokines from surrounding cells including endothelial, epithelial, smooth muscle 
cells and fibroblasts. Elevated levels of eosinophil chemoattractants including eotaxin, 
MIP-la, IL-16, RANTES and IL- 8  have been demonstrated in BAL from animal 
models or antigen-challenged asthmatics (Jose et al. 1994b; Lukacs et al. 1997; Teran 
et al. 1996; Cruikshank et al. 1997). As described in the introduction, chemokines are 
thought to aid transendothelial migration by the formation of hapatotactic and 
chemotactic gradients. In addition to the induction of chemotaxis RANTES and
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MIP-la promote isotype switching increasing B lymphocyte production of IgE and 
IgG4 (Kimata et al. 1996). However, unlike the IL-4 and IL-13 response, RANTES 
and MIP-la induced isotype switching is not enhanced by TNFa (Aversa et al. 1993; 
Kimata etal. 1996).
Following the initial eosinophil accumulation the process could be self- 
perpetuating as eosinophils themselves are known producers of and have receptors for 
TNFa (Costa et al. 1993; Roubin et al. 1987), IL-4 (Nonaka et al. 1995; Baskar et al. 
1990), IL-5 (Yamaguchi et al. 1988; Broide et al. 1992), eotaxin (Garcia-Zepeda et al. 
1996), MIP-la (Costa et al. 1993; Rot et al. 1992) and IL-8 (Yousefi et al. 1995; Kita 
et al. 1995; Erger et al. 1995). The inflammatory response may be resolved by anti­
inflammatory cytokines such as IL-13, IL-10 and by the production of receptor 
antagonists (e.g. IL-lra, soluble TNF receptors).
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Figure 8.2: (please see next page)
Fieure 8.2: (on the facing page) The potential cytokine network involved in allergic airway inflammation. Antigen activation of mast 
cells induces degranulation and cytokine release including IL-4, IL-13 and TNFa. TNFa activation of resident and infiltrating cells 
in the lung induces the synthesis and release of eosinophil chemoattractants especially eotaxin, EL-8, RANTES and M IP-la. TNFa 
also upregulates the expression of adhesion molecules on the endothelium and epithelial cells. IL-4 and EL-13 selectively increase 
VCAM-1 expression. Eosinophils migration from the microvasculature (A) into the lung tissue is directed by adhesion molecule and 
chemokine expression. The release of IL-5 from T lymphocytes promotes eosinophilia and the survival and activation of eosinophils. 
Activated eosinophils degranulate to release toxic mediators such as major basic protein (mbp) and super oxide anions (O2 ), which 
contribute to epithelial destruction (B). Although IL-13 inhibits the production of TNFa and chemokines from macrophages, smooth 
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8.8 Implication as possible therapeutic agents
The present treatments for asthma, most importantly p2 agonists and 
glucocorticosteroids, are highly effective at alleviating the visible symptoms of the 
disease and thus improving the patients quality of life, but they do not cure asthma. 
Furthermore, the frequent and long term use of many anti-asthmatic drugs increases 
the side-effects associated with the therapies, e.g. frequent use of the p2  agonist 
fenoterol was linked to increased mortality (Crane et al. 1989). Effective new 
therapies are required which relieve not only the bronchospasm but also the 
inflammatory reaction occurring within the lung. By inhibiting the eosinophil influx 
into the lung permanent architectural damage to the tissue should be prevented. From 
this report it is clear that TNFa is an important mediator of eosinophil accumulation 
and that specific inhibitors of TNFa would potentially be of therapeutic benefit. IL-13 
also demonstrated anti-inflammatory activity suppressing antigen-induced eosinophil 
infiltration. Interestingly, as IL-13 inhibited TNFa-induced eosinophil accumulation 
this suggests that IL-13 may be a useful pharmacological tool in modulating cytokine- 
driven inflammatory reactions. Further investigation is required into the mechanisms 
of action of IL-13.
8.9 Final conclusions
In this thesis I report the expression, purification and in vivo bioactivity of 
gpTNFa. Mature gp TNFa was expressed as a 154 amino acid, 17kDa, protein which 
was approximately 80% homologous with other mammalian TNFa sequences. The in 
vivo data presented in this thesis indicate the importance of TNFa in the generation of 
lung eosinophilia in the guinea-pig. Following intratracheal instillation of gpTNFa 
there was a pronounced and protracted eosinophilia. This response was inhibited by 
pre-incubating gpTNFa with anti TNFa antibody and by heat inactivating the protein 
prior to instillation. The instillation of human TNFa induced only a weak leukocyte 
accumulation with different cellular characteristics than the gpTNFa-induced response
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further indicating the potential danger of evaluating the activities of proteins when not 
using the host species. In a guinea-pig model of allergic lung inflammation, which 
demonstrated antigen-induced lung eosinophil infiltration and bronchial 
hyperreactivity, enhanced TNFa levels were detected after antigen challenge. The role 
of TNFa in generating allergic airway eosinophilia was reinforced by the 
administration of an anti TNFa antibody which reduced BAL eosinophil numbers.
A novel finding presented in this report is the inhibitory action of IL-13. IL-13 
inhibited both gpTNFa- and antigen-induced airway eosinophilia. Although the 
mechanisms by which IL-13 induced this effect require further characterisation, IL-13 
inhibited migration of eosinophils from the microvasculature into the lung tissue and 
thus the effect was not simply as a possible consequence of an increase in the 
expression of adhesion molecules retaining the eosinophils in the lung tissue. 
Furthermore, IL-13 reduced the chemokine bioactivity present in the BAL of antigen 
challenged animals.
In conclusion, this report demonstrates that TNFa is an important mediator of 
airway eosinophil accumulation in vivo. Furthermore, agents which inhibit the actions 
or production of TNFa may be potential therapies in the treatment of diseases which 
are characterised by airway eosinophilia. In addition, the ability of IL-13 to prevent 
antigen and gpTNFa-induced eosinophil accumulation suggests that IL-13 represents 
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